Compound

By developing new compounds that directly act on the TMEM16A channel, the problem of poor effectiveness of existing TMEM16A regulators in clinical applications has been solved, continuous anion secretion and mucosal cilia clearance have been achieved, and respiratory defense has been improved, and suitable for a variety of breathing Systemic disease.

CN111683926BActive Publication Date: 2024-11-08TMEM16A LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980010318.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-01-26
Filing Date
2019-01-25
Publication Date
2024-11-08
Estimated Expiration
2039-03-27

AI Technical Summary

Technical Problem

Existing TMEM16A modulators, such as Denifol, cannot provide clinical benefits in larger patient populations, mainly due to the adverse effects of transient elevated anion secretion and increased intracellular calcium, resulting in the insufficiency of mucus removal mechanisms. , cannot effectively improve the defense of the respiratory tract.

Method used

A new compound has been developed as a forward regulator of TMEM16A, which is suitable for various respiratory diseases by acting directly on the TMEM16A channel to enhance its opening, continuously improving anion secretion and mucosal cilia clearance, independent of CFTR function.

Benefits of technology

This compound can last long enhance anion secretion and mucociliary clearance, improve respiratory defense, and is suitable for cystic fibrosis, chronic bronchitis, asthma and other diseases, providing clinical therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111683926B_ABST
    Figure CN111683926B_ABST
Patent Text Reader

Abstract

Compounds of general formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , X 1 , X 2 , Z and Y are as defined herein, which are calcium-activated chloride channel (CaCC) positive regulators, TMEM16A. The compounds can be used to treat diseases and disorders affected by TMEM16A regulation, especially respiratory diseases and disorders. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to novel compounds having activity as positive modulators of calcium-activated chloride channel (CaCC) (TMEM16A). The present invention also relates to methods for preparing the compounds and pharmaceutical compositions containing the compounds, and the use of these compounds in treating diseases and conditions modulated by TMEM16A, in particular respiratory diseases and conditions.

[0002] Humans breathe in up to 12,000 liters of air every day, and may also be carrying pathogens (bacteria, viruses, and fungal spores) into the respiratory tract. To protect against these airborne pathogens, the lungs have developed innate defense mechanisms to minimize the likelihood of respiratory infection and colonization. One such mechanism is the mucus clearance system, which pushes secreted mucus up and out of the respiratory tract through the coordinated beating of cilia and the clearing force of coughing. This continuous "clearance action" of the lungs continuously removes inhaled particles and microorganisms, thereby reducing the risk of infection.

[0003] In recent years, it has been recognized that hydration of the mucus gel is critical to achieving mucus clearance (Boucher 2007; Matsui et al., 1998). In the normal healthy airway, the mucus gel is typically 97% w / v water and 3% w / v solids, under which conditions mucus can be cleared by mucociliary action. Hydration of the respiratory mucosa is regulated by the coordinated activity of many ion channels and transporters. Anion (Cl) transport is mediated by the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium activated chloride conductance (CaCC; TMEM16A). - / HCO 3 - ) secretion balance and through epithelial Na + Na channel (ENaC) + Absorption determines the hydration state of the respiratory mucosa. As ions are transported across the epithelium, water is forced to follow due to osmotic pressure, so fluid is either secreted or absorbed.

[0004] In respiratory diseases such as chronic bronchitis and cystic fibrosis, the % solids in the mucus gel increases as hydration decreases and mucus clearance decreases (Boucher, 2007). In cystic fibrosis, when loss-of-function mutations in CFTR occur, which reduce the ability of the airways to secrete fluid, the % solids can increase to 15%, which is thought to cause small airway obstruction and loss of mucus clearance. Strategies to increase airway mucus hydration include stimulating anions and thereby stimulating fluid secretion or inhibiting Na+ production. + To this end, stimulation of TMEM16A channel activity would increase anion secretion and, therefore, increase fluid accumulation in the respiratory mucosa, hydrate mucus, and enhance mucus clearance mechanisms.

[0005] TMEM16A, also known as calcium-activated chloride channel protein 1 (Anoctamin-1, Ano1), is a molecular recognition of calcium-activated chloride channels (Caputo et al. 2008; Yang et al., 2008). TMEM16A channels open in response to elevated intracellular calcium levels and allow bidirectional flow of chloride ions, bicarbonate and other anions across the cell membrane. Functionally, TMEM16A channels have been proposed to regulate transepithelial ion transport, gastrointestinal motility, nociception and cell migration / proliferation (Pedemonte & Galietta, 2014).

[0006] TMEM16A channels are expressed by epithelial cells of different organs, including lungs, liver, kidneys, pancreas and salivary glands. In the respiratory epithelium, TMEM16A is expressed at high levels in goblet cells, ciliated cells and submucosal glands that produce mucus. Physiologically, TMEM16A is activated by stimulants that mobilize intracellular calcium, particularly purinergic agonists (ATP, UTP), which are released by the respiratory epithelium in response to periodic shear stress caused by breathing and other mechanical stimuli such as coughing. In addition to increasing anion secretion to enhance hydration of the respiratory tract, the activation of TMEM16A plays an important role in bicarbonate secretion. It is reported that bicarbonate secretion is an important regulator of mucus properties and control of the pH value of the respiratory chamber, thus controlling the activity of natural antimicrobial agents such as defensins (Pezzulo et al., 2012).

[0007] Indirect regulation of TMEM16A through an increase in intracellular calcium has been explored clinically, such as Denufosol (Kunzelmann & Mall, 2003). Although encouraging preliminary results were observed in a small number of patient groups, this approach did not provide clinical benefits in larger patient groups (Accurso et al. 2011; Kellerman et al. 2008). This lack of clinical effect is attributed only to a transient increase in anion secretion (which is a result of Denufosol's short half-life on the epithelial surface and receptor / pathway desensitization), as well as the adverse effects of elevated intracellular calcium, such as increased mucus release from goblet cells (Moss, 2013). In the case of low-level calcium elevation, compounds that act directly on TMEM16A to enhance channel opening are expected to permanently enhance patients' anion secretion and mucociliary clearance and improve innate defenses. Because TMEM16A activity is independent of CFTR function, TMEM16A positive modulators have the potential to provide clinical benefit to all patients with CF and non-CF respiratory diseases characterized by mucus congestion, including chronic bronchitis and severe asthma.

[0008] TMEM16A modulation has been suggested for the treatment of dry mouth (xerostomia), dry eyes, cholestasis, and gastrointestinal dysmotility caused by salivary gland dysfunction and radiation therapy in Sjögren's syndrome.

[0009] The present inventors have developed novel compounds which are positive modulators of TMEM16A and are therefore useful in treating diseases and disorders in which modulation of TMEM16A plays a role, particularly respiratory diseases and disorders.

[0010] In the first aspect of the present invention, there is provided a compound of general formula (I), including all tautomeric forms, all enantiomers and isotopic variants thereof, and salts and solvates thereof:

[0011]

[0012] in:

[0013] R 1 H、CN、C(O)OR 12 , C 1-3 Alkyl, C 2-3 Alkenyl or C 2-3 Alkynyl, any of the alkyl, alkenyl or alkynyl groups is optionally substituted by one or more substituents, suitably by one substituent, selected from fluorine, OR 12 、N(R 12 ) 2 、C(O)OR 12 、C(O)N(R 12 )2 、C(O)R 12 and N(R 13 )C(O)R 12 ;

[0014] Where R 12 and R 13 Each independently selected from H, C 1-6 Alkyl and C 1-6 Fluoroalkyl

[0015] R 2 Is H or C 1-6 Alkyl, which is optionally substituted with OR 12 replace;

[0016] R 3 yes:

[0017] C 1-10 Alkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, any of which is optionally substituted by one or more substituents, suitably by one substituent, selected from fluorine, CN, R 14 OR 14 , OR 15 、N(R 15 ) 2 、C(O)OR 15 、C(O)N(R 15 ) 2 、N(R 16 )C(O)R 15 、N(R 15 )S(O) 2 R 14 、N(R 15 )S(O) 2 R 16 and N(R 15 )C(O)OR 16 ;or

[0018] A 3- to 7-membered carbocyclic or heterocyclic ring system or a 6- to 10-membered aryl or 5- to 10-membered heteroaryl ring system, each of which is optionally substituted with one or more substituents selected from the group consisting of halo, CN, C 1-4 Alkyl, C 1-4 Haloalkyl, OR 17 and N(R 17 ) 2 ;

[0019] Where R 14 is a 6- to 10-membered aryl or 5- to 10-membered heteroaryl ring system or a 3- to 7-membered carbocyclic or heterocyclic ring system, any of which is optionally substituted by one or more substituents selected from the group consisting of halo, C1-4 Alkyl, C 1-4 Haloalkyl, OR 17 and N(R 17 ) 2 ; where R 17 Each independently is H, C 1-4 Alkyl or C 1-4 Haloalkyl;

[0020] R 15 and R 16 Each independently is H, C 1-6 Alkyl or C 1-6 haloalkyl; or

[0021] R 2 and R 3 Together with the carbon atoms to which they are attached, they form a 3- to 10-membered carbocyclic or heterocyclic ring system, which is optionally substituted by one or more substituents selected from the group consisting of halo, CN, OR 9 、N(R 9 ) 2 、C(O)OR 9 、C(O)N(R 9 ) 2 、C(O)R 9 、N(R 9 )C(O)R 9 and optionally halogenated, OR 9 or N(R 9 ) 2 Substituted C 1-4 Alkyl; or

[0022] R 1 , R 2 and R 3 Together with the carbon atoms to which they are attached, they form a bridged 5- to 10-membered carbocyclic or heterocyclic ring system or phenyl, any of which is optionally substituted with one or more substituents selected from the group consisting of halo, CN, OR 9 、N(R 9 ) 2 、C(O)OR 9 、C(O)N(R 9 ) 2 、C(O)R 9 、N(R 9 )C(O)R 9 and optionally halogenated, OR 9 or N(R 9 ) 2 Substituted C 1-4 alkyl;

[0023] R 9Each independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0024] X 1 and X 2 Each of the 8 ;

[0025] R 8 H, halide, OH, O(C 1-4 alkyl), CN or NH 2 ;

[0026] Y is a bond or a straight chain of C 1-6 An alkylene chain, which is optionally substituted by one or more substituents R 18 Substitution, where two substituents R 18 can be attached to the same or different carbon atoms;

[0027] Where R 18 Each is independently C 1-3 Alkyl or C 1-3 A haloalkyl group, wherein -CH 2 - is optionally substituted by -NH- or -O-, and wherein both R 18 The groups may be combined with the atom or atoms to which they are attached to form a 3- to 6-membered carbocyclic or heterocyclic ring system;

[0028] Z is -C(O)- or -C(O)NH-;

[0029] R 4 is a 6- to 14-membered aryl, a 5- to 14-membered heteroaryl, or a 5- to 10-membered carbocyclic ring system, any of which is optionally substituted with one or more substituents selected from:

[0030] Halo, CN, nitro, R 19 , OR 19 , OR 6 , SR 6 NR 6 R 7 、C(O)R 6 、C(O)R 19 、C(O)OR 6 、C(O)N(R 6 )(R 7 )、N(R 7 )C(O)R 6 ;

[0031] C 1-6 Alkyl or O(C 1-6alkyl), any of which is optionally substituted by one or more substituents selected from the group consisting of halo, CN, nitro, R 19 , OR 6 , SR 6 NR 6 R 7 、C(O)R 6 C(O)OR 6 、C(O)N(R 6 )(R 7 ) and N(R 7 )C(O)R 6 ;and

[0032] Oxo, when R 4 This is true when not completely aromatic in nature;

[0033] Where R 19 is a 5- or 6-membered aryl or heteroaryl ring system or a 3- to 7-membered carbocyclic or heterocyclic ring system, any of which is optionally substituted by one or more substituents selected from the group consisting of halo, C 1-4 Alkyl, C 1-4 Haloalkyl, OH, O(C 1-4 alkyl), O(C 1-4 haloalkyl);

[0034] R 6 It is H, C 1-6 Alkyl, C 1-6 haloalkyl, benzyl, 3- to 7-membered carbocyclic group or 3- to 7-membered heterocyclic group;

[0035] R 7 It is H, C 1-6 Alkyl or C 1-6 haloalkyl; or

[0036] R 6 and R 7 Together with the nitrogen atom to which they are attached, may form a 4 to 7-membered heterocyclic ring, which optionally contains one or more additional heteroatoms and is optionally substituted by one or more substituents selected from oxo and halo; and

[0037] R 5a and R 5b Each of which is independently H, C 1-4 Alkyl or halo;

[0038] It is used in medical applications.

[0039] In this specification, unless the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprising" or "containing" are used in an inclusive sense, that is, stating the presence of stated features but not excluding the presence or addition of other features in various embodiments of the invention.

[0040] In this specification, the term "medical use" refers to the use for administration to humans or animals, especially humans or mammals, such as domestic or livestock mammals, for the treatment or prevention of diseases or medical symptoms. The term "pharmaceutical composition" refers to a composition suitable for medical use, and "pharmaceutically acceptable" applies to the active agent of the pharmaceutical composition, and other similar terms should be interpreted accordingly.

[0041] In this specification, the term "C 1-6 "Alkyl" refers to a straight or branched fully saturated hydrocarbon group having 1 to 6 carbon atoms, and the term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl. Other alkyl groups, such as C 1-10 Alkyl groups are as defined above but contain different numbers of carbon atoms.

[0042] The term "C 2-6 "Alkenyl" refers to a straight or branched hydrocarbon group having 1 to 6 carbon atoms and at least one carbon-carbon double bond, and the term includes ethenyl, propen-1-yl, propen-2-yl, buten-1-yl and buten-2-yl. Other alkenyl groups, such as C 2-10 Alkenyl, as defined above but containing a different number of carbon atoms.

[0043] The term "C 2-6 "Alkynyl" refers to a straight or branched hydrocarbon group having 1 to 6 carbon atoms and at least one carbon-carbon triple bond, and the term includes ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl and butyn-2-yl. Other alkynyl groups, such as C 2-10 Alkynyl groups are as defined above but contain a different number of carbon atoms.

[0044] The term "C 1-6 "Alkylene" refers to a straight or branched fully saturated hydrocarbon chain having 1 to 6 carbon atoms. Examples of alkylene include -CH 2 -、-CH 2 CH 2 -、CH(CH 3 )-CH 2 -、CH 2 CH(CH 3 )-、-CH 2 CH 2 CH 2 -、-CH 2 CH(CH 2 CH3 )- and -CH 2 CH(CH 2 CH 3 )CH 2 -. Other alkylene groups, such as C 1-3 Alkylene is as defined above, except containing the specified number of carbon atoms (eg, 1 to 3).

[0045] Unless otherwise indicated, the terms "carbocycle" and "carbocyclyl" refer to non-aromatic hydrocarbon ring systems containing 3 to 10 ring carbon atoms, and optionally containing one or more double bonds. A carbocyclic group may be a monocyclic ring or may contain two or three rings which may be fused or bridged, wherein the carbon atoms in the bridge are included in the number of ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl, and bridged systems such as bicyclo[1.1.1]pentyl, bicyclo-[2.2.1]heptyl, bicyclo-[2.2.2]octyl and adamantyl.

[0046] In the context of this specification, the terms "heterocycle" and "heterocyclyl" refer to non-aromatic ring systems containing 3 to 10 ring atoms, including at least one heteroatom selected from N, O and S. The heterocyclic group may be a single ring or may contain two or three rings which may be fused or bridged, wherein the bridging atom is included in the number of ring atoms. Examples include tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl and thiomorpholinyl, as well as fused systems such as cyclopropyl-fused pyrrolidine.

[0047] In the context of this specification, the terms "aryl" and "aromatic" refer to a ring system having 5 to 14 ring carbon atoms and comprising up to three rings having aromatic character. When an aryl group comprises more than one ring, not all rings must be completely aromatic in character. Examples of aromatic groups are benzene, naphthalene, fluorene, tetrahydronaphthalene, indane and indene.

[0048] In the context of this specification, the terms "heteroaryl" and "heteroaromatic" refer to a ring system having 5 to 14 ring atoms with aromatic character, wherein at least one ring atom is a heteroatom selected from N, O and S and contains up to three rings. When the heteroaryl group contains more than one ring, not all rings must be aromatic. Examples of heteroaryl groups include pyridine, pyrimidine, indole, indazole, thiophene, benzothiophene, benzoxazole, benzofuran, dihydrobenzofuran, tetrahydrobenzofuran, benzimidazole, benzimidazolinone, quinoline and indoline.

[0049] The term "oxo" refers to a C=O substituent wherein the carbon atom is a ring atom of a carbocyclyl, heterocyclyl, or an aryl or heteroaryl ring that does not have aromatic character.

[0050] The term "halogen" refers to fluorine, chlorine, bromine or iodine, and the term "halo" refers to a fluorine, chlorine, bromine or iodine group. Similarly, "halide" refers to fluoride, chloride, bromide or iodide.

[0051] The term "C 1-6 "Haloalkyl" as used herein refers to a C 1-6 Alkyl groups wherein one or more hydrogen atoms are replaced by a halo group. Any number of hydrogen atoms may be replaced, up to full halogen substitution. Examples include trifluoromethyl, chloroethyl and 1,1-difluoroethyl. Fluoroalkyl groups are haloalkyl groups wherein the halogen is fluorine.

[0052] The term "isotopic variant" refers to an isotopically labeled compound that is identical to those described in formula (I), but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature, or in which the proportion of atoms having an atomic mass or mass number less common in nature is increased (the latter concept is called "isotopic enrichment"). Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, iodine and chlorine, such as 2H (deuterium), 3H, 11C, 13C, 14C, 18F, 123I or 125I (e.g. 3H, 11C, 14C, 18F, 123I or 125I), which may be naturally occurring or non-naturally occurring isotopes.

[0053] The compounds of general formula (I) are modulators of TMEM16A. Therefore, in another aspect of the present invention, there is provided a compound of general formula (I) as defined above for use in the treatment or prevention of diseases and disorders affected by the modulation of TMEM16A.

[0054] Also provided herein is the use of a compound of formula (I) in the preparation of a medicament for treating or preventing diseases and disorders affected by TMEM16A modulation.

[0055] Also provided herein are methods for treating or preventing diseases and disorders affected by TMEM16A modulation, the methods comprising administering to a patient in need of such treatment an effective amount of a compound of formula (I).

[0056] Such diseases and conditions affected by TMEM16A modulation include respiratory diseases and conditions, dry mouth (xerostomia), overactive bowel, cholestasis, and ocular symptoms.

[0057] Also provided:

[0058] - Compounds of general formula (I) for use in the treatment or prevention of diseases and disorders of the respiratory system.

[0059] - A compound of formula (I) for use in the treatment or prevention of dry mouth (xerostomia).

[0060] - A compound of formula (I) for use in the treatment or prevention of intestinal hyperactivity.

[0061] - A compound of formula (I) for use in the treatment or prevention of cholestasis.

[0062] - A compound of formula (I) for use in the treatment or prevention of ocular symptoms.

[0063] Also provided:

[0064] Use of a compound of general formula (I) in the preparation of a medicament for treating or preventing respiratory diseases and disorders.

[0065] Use of a compound of general formula (I) in the preparation of a medicament for treating or preventing dry mouth (xerostomia).

[0066] Use of a compound of general formula (I) in the preparation of a medicament for treating or preventing intestinal hyperactivity.

[0067] Use of the compound of general formula (I) in the preparation of a medicament for treating or preventing cholestasis.

[0068] Use of the compound of general formula (I) in the preparation of a medicament for treating or preventing eye symptoms.

[0069] Further provided:

[0070] - A method for the treatment or prevention of diseases and disorders of the respiratory system, which method comprises administering to a patient in need of such treatment an effective amount of a compound of general formula (I).

[0071] - A method for the treatment or prevention of dry mouth (xerostomia), which method comprises administering to a patient in need of such treatment an effective amount of a compound of general formula (I).

[0072] A method for treating or preventing intestinal hyperactivity, which comprises administering an effective amount of a compound of general formula (I) to a patient in need of such treatment.

[0073] A method for treating or preventing cholestasis, which comprises administering an effective amount of a compound of general formula (I) to a patient in need of such treatment.

[0074] A method for treating or preventing ocular symptoms, which comprises administering an effective amount of a compound of general formula (I) to a patient in need of such treatment.

[0075] Respiratory diseases and conditions which may be treated or prevented using compounds of formula (I) include cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, bronchiectasis including non-cystic fibrosis bronchiectasis, asthma and primary ciliary dyskinesia.

[0076] Dry mouth (xerostomia) which can be treated or prevented by the compounds of general formula (I) is caused by Sjögren's syndrome, radiation therapy or xerogenic drugs.

[0077] Intestinal hyperactivity that may be treated or prevented by the compounds of general formula (I) may be associated with gastric dyspepsia, gastroparesis, chronic constipation or irritable bowel syndrome.

[0078] Ocular symptoms that can be treated or prevented using the compounds of general formula (I) include dry eye.

[0079] In some cases, in the compounds of formula (I), Z is -C(O)-, and R 5b is H, so that the compound has the formula (Iz):

[0080]

[0081] Where R 1 , R 2 , R 3 , R 4 , R 5a and Y is as defined in the general formula (I).

[0082] In some cases, in the compounds of formula (I), Z is -C(O)NH-, and R 5b is H, so that the compound has the general formula (Iy):

[0083]

[0084] Where R 1 , R 2 , R 3 , R 4 , R 5a and Y is as defined in the general formula (I).

[0085] In some compounds of Formula (Iz), Y is not a bond.

[0086] In some cases, the compound of formula (I) is a compound of formula (Ix), including all tautomeric forms, all enantiomers and isotopic variations, and salts and solvates thereof:

[0087]

[0088] in:

[0089] R 1 is H, CN or C 1-3 Alkyl, which is optionally substituted by one or more substituents selected from the group consisting of halo, OR 12 、N(R12 ) 2 、C(O)OR 12 、C(O)N(R 12 ) 2 、C(O)R 12 and N(R 13 )C(O)R 12 ;

[0090] Where R 12 and R 13 Each independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0091] R 2 It is C 1-6 alkyl;

[0092] R 3 It is C 1-6 Alkyl, which is optionally substituted by one or more substituents selected from the group consisting of halo, OH, O(C 1-6 alkyl), C(O)O-(C 1-6 alkyl) and N(H)C(O)O-(C 1-6 alkyl); or

[0093] R 2 and R 3 Together with the carbon atoms to which they are attached, they form a 3- to 10-membered carbocyclic or heterocyclic ring system, which is optionally substituted by one or more substituents selected from the group consisting of halo, OR 9 、N(R 9 ) 2 、C(O)OR 9 、C(O)N(R 9 ) 2 、C(O)R 9 and N(R 9 )C(O)R 9 ;or

[0094] R 1 , R 2 and R 3 Together with the carbon atoms to which they are attached, they form a bridged 5- to 10-membered carbocyclic or heterocyclic ring system, which is optionally substituted by one or more substituents selected from the group consisting of halo, OR 9 、N(R 9 ) 2 、C(O)OR 9 、C(O)N(R 9 ) 2 、C(O)R 9 、N(R 9 )C(O)R9 ;

[0095] R 9 Each independently selected from H, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0096] X 1 and X 2 Each of the 8

[0097] R 8 is H, halide, OH, CN or NH 2 ;

[0098] Y is a bond or C 1-6 Alkylene;

[0099] R 4 is a 6- to 10-membered aryl, a 5- to 10-membered heteroaryl, or a 5- to 10-membered carbocyclic or heterocyclic ring system, any of which is optionally substituted with one or more substituents selected from:

[0100] Halo, CN, nitro;

[0101] OR 6 , SR 6 NR 6 R 7 、C(O)R 6 C(O)OR 6 、C(O)N(R 6 )(R 7 )、N(R 7 )C(O)R 6 ;

[0102] C 1-6 Alkyl, which is optionally substituted by one or more substituents selected from the group consisting of halo, CN, nitro, OR 6 , SR 6 NR 6 R 7 、C(O)R 6 C(O)OR 6 、C(O)N(R 6 )(R 7 ) and N(R 7 )C(O)R 6 ;and

[0103] Oxo, when R 4 This is true when not completely aromatic in nature;

[0104] Where R 6 It is H, C 1-6Alkyl, C 1-6 Haloalkyl, 3-7 membered carbocyclic group or 3-7 membered heterocyclic group;

[0105] R 7 It is H, C 1-6 Alkyl or C 1-6 haloalkyl; or

[0106] R 6 and R 7 Together with the nitrogen atom to which they are attached, may form a 4 to 7-membered heterocyclic ring, which optionally contains one or more further heteroatoms and is optionally substituted by one or more oxo substituents;

[0107] R 5 It is H, C 1-4 Alkyl or halo.

[0108] In some suitable compounds of the present invention, R 1 H、CN、C(O)OR 12 or methyl, ethyl or ethynyl, which may be substituted with one or more substituents selected from the group consisting of fluorine, OR 12 、N(R 12 ) 2 、C(O)OR 12 、C(O)N(R 12 ) 2 、C(O)R 12 and N(R 13 )C(O)R 12 ;

[0109] Where R 12 and R 13 are each independently as defined above, but are more suitably H or C 1-4 alkyl.

[0110] More appropriately, R 1 is H, CN, C(O)OH, C(O)OMe or methyl, ethyl or ethynyl, any of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of fluorine, OH, methoxy, C(O)OC 1-4 Alkyl, NHC(O)C 1-4 Alkyl, C(O)NHC 1-4 Alkyl, NHC 1-4 Alkyl and NHC 1-4 Fluoroalkyl.

[0111] In some more suitable compounds, R 1 is H, CN, ethynyl or methyl, either of which may be unsubstituted or substituted by OH; in particular H, CN or methyl.

[0112] Among some suitable compounds of the present invention:

[0113] R 2 is methyl or ethyl, in particular methyl; and

[0114] R 3 It is C 1-4 Alkyl, or more suitably C 1-3 Alkyl, such as methyl, ethyl or isopropyl; any of which is optionally substituted by one or more substituents selected from the group consisting of hydroxy, methoxy, ethoxy, -C(O)O-(C 1-4 alkyl) and -N(H)C(O)O-(C 1-4 alkyl).

[0115] In this case, more preferably, R 3 unsubstituted or substituted with a single substituent selected from methoxy, ethoxy and -N(H)C(O)O-(C 1-4 alkyl), especially methoxy or / and -N(H)C(O)O-(C 1-4 alkyl).

[0116] In these compounds, R 1 Suitably it is methyl.

[0117] In other suitable compounds of the present invention, R 2 Is H or C 1-4 Alkyl is more suitably H, methyl or ethyl, especially H or methyl.

[0118] In some suitable compounds of the present invention, R 3 It is C 1-10 Alkyl, more preferably C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, any of which may be optionally substituted as described above.

[0119] More appropriately, R 3 It is C 1-10 Alkyl, more preferably C 1-6 Alkyl or C 2-3 Alkynyl.

[0120] More appropriately, when R 3 When alkyl, alkenyl or alkynyl, it is unsubstituted or substituted with a single substituent selected from the group consisting of fluorine, R 14 OR 14 , OR 15 、C(O)OR 15 、N(R 16 )S(O) 2 R 15 and N(R16 )C(O)OR 15 ; where R 14 , R 15 and R 16 As described above.

[0121] Among these compounds, R 14 is selected from phenyl, pyridyl and a 5- or 6-membered heterocyclic ring, especially a nitrogen-containing ring, and more particularly a 6-membered nitrogen-containing ring, such as morpholine, piperidine or piperazine. More suitably, R 15 Select from H or C 1-4 Alkyl. 16 Suitably H.

[0122] The R 3 Examples of groups include:

[0123] Methyl or ethyl, optionally substituted with OH, F, phenyl, O-phenyl, morpholine, NHS(O) 2 C 1-4 Alkyl or NHC(O)C 1-4 Alkyl substitution;

[0124] Propynyl, for example prop-1-ynyl and ethynyl.

[0125] In other suitable compounds, R 3 is a 3- to 7-membered carbocyclic or heterocyclic ring system, especially C 3-7 Cycloalkyl groups, such as cyclopropyl, may be substituted as defined above, but are more suitably unsubstituted.

[0126] In other suitable compounds of general formula (I), R 3 is a 6- to 10-membered aryl or 5- to 10-membered heteroaryl ring system, any of which is optionally substituted as described above.

[0127] In this case, more preferably, R 3 is optionally substituted phenyl or 5- or 6-membered heteroaryl as defined above, in particular phenyl or pyridinyl.

[0128] The R 3 The group may be unsubstituted or substituted as defined above, in particular selected from OR 17 and N(R 17 ) 2 A suitable substituent is substituted, wherein R 17 Each is independently as defined above, but is more suitably H or methyl.

[0129] In some particularly suitable compounds of the invention, R 1 is methyl or CN, and R 2 and R 3All are methyl.

[0130] In some suitable compounds of the present invention, R 2 and R 3 Combined with the carbon atom to which they are attached they form a carbocyclic or heterocyclic ring system.

[0131] By R 2 and R 3 Suitable carbocyclic rings formed include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; and bridged systems such as bicyclo[1.1.1]pentyl, bicyclo-[2.2.1]heptyl, bicyclo-[2.2.2]octyl and adamantyl, (provided that R 2 and R 3 The atoms connected are not bridge atoms).

[0132] By R 2 and R 3 More suitable carbocyclic rings formed include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0133] By R 2 and R 3 Suitable heterocycles formed include: tetrahydropyran-yl, such as tetrahydropyran-4-yl; tetrahydrofuran-yl, such as tetrahydrofuran-3-yl; oxetanyl, such as oxetan-3-yl; piperidinyl, such as piperidin-2-yl and piperidin-4-yl; morpholinyl, piperazinyl and cyclopropyl-fused pyrrolidine.

[0134] By R 2 and R 3 More suitable heterocyclic rings formed include: tetrahydropyran-yl, such as tetrahydropyran-4-yl; tetrahydrofuran-yl, such as tetrahydrofuran-3-yl; oxetanyl, such as oxetan-3-yl; piperidinyl, such as piperidin-2-yl and piperidin-4-yl; and cyclopropyl-fused pyrrolidine.

[0135] By R 2 and R 3 Any ring system formed may be substituted as described above. In some cases, the ring system is unsubstituted or is selected from OR 9 and C(O)OR 9 A single substituent is substituted, wherein R 9 As defined above, but suitably C 1-4 Alkyl, for example tert-butyl.

[0136] In other suitable compounds, R 2 and R 3 The resulting carbocyclic or heterocyclic ring system may be unsubstituted or substituted by one or more substituents, for example 1 or 2 substituents selected from halogen, OR 9 、C(O)OR9 , unsubstituted C 1-4 Alkyl and halogen or OR 9 Substituted C 1-4 The alkyl substituent is preferably substituted by 1 or 2 groups selected from fluorine, OR 9 、C(O)OR 9 , unsubstituted C 1-4 Alkyl and fluorinated or OR 9 Substituted C 1-4 The alkyl group is substituted with a substituent.

[0137] In particular, by R 2 and R 3 The resulting carbocyclic or heterocyclic ring system may be unsubstituted or substituted by one or more substituents, for example 1 or 2 substituents selected from fluorine, OH, C(O)O(C 1-4 Alkyl), unsubstituted C 1-4 Alkyl or C substituted by OH 1-4 alkyl.

[0138] In some compounds, where R 2 and R 3 To form a carbocyclic or heterocyclic ring system, R 1 It's H.

[0139] In other compounds of this type, R 1 It is methyl.

[0140] In other compounds of this type, R 1 It is a methyl group substituted by OH.

[0141] In other such compounds, R 1 For CN.

[0142] In other such compounds, R 1 It is ethynyl.

[0143] In other such compounds, R 1 C(O)OR 12 , such as C(O)OCH 3 .

[0144] Among particularly suitable compounds, R 2 and R 3 To form a carbocyclic or heterocyclic ring system: R 1 is H or cyano, R 2 and R 3 Forming a 5- or 6-membered carbocyclic or heterocyclic ring system, in particular a 6-membered ring system, for example cyclohexyl or tetrahydropyranyl, such as tetrahydropyran-4-yl.

[0145] In other suitable compounds of the present invention, R 1 , R 2 and R 3 In combination with the carbon atom to which it is attached it forms a bridged carbocyclic or heterocyclic ring system, in particular a carbocyclic ring system, for example bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo-[2.2.1]heptyl, bicyclo-[2.2.2]octyl or adamantyl.

[0146] In some cases, the carbocyclic ring system can be selected from 3-bicyclo[1.1.1]pentyl, bicyclo-[2.2.1]heptyl, bicyclo-[2.2.2]octyl and 1-adamantyl.

[0147] In other cases, the carbocyclic ring system may be selected from bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl and adamantyl, in particular 3-bicyclo[1.1.1]pentyl, 1-bicyclo[2.1.1]hexyl and 1-adamantyl.

[0148] Suitably, the ring system is unsubstituted or is selected from OR 9 and C(O)OR 9 A single substituent is substituted, wherein R 9 As defined above, but suitably is H, methyl or ethyl, especially H or methyl, and more especially methyl. More suitably, the ring system is unsubstituted.

[0149] Alternatively, the ring system may be unsubstituted or substituted with one or more substituents, suitably one or two substituents and more suitably a single substituent, selected from fluoro, cyano, C 1-4 Alkyl, OR 9 and C(O)OR 9 , where R 9 As defined above, but suitably is H, methyl or ethyl, especially H or methyl, and more especially methyl.

[0150] In other suitable compounds of the present invention, R 1 , R 2 and R 3 Combined with the carbon atom to which it is attached it forms a phenyl group which may be substituted as defined above but is more suitably unsubstituted.

[0151] In some suitable compounds of formula (I), X 1 is N, and X 2 CR 8 , where R 8 As defined above. In particular, X 1 N and X 2 For CH.

[0152] Suitably in such compounds, when -Z is C(O)-, and Y is a bond, R 4 Other than a 5- to 10-membered heteroaryl ring system, the ring system is linked to the linker Y via a ring nitrogen atom.

[0153] In other suitable compounds of general formula (I), X 1 and X 2 All CR 8 , where R 8 Each is independently as defined above.

[0154] In this type of compound, R 4 Suitably this is phenyl having an OH substituent in the 2- or 3-position, and optionally having one or more further substituents as defined above.

[0155] More appropriately, R 4 is phenyl having an OH substituent in the 2-position and optionally having one or more further substituents as defined above.

[0156] In other suitable compounds of general formula (I), X 1 CR 8 , where R 8 As defined above, and X 2 is N.

[0157] In some suitable compounds of this type, Z is -C(O)- and Y is not a bond. Thus, Y may be optionally substituted with one or more substituents R as defined above. 18 Substituted straight chain C 1-6 Alkylene chain.

[0158] In other compounds, where X 1 CR 8 , X 2 is N, Z is -C(O)NH-, and Y is a bond, R 4 Suitably it is not a 12-membered heteroaryl ring system.

[0159] In other suitable compounds of general formula (I), wherein X 1 CR 8 , where R 8 As defined above, and X 2 N: When R 1 and R 2 When both are H, R 3 is not an optionally substituted 5- or 6-membered aryl or heteroaryl ring system as described above; and wherein when R 1 When H is 2 and R 3 They do not combine to form a cyclohexyl ring.

[0160] In other suitable compounds of formula (I), X 1 and X 2 All are N.

[0161] In these compounds, suitably when R 1 and R 2 One of them is H, and R 1 and R 2 When the other is H or methyl, R 3 It is not substituted or unsubstituted phenyl.

[0162] In the compounds of the present invention, when X 1 and / or X 2 CR 8 , R 8 Suitably, R is H or a halogen, such as H or fluorine. 8 is H, halogen, OH, methoxy or ethoxy, in particular H, fluorine, chlorine, OH or methoxy.

[0163] As mentioned above, in more suitable compounds of the present invention, Z is -C(O)- or C(O)NH, and the compound has the general formula (Iz), (Iy) or (Ix).

[0164] In some more suitable compounds of the present invention, Y is C 1-3 Alkylene, more preferably -CH 2 -、-CH(CH 3 )CH 2 -or-CH 2 CH 2 -. More suitably, Y is -CH 2 -or-CH 2 CH 2 -, and in particularly suitable compounds, Y is -CH 2 -.

[0165] In other suitable compounds of the invention, Y is a bond.

[0166] In other suitable compounds of the present invention, Y is optionally substituted by one or more substituents R 18 Substituted straight chain C 1-3 Alkylene, where R 18 As defined above, and wherein the two substituents R 18 The groups may be attached to the same or different carbon atoms.

[0167] Suitably, in such compounds, each R 18 are independently methyl or ethyl, or two R 18The groups are attached to the same carbon atom to combine to form a cyclopropyl, cyclobutyl or cyclopentyl ring.

[0168] More suitably, Y is a bond or -C 1-3 Alkylene-.

[0169] Examples of the linking group Y include a bond, -CH 2 -、-CH(CH 3 )-、-CH 2 CH 2 -and

[0170] In other suitable compounds of formula (I), Y is -CH 2 -、-CH 2 CH 2 -、-CH(CH 3 )CH 2 -、-CH 2 CH(CH 3 )-or-CH 2 CH 2 CH 2 -, especially -CH 2 -or-CH 2 CH 2 -, more especially -CH 2 -.

[0171] In some suitable compounds of formula (I), R 5b is H or a halogen, such as fluorine.

[0172] More generally, R 5b is H, so that the compound is a compound of the above general formula (Iz), (Iy) or (Ix).

[0173] In some suitable compounds of formula (I), (Iz) and (Iy), R 5a It is H, C 1-4 Alkyl or halogen, such as fluorine.

[0174] In some suitable compounds of formula (I), (Iz) and (Iy), R 5a is methyl or ethyl, especially methyl.

[0175] In other suitable compounds of formula (I), (Iz) and (Iy), R 5a are the halogens, especially fluorine.

[0176] More generally, in the compounds of formula (I), (Iz) and (Iy), R 5a It's H.

[0177] In some suitable compounds of formula (Ix), R5 It's H.

[0178] In other suitable compounds of the general formula (Ix), R 5 It is C 1-4 Alkyl, more typically methyl or ethyl, and especially methyl.

[0179] In other suitable compounds of the present invention, R 5 are the halogens, especially fluorine.

[0180] In typical compounds of formula (I), R 5a and R 5b Both are H.

[0181] In the compounds of the present invention, R 4 is a 6-14-membered aryl, a 5-14-membered heteroaryl or a 5- to 10-membered carbocyclic ring system, any of which is optionally substituted as defined above. More suitably, R 4 is a 6- to 10-membered aryl, a 5- to 10-membered heteroaryl, or a 5- to 10-membered carbocyclic or heterocyclic ring system, any of which is optionally substituted by one or more substituents as described above.

[0182] In some more suitable compounds of formula (I), R 4 is a 6- to 11-membered aryl group, for example a group selected from phenyl, naphthyl, indanyl, 1,2,3,4-tetrahydronaphthyl and benzocycloheptyl, any of which is optionally substituted as described above.

[0183] In other more suitable compounds of general formula (I), R 4 is a 5- to 10-membered heteroaryl group, for example a group selected from pyridyl, quinolyl, quinoxalinyl, indazolyl, indolyl, benzoxazolyl, dihydrobenzofuranyl, furanyl and thienyl, any of which is optionally substituted as described above.

[0184] In some other more suitable compounds of general formula (I), R 4 is a carbocyclic group, for example a group selected from cyclohexyl and adamantyl, either of which is unsubstituted or substituted as described above.

[0185] In some suitable compounds of the present invention, R 4 is phenyl which is optionally substituted by one or more substituents as described above.

[0186] Or, R 4 is a 5-10-membered heteroaryl group optionally substituted by one or more substituents as described above, in which case R 4 is pyridyl, pyrrolyl, thienyl, furyl, benzoxazolyl, imidazolyl, indolyl or indazolyl.

[0187] In some suitable compounds, R 4 Substituted with one or more substituents selected from the following:

[0188] Halogen, CN;

[0189] OR 6 NR 6 R 7 、C(O)OR 6 、C(O)N(R 6 )(R 7 );

[0190] C optionally substituted by one or more substituents selected from the following 1-6 Alkyl: halogen, CN, OR 6 NR 6 R 7 、C(O)OR 6 and C(O)N(R 6 )(R 7 );

[0191] Where R 6 It is H, C 1-6 Alkyl, C 1-6 Haloalkyl, 3-7 membered carbocyclic group or 3-7 membered heterocyclic group;

[0192] R 7 It is H, C 1-6 Alkyl or C 1-6 haloalkyl; or

[0193] R 6 and R 7 Together with the nitrogen atom to which they are attached they may form a 5- or 6-membered heterocyclic ring which optionally contains one or more further heteroatoms and which is optionally substituted by one or more oxo substituents.

[0194] In other suitable compounds, wherein R 4 is an aryl group, which is more preferably unsubstituted or substituted by one or more substituents selected from the following:

[0195] Halogen, CN, R 19 , OR 19 ;

[0196] OR 6 、C(O)OR 6 ;

[0197] C 1-4 Alkyl or O(C 1-4 alkyl), which is optionally substituted by one or more substituents selected from the group consisting of halogen, CN, R 19 , OR19 , OR 6 and NR 6 R 7 ;

[0198] Where R 6 , R 7 and R 19 As defined above.

[0199] However, more preferably, R 6 It is H, C 1-4 Alkyl or C 1-4 haloalkyl, or for NR 6 R 7 , R 6 With R 7 Combined with the nitrogen atom to which it is attached, it forms a 5- or 6-membered heterocyclic ring which optionally contains one or more further heteroatoms and which is optionally substituted by one or more halo substituents.

[0200] R 19 More suitably it is a 3- to 6-membered carbocyclyl or phenyl, any of which is optionally substituted by one or more substituents selected from halogen, methyl and methoxy.

[0201] In particularly suitable compounds, R 4 is phenyl substituted in the 2- or 3-position by an OH group and optionally substituted by one or more further substituents as defined for general formula (I), more suitably substituted by one or more further substituents, for example one selected from the other substituents as defined immediately above.

[0202] When R 4 When it is a bicyclic aryl group, it is more preferably unsubstituted or substituted by one or two substituents selected from OH and halogen.

[0203] When R 4 When heteroaryl, it is more preferably unsubstituted or substituted by one or more substituents selected from OH and halogen.

[0204] When R 4 When it is a carbocyclic group, it is more preferably unsubstituted or substituted by one or more substituents selected from OH and halogen.

[0205] More suitably, it is unsubstituted.

[0206] In particularly suitable compounds of the invention, Y is -CH 2 -, R 4 is phenyl and the compound is a compound of general formula (Ia):

[0207]

[0208] in

[0209] R 1 , R 2 , R 3 , R 5a , X 1 and X 2 As defined in general formula (I);

[0210] R 10 H, OH, halogen, C 1-6 Alkyl, -O(C 1-6 alkyl);

[0211] R 11 are independently H, halogen, OH, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, -O(C 1-6 alkyl) or C(O)O-(C 1-6 alkyl); and

[0212] n is 1 or 2.

[0213] More suitably, the compound is a compound of formula (Ib) or (Ic):

[0214]

[0215]

[0216] in

[0217] R 1 , R 2 , R 3 , R 5a , X 1 and X 2 As defined in general formula (I);

[0218] R 11a H, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl or C(O)O(C 1-4 alkyl);

[0219] R 11b H, halogen, C 1-4 Alkyl or C 1-4 haloalkyl; and

[0220] R 11c H, halogen, CN, C 1-4 Alkyl or C 1-4 Halogenated alkyl.

[0221] In particularly suitable compounds of the general formula (Ib), R 11a and R11b One or both of them are H.

[0222] In some such compounds of Formula (Ib), R 11a H, halogen, C 1-4 Alkyl or C(O)O(C 1-4 alkyl), and R 11b It's H.

[0223] More appropriately, R 11a It is H, Cl, C 1-4 Alkyl or C(O)OCH 3 , and R 11b It's H.

[0224] In some compounds of formula (Ib), R 11a is chlorine and R 11b It's H.

[0225] In other such compounds of formula (Ib), R 11a is H, and R 11b is H, halo or C 1-6 Halogenated alkyl.

[0226] More appropriately, R 11a is H, and R 11b is H, chloro, bromo or trifluoromethyl.

[0227] Alternatively, in other particularly suitable compounds of the general formula (Ib), R 11a and R 11b Both are halo, in particular chloro or bromo.

[0228] In some particularly suitable compounds of formula (Ic), R 11a It's H.

[0229] More preferably, in the compound of general formula (Ic), R 11b C 1-4 Alkyl or C 1-4 Haloalkyl, for example tert-butyl.

[0230] In the compounds of general formula (Ia) and (Ib), suitable R 1 , R 2 , R 3 , R 5 , X 1 and X 2 The groups are as described above for compounds of general formula (I). However, more suitably, X 1 N, X 2 is CH, and R 5b is H, so that the compound is of the general formula (Id) or (Ie):

[0231]

[0232]

[0233] Where R 1 , R 2 , R 3 , R 11a , R 11b and R 11c are as defined above in the compounds of formula (Ib) and (Ic).

[0234] Particularly suitable groups R in the general formula (Id) are 11a and R 11b As defined above in the general formula (Ib), particularly suitable radicals R in the general formula (Ie) are 11a and R 11b As defined above in formula (Ic).

[0235] Suitable compounds of general formula (I) include:

[0236] Specific examples of compounds of general formula (I) include the following:

[0237] N-tert-butyl-4-[[2-(2-hydroxyphenyl)acetyl]amino]pyridine-2-carboxamide (Compound 1);

[0238] N-(1,1-dimethylpropyl)-3-[[2-(2-hydroxyphenyl)acetyl]amino]benzamide (Compound 1.1);

[0239] N-(1-adamantyl)-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 1.2);

[0240] N-(1-adamantyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 1.3);

[0241] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-methoxy-1,1-dimethyl-propyl)pyridine-2-carboxamide (Compound 1.4);

[0242] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylpropyl)benzamide (Compound 1.5);

[0243] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide (Compound 1.6);

[0244] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclohexyl)pyridine-2-carboxamide (Compound 1.7);

[0245] N-[3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]-3-methyl-butyl]carbamic acid tert-butyl ester (Compound 1.8);

[0246] 3-[[2-(2-Hydroxyphenyl)acetyl]amino]-N-(2-methoxy-1,1-dimethyl-ethyl)benzamide (Compound 1.9);

[0247] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-cyclohexyl-pyridine-2-carboxamide (Compound 1.10);

[0248] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2);

[0249] N-tert-butyl-3-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.1);

[0250] N-tert-butyl-3-[[2-(3-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.2);

[0251] N-tert-butyl-3-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.3);

[0252] N-tert-butyl-3-[[2-(2,6-dihydroxyphenyl)acetyl]amino]benzamide (Compound 2.4);

[0253] N-tert-butyl-3-[3-(2-hydroxyphenyl)propionylamino]benzamide (Compound 2.5);

[0254] N-tert-butyl-3-[[2-(2-hydroxy-6-methoxy-phenyl)acetyl]amino]benzamide (Compound 2.6);

[0255] N-tert-butyl-3-[2-(2-hydroxyphenyl)propionylamino]benzamide (Compound 2.7);

[0256] N-tert-butyl-3-[[2-(2-hydroxy-3-methoxy-phenyl)acetyl]amino]benzamide (Compound 2.8);

[0257] N-tert-butyl-3-[[2-(3,5-difluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.9);

[0258] 3-[[2-(5-Bromo-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-benzamide (Compound 2.10);

[0259] N-tert-butyl-3-[[2-(2,3-difluoro-6-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.11);

[0260] N-tert-butyl-3-[[2-(4,5-difluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.12);

[0261] N-(1,1-dimethylpropyl)-3-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.13);

[0262] N-tert-butyl-3-[[2-(2-hydroxy-4-methoxy-phenyl)acetyl]amino]benzamide (Compound 2.14);

[0263] N-tert-butyl-3-[[2-(2-fluoro-6-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.15);

[0264] N-tert-butyl-3-[[2-(2,3-dihydroxyphenyl)acetyl]amino]benzamide (Compound 2.16);

[0265] N-tert-butyl-3-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]benzamide (Compound 2.17);

[0266] 3-[2-[3-(tert-Butylcarbamoyl)anilino]-2-oxo-ethyl]-4-hydroxy-benzoic acid methyl ester (Compound 2.18);

[0267] N-tert-butyl-3-[[2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetyl]amino]benzamide (Compound 2.19);

[0268] N-tert-butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3);

[0269] N-(1,1-dimethylpropyl)-4-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.1a);

[0270] N-tert-butyl-4-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.2a);

[0271] N-tert-butyl-4-[[2-(2-chloro-6-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.3a);

[0272] 4-[[2-(4-bromo-5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 3.4a);

[0273] 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide (Compound 3.5a);

[0274] 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide (Compound 3.6a);

[0275] N-tert-butyl-4-[2-(2,5-dibromo-3-fluoro-6-hydroxyphenyl)acetylamino]pyridine-2-carboxamide (Compound 3.7a);

[0276] N-tert-butyl-4-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 3.5b);

[0277] N-tert-butyl-4-[[2-(4-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.6b);

[0278] N-tert-butyl-4-[[2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 3.7b);

[0279] N-tert-butyl-4-[[2-(2-hydroxy-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.8b);

[0280] N-tert-butyl-4-[(6-hydroxyindane-1-carbonyl)amino]pyridine-2-carboxamide (Compound 3.9b);

[0281] N-tert-butyl-4-[(7-hydroxyindane-1-carbonyl)amino]pyridine-2-carboxamide (Compound 3.10b);

[0282] N-tert-butyl-4-[[2-(2,5-dibromo-3-chloro-6-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.11b);

[0283] N-tert-butyl-4-[[2-(3-hydroxyphenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.12b);

[0284] N-tert-butyl-4-[[2-(2-fluoro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.13b);

[0285] N-tert-butyl-4-[[2-(4-chloro-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.14b);

[0286] N-tert-butyl-4-[[2-(2-chloro-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.15b);

[0287] N-tert-butyl-4-[[2-(2-chloro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.16b);

[0288] N-tert-butyl-4-[[2-(3-chloro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.17b);

[0289] N-tert-butyl-3-[[2-(3-hydroxyphenyl)acetyl]amino]benzamide (Compound 4);

[0290] N-tert-butyl-3-[[2-(1H-indazol-3-yl)acetyl]amino]benzamide (Compound 4.1);

[0291] N-tert-butyl-3-[[2-(5-fluoro-1H-indol-3-yl)acetyl]amino]benzamide (Compound 4.2);

[0292] N-tert-butyl-3-[[2-(2-hydroxyphenyl)acetyl]amino]benzamide (Compound 4.3);

[0293] N-tert-butyl-3-[[2-(7-fluoro-2-methyl-1H-indol-3-yl)acetyl]amino]benzamide (Compound 4.4);

[0294] N-tert-butyl-3-[[2-(1H-indol-3-yl)acetyl]amino]benzamide (Compound 4.5);

[0295] N-tert-butyl-3-[(2-phenylacetyl)amino]benzamide (Compound 4.6);

[0296] N-tert-butyl-3-[[2-(2-fluoro-6-methoxy-phenyl)acetyl]amino]benzamide (Compound 4.7);

[0297] N-tert-butyl-3-[[2-(2,3-difluoro-6-methoxy-phenyl)acetyl]amino]benzamide (Compound 4.8);

[0298] N-tert-butyl-3-[[2-[2-methoxy-4-(trifluoromethyl)phenyl]acetyl]amino]benzamide (Compound 4.9);

[0299] N-tert-butyl-4-[[2-(2-thienyl)acetyl]amino]pyridine-2-carboxamide (Compound 5);

[0300] 4-[[2-(2-adamantyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 5.1);

[0301] N-tert-butyl-4-[[2-(4-fluoro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.2);

[0302] N-tert-butyl-4-[[2-(5-chloro-2-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.3);

[0303] N-tert-butyl-4-[[2-(2-furyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.4);

[0304] N-tert-butyl-4-[[2-(3-chlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.5);

[0305] N-tert-butyl-4-[[2-(1H-indol-3-yl)acetyl]amino]pyridine-2-carboxamide (Compound 5.6);

[0306] N-tert-butyl-4-[[2-(o-tolyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.7);

[0307] N-tert-butyl-4-[[2-(3,4-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.8);

[0308] N-tert-butyl-4-[[2-(3-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.9);

[0309] N-tert-butyl-4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.10);

[0310] N-tert-butyl-4-[[2-(p-methylphenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.11);

[0311] N-tert-butyl-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.12);

[0312] N-tert-butyl-4-[[2-(4-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.13);

[0313] N-tert-butyl-4-[[2-(m-tolyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.14);

[0314] 4-[[2-(1,3-Benzoxazol-6-yl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 5.15);

[0315] N-tert-butyl-4-[[2-(2-chloro-3-pyridinyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.16);

[0316] N-tert-butyl-4-[[2-(2,6-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.17);

[0317] N-tert-butyl-4-[[2-(4-chloro-3-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.18);

[0318] N-tert-butyl-4-[[2-(3,5-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.19);

[0319] N-tert-butyl-4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.20);

[0320] N-tert-butyl-4-[[2-(3-chloro-4-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.21);

[0321] N-tert-butyl-4-(indane-1-carbonylamino)pyridine-2-carboxamide (Compound 5.22);

[0322] N-tert-butyl-4-[(2-quinoxalin-6-ylacetyl)amino]pyridine-2-carboxamide (Compound 5.23);

[0323] N-tert-butyl-4-[[2-(2-naphthyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.24);

[0324] N-tert-butyl-4-(2,3-dihydrobenzofuran-3-carbonylamino)pyridine-2-carboxamide (Compound 5.25);

[0325] N-tert-butyl-4-(6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-carbonylamino)pyridine-2-carboxamide (Compound 5.26);

[0326] N-tert-butyl-4-(1,2,3,4-tetrahydronaphthalene-1-carbonylamino)pyridine-2-carboxamide (Compound 5.27);

[0327] N-tert-butyl-4-[[2-(6-quinolinyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.29);

[0328] N-tert-butyl-4-[[1-(3-chlorophenyl)cyclopropanecarbonyl]amino]pyridine-2-carboxamide (Compound 5.31);

[0329] N-tert-butyl-4-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)acetyl]amino]pyridine-2-carboxamide (Compound 5.32);

[0330] N-(1,1-dimethylprop-2-ynyl)-4-[(2-isochroman-1-ylacetyl)amino]pyridine-2-carboxamide (Compound 5.33);

[0331] 4-[[2-(4,4-difluorocyclohexyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 5.34);

[0332] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 5.35);

[0333] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)-1H-pyrazol-4-yl]acetyl]amino]pyridine-2-carboxamide (Compound 5.36);

[0334] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 5.37);

[0335] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 5.38);

[0336] 4-[[2-(2,3-dihydro-1,4-benzoxazin-4-yl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 5.39);

[0337] N-tert-butyl-4-[[2-(5-cyano-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 6);

[0338] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2,2-tetramethylpropyl)benzamide (Compound 7);

[0339] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylbutyl)benzamide (Compound 7.1);

[0340] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylbutyl)pyridine-2-carboxamide (Compound 7.2);

[0341] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-cyclohexyl-benzamide (Compound 7.3);

[0342] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-tetrahydropyran-4-yl-benzamide (Compound 7.4);

[0343] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2-trimethylpropyl)benzamide (Compound 7.5);

[0344] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2-trimethylpropyl)pyridine-2-carboxamide (Compound 7.6);

[0345] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-isopropyl-pyridine-2-carboxamide (Compound 7.7);

[0346] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)benzamide (Compound 7.8);

[0347] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 7.9);

[0348] 3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)benzamide (Compound 7.10);

[0349] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-tetrahydropyran-4-yl-pyridine-2-carboxamide (Compound 7.11);

[0350] 4-[2-(5-chloro-2-hydroxyphenyl)acetylamino]-N-[(1s,4s)-4-hydroxycyclohexyl]pyridine-2-carboxamide (Compound 7.12);

[0351] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-sec-butyl-pyridine-2-carboxamide (Compound 7.13);

[0352] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-hydroxy-1,1,2-trimethyl-propyl)pyridine-2-carboxamide (Compound 7.14);

[0353] N-(3-Bicyclo[1.1.1]pentyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 7.15);

[0354] 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide (Compound 7.16);

[0355] 3-[[3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzoyl]amino]piperidine-1-carboxylic acid tert-butyl ester (Compound 8);

[0356] 3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]piperidine-1-carboxylic acid tert-butyl ester (Compound 8.1);

[0357] 4-[[3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]benzoyl]amino]-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (Compound 8.2);

[0358] (1r,5s,6s)-6-{4-[2-(5-chloro-2-hydroxyphenyl)acetylamino]pyridine-2-amido}-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (Compound 8.3);

[0359] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-fluoro-benzamide (Compound 9);

[0360] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-methyl-benzamide (Compound 9.1);

[0361] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylpropyl)pyridine-2-carboxamide (Compound 9.2);

[0362] N-tert-butyl-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 10);

[0363] N-tert-butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-hydroxy-benzamide (Compound 11);

[0364] N-tert-butyl-3-[[2-(5-cyano-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 12);

[0365] 3-[2-[[2-(tert-Butylcarbamoyl)-4-pyridinyl]amino]-2-oxo-ethyl]-4-hydroxy-benzoic acid methyl ester (Compound 13);

[0366] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-hydroxy-benzamide (Compound 14);

[0367] N-tert-butyl-4-[[2-(2-hydroxy-5-methyl-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 15);

[0368] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-methoxy-benzamide (Compound 16);

[0369] N-tert-Butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-fluoro-benzamide (Compound 17);

[0370] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-benzamide (Compound 18);

[0371] N-tert-butyl-4-[[2-(3-hydroxy-2-pyridinyl)acetyl]amino]pyridine-2-carboxamide (Compound 19);

[0372] N-tert-butyl-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 20);

[0373] N-tert-butyl-4-[[(1R) or (1S)-indane-1-carbonyl]amino]pyridine-2-carboxamide (Compound 21a);

[0374] N-tert-butyl-4-[[(1R) or (1S)-indane-1-carbonyl]amino]pyridine-2-carboxamide (Compound 21b);

[0375] N-tert-Butyl-4-[(2-phenylacetyl)amino]pyridine-2-carboxamide (Compound 22);

[0376] 4-(3,3-dimethylbutyrylamino)-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 22.1);

[0377] 4-[(2-Cyclopentylacetyl)amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 22.2);

[0378] 4-[[2-(3-chloro-4-pyridinyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 22.3);

[0379] 4-[[2-(4-Chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 23);

[0380] 4-[[2-(3-chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 23.1);

[0381] 4-[[2-(2-Chloro-5-fluoro-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 23.2);

[0382] N-tert-butyl-4-(indane-2-carbonylamino)pyridine-2-carboxamide (Compound 23.3);

[0383] N-tert-butyl-4-[[2-[2-(difluoromethoxy)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 23.4);

[0384] N-tert-butyl-4-[[2-[2-(difluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 23.5);

[0385] N-tert-butyl-4-[[2-(3,4-difluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.6);

[0386] N-tert-butyl-4-[[2-(3,5-difluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.7);

[0387] N-tert-butyl-4-[[2-(2,3-difluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.8);

[0388] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-tetrahydropyran-4-yl-pyridine-2-carboxamide (Compound 23.9);

[0389] N-(1-cyanocyclobutyl)-4-[[2-(6-quinolinyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.11);

[0390] N-tert-butyl-4-[[2-[2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 23.12);

[0391] 4-[[2-(2-bromophenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 23.13);

[0392] N-tert-butyl-4-[[2-(2-cyanophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.14);

[0393] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 23.15);

[0394] N-(4-cyanotetrahydropyran-4-yl)-4-[[2-(6-quinolinyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.16);

[0395] 4-[[2-(2-Chloro-5-methoxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 24);

[0396] N-(3-Bicyclo[1.1.1]pentyl)-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 25);

[0397] -[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 25.1);

[0398] N-tert-butyl-4-[[2-(2-hydroxy-5-phenyl-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 26);

[0399] N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-4-(pyrrolidin-1-ylmethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 27);

[0400] N-tert-butyl-4-[[2-[4-[(tert-butylamino)methyl]-5-chloro-2-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 27.1);

[0401] N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-4-(morpholinomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 27.2);

[0402] N-tert-butyl-4-[[2-[5-chloro-4-[(3,3-difluoropyrrolidin-1-yl)methyl]-2-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 27.3);

[0403] N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxamide (Compound 28);

[0404] N-tert-butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-3-fluoro-pyridine-2-carboxamide (Compound 28.1);

[0405] 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide (Compound 30);

[0406] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 30.1);

[0407] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[2.1.1]hexyl)pyridine-2-carboxamide (Compound 30.2);

[0408] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyclopropyl-1-methyl-ethyl)pyridine-2-carboxamide (Compound 30.3);

[0409] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 30.3a);

[0410] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-methyl-3-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide (Compound 30.4);

[0411] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyano-3-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide (Compound 30.5);

[0412] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(2,2-difluorocyclopropyl)pyridine-2-carboxamide (Compound 30.6);

[0413] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 30.7);

[0414] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide (Compound 30.8);

[0415] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(3-fluoro-1-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide (Compound 30.9);

[0416] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(2-fluoro-1,1-dimethyl-ethyl)pyridine-2-carboxamide (Compound 30.10);

[0417] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(4-ethynyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 30.11);

[0418] 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyanocyclopentyl)pyridine-2-carboxamide (Compound 30.12);

[0419] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(2,2-difluoro-1,1-dimethyl-ethyl)pyridine-2-carboxamide (Compound 30.13);

[0420] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 31);

[0421] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclopentyl)pyridine-2-carboxamide (Compound 31.2);

[0422] 4-[2-(5-chloro-2-hydroxyphenyl)acetylamino]-N-[(1s,2s)-2-hydroxycyclohexyl]pyridine-2-carboxamide (Compound 31.3);

[0423] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2S)-2-hydroxycyclohexyl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2R)-2-hydroxycyclohexyl]pyridine-2-carboxamide (Compound 31.3a);

[0424] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-ethynyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 31.4);

[0425] N-[(6-amino-2-pyridinyl)methyl]-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 32);

[0426] 12-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]dodecanoic acid (Compound 32.1);

[0427] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-pyridylmethyl)pyridine-2-carboxamide (Compound 32.2);

[0428] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-pyridinylmethyl)pyridine-2-carboxamide (Compound 32.3);

[0429] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-pyridinylmethyl)pyridine-2-carboxamide (Compound 32.4);

[0430] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(2-hydroxyphenyl)methyl]pyridine-2-carboxamide (Compound 32.5);

[0431] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethyl-2-morpholino-ethyl)pyridine-2-carboxamide (Compound 32.6);

[0432] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-hydroxy-1,1-dimethyl-ethyl)pyridine-2-carboxamide (Compound 32.7);

[0433] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3,3-difluoro-4-piperidinyl)pyridine-2-carboxamide (Compound 32.8);

[0434] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1H-imidazol-2-yl)pyridine-2-carboxamide (Compound 32.9);

[0435] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2R)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 33);

[0436] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 34);

[0437] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 35);

[0438] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3R)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3S)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 35a);

[0439] -[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3R)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide or 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3S)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 35b);

[0440] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-hydroxy-4-methyl-cyclohexyl)pyridine-2-carboxamide as a 6:4 mixture of stereoisomers (Compound 35.1);

[0441] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1s,2r)-2-(hydroxymethyl)cyclohexyl]pyridine-2-carboxamide (Compound 35.2);

[0442] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1s,3r)-3-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 35.3);

[0443] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-1-methyl-ethyl]pyridine-2-carboxamide (Compound 35.4);

[0444] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-hydroxycyclohexyl)pyridine-2-carboxamide as a mixture of stereoisomers (Compound 35.6);

[0445] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-phenoxypropyl)pyridine-2-carboxamide (Compound 35.7);

[0446] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide (Compound 35.8);

[0447] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-methyl-1-(2-pyridinyl)ethyl]pyridine-2-carboxamide (Compound 35.9);

[0448] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-phenylpropyl)pyridine-2-carboxamide (Compound 35.10);

[0449] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[2-hydroxy-1-(2-pyridinyl)ethyl]pyridine-2-carboxamide (Compound 35.11);

[0450] 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(5-methoxy-2-pyridinyl)methyl]pyridine-2-carboxamide (Compound 35.12);

[0451] 3-[[4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]-3-methyl-butyric acid ethyl ester (Compound 35.13);

[0452] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-hydroxy-1,1-dimethyl-propyl)pyridine-2-carboxamide (Compound 35.14);

[0453] N-benzyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 35.15);

[0454] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-phenyl-pyridine-2-carboxamide (Compound 35.16);

[0455] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 35.17);

[0456] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 35.18);

[0457] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2R)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 35.19);

[0458] 3-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclohexyl)benzamide (Compound 35.20);

[0459] N-(1,1-dimethylprop-2-ynyl)-3-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 35.21);

[0460] N-cyclohexyl-3-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 35.22);

[0461] 3-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]benzamide (Compound 35.23);

[0462] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclohexyl)pyridine-2-carboxamide (Compound 35.24);

[0463] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide (Compound 35.25);

[0464] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)oxetan-3-yl]pyridine-2-carboxamide (Compound 35.26);

[0465] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-methoxy-1-methyl-ethyl)pyridine-2-carboxamide (Compound 35.27);

[0466] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1-hydroxycyclobutyl)methyl]pyridine-2-carboxamide (Compound 35.28);

[0467] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 36);

[0468] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1,2-dimethyl-propyl)pyridine-2-carboxamide (Compound 37);

[0469] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopentyl)pyridine-2-carboxamide (Compound 38);

[0470] N-(4-tert-Butylcyclohexyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 39);

[0471] N-tert-butyl-4-[[2-(2-chloro-3-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 40);

[0472] N-tert-butyl-4-[[2-(2-chloro-5-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 40.1);

[0473] N-(4-cyanotetrahydropyran-4-yl)-3-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 41);

[0474] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[4-(2-hydroxyethyl)tetrahydropyran-4-yl]pyridine-2-carboxamide (Compound 42);

[0475] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1,1-dimethyl-3-(2,2,2-trifluoroethylamino)propyl]pyridine-2-carboxamide (Compound 43);

[0476] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[2.1.1]hexyl)pyridine-2-carboxamide (Compound 44);

[0477] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(2,2-dimethylpropionylamino)-1,1-dimethyl-propyl]pyridine-2-carboxamide (Compound 45);

[0478] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-hydroxy-1-methyl-ethyl)pyridine-2-carboxamide (Compound 46);

[0479] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 46a);

[0480] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 46b);

[0481] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-cyanotetrahydrofuran-3-yl)pyridine-2-carboxamide (Compound 47);

[0482] 2-[4-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]tetrahydropyran-4-yl]acetic acid methyl ester (Compound 47.1);

[0483] 4-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]tetrahydropyran-4-carboxylic acid methyl ester (Compound 47.2);

[0484] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-cyanoxetan-3-yl)pyridine-2-carboxamide (Compound 47.3);

[0485] 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide (Compound 48);

[0486] N-(4-cyanotetrahydropyran-4-yl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 48.1);

[0487] N-[3-(tert-Butylamino)-1,1-dimethyl-3-oxo-propyl]-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 49);

[0488] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(methylsulfonylamino)-1,1-dimethyl-propyl]pyridine-2-carboxamide (Compound 50);

[0489] N-(3-Acetylamino-1,1-dimethyl-propyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 51);

[0490] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[4-(hydroxymethyl)tetrahydropyran-4-yl]pyridine-2-carboxamide (Compound 53);

[0491] N-tert-butyl-4-[[2-[3-(1-hydroxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 54);

[0492] N-tert-Butyl-5-chloro-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 55);

[0493] N-tert-butyl-4-[[2-[5-chloro-2-[(4-methoxyphenyl)methoxy]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 56);

[0494] N-tert-butyl-4-[[(1S) or (1R)-4-chloro-7-hydroxy-indane-1-carbonyl]amino]pyridine-2-carboxamide and Example 57b: N-tert-butyl-4-[[(1S) or (1R)-4-chloro-7-hydroxy-indane-1-carbonyl]amino]pyridine-2-carboxamide (Compound 57a);

[0495] N-tert-butyl-4-[[(1S) or (1R)-4-chloro-7-hydroxy-indane-1-carbonyl]amino]pyridine-2-carboxamide and Example 57b: N-tert-butyl-4-[[(1S) or (1R)-4-chloro-7-hydroxy-indane-1-carbonyl]amino]pyridine-2-carboxamide (Compound 57b);

[0496] N-tert-butyl-4-[[2-(2-cyclopropylphenyl)acetyl]amino]pyridine-2-carboxamide (Compound 58);

[0497] 4-[[2-(3-Bromo-5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 59);

[0498] N-(4-fluoro-1-bicyclo[2.1.1]hexyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 60);

[0499] N-(1-cyano-2-hydroxy-1-methyl-ethyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 60.1);

[0500] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 60.2);

[0501] N-tert-butyl-4-[[2-(5-chloro-2-hydroxy-3-isopropyl-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 61);

[0502] N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-3-(1-methoxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 62);

[0503] 4-[[2-(6-Quinolinyl)acetyl]amino]-N-tetrahydropyran-4-yl-pyridine-2-carboxamide (Compound 63);

[0504] 4-(Benzylcarbamoylamino)-N-tert-butyl-pyridine-2-carboxamide (Compound 64);

[0505] N-tert-butyl-4-(cyclohexylmethylcarbamoylamino)pyridine-2-carboxamide (Compound 64.1);

[0506] N-tert-butyl-4-(2-phenylethylcarbamoylamino)pyridine-2-carboxamide (Compound 64.2);

[0507] N-tert-butyl-4-[[(1R)-1-phenylethyl]carbamoylamino]pyridine-2-carboxamide (Compound 64.3);

[0508] N-tert-butyl-4-[[(1S)-1-phenylethyl]carbamoylamino]pyridine-2-carboxamide (Compound 64.4);

[0509] N-tert-butyl-4-[(2-chlorophenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 64.5);

[0510] N-tert-butyl-4-(1H-indol-3-ylcarbamoylamino)pyridine-2-carboxamide (Compound 64.6);

[0511] N-tert-butyl-4-[(3-chlorophenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 64.7);

[0512] N-tert-butyl-4-[(4-chlorophenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 64.8);

[0513] N-tert-butyl-4-[(2-hydroxyphenyl)carbamoylamino]pyridine-2-carboxamide (Compound 65);

[0514] N-tert-butyl-4-[(2-methoxyphenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 65.1);

[0515] N-tert-butyl-4-[(2-hydroxyphenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 65.2);

[0516] N-tert-butyl-4-[(3-hydroxyphenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 65.3);

[0517] N-tert-butyl-4-[(4-hydroxyphenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 65.4);

[0518] N-tert-butyl-4-[[2-[2-hydroxy-5-(1-hydroxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 66);

[0519] N-tert-butyl-4-[[2-[2-hydroxy-5-[1-(2,2,2-trifluoroethylamino)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 67);

[0520] N-tert-butyl-4-[[2-[3-(cyanomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 68);

[0521] N-tert-butyl-4-[[2-[3-(methoxymethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 69);

[0522] N-tert-butyl-4-[[2-[2-hydroxy-5-(morpholinomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 70);

[0523] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-cyanotetrahydrofuran-3-yl)benzamide (Compound 71);

[0524] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclohexyl)benzamide (Compound 71.1);

[0525] 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 72);

[0526] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)-2-methoxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 73);

[0527] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylbut-2-ynyl)pyridine-2-carboxamide (Compound 73.1);

[0528] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)benzamide (Compound 74);

[0529] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]benzamide (Compound 74.1);

[0530] N-tert-butyl-4-[[2-[2-hydroxy-5-(3-hydroxypropyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 75);

[0531] 4-[[2-(5-Chloro-4-fluoro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide (Compound 76);

[0532] 4-[[2-(2,5-difluorophenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 77);

[0533] 4-[[2-(2,5-difluorophenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[2.1.1]hexyl)pyridine-2-carboxamide (Compound 77.1);

[0534] 4-[[2-(4-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 78);

[0535] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 78.1);

[0536] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 78.2);

[0537] 4-[(2-Chroman-4-ylacetyl)amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 79);

[0538] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(1-isopropyl-3,5-dimethyl-pyrazol-4-yl)acetyl]amino]pyridine-2-carboxamide (Compound 79.1);

[0539] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(1H-indazol-4-yl)acetyl]amino]pyridine-2-carboxamide (Compound 79.2);

[0540] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(1H-indol-7-yl)acetyl]amino]pyridine-2-carboxamide (Compound 79.3);

[0541] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)benzamide (Compound 80);

[0542] N-(1-cyano-1-methyl-ethyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 81);

[0543] N-(1-cyano-2-hydroxy-1-methyl-ethyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 81.1);

[0544] 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-isopropyl-pyridine-2-carboxamide (Compound 81.2);

[0545] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 81.3);

[0546] N-(4-Fluoro-1-bicyclo[2.1.1]hexyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 81.4);

[0547] 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide (Compound 81.5);

[0548] N-tert-butyl-6-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyrimidine-4-carboxamide (Compound 82);

[0549] N-(1-cyano-1-methyl-ethyl)-4-(thiophene-3-carbonylamino)pyridine-2-carboxamide (Compound 83);

[0550] N-(1-cyano-1-methyl-ethyl)-4-[(2-cyclohexylacetyl)amino]pyridine-2-carboxamide (Compound 83.1);

[0551] N-(1-cyano-1-methyl-ethyl)-4-(cyclohexanecarbonylamino)pyridine-2-carboxamide (Compound 83.2);

[0552] N-(1-cyano-1-methyl-ethyl)-4-[(3,3-difluorocyclopentanecarbonyl)amino]pyridine-2-carboxamide (Compound 83.3);

[0553] N-(1-cyano-1-methyl-ethyl)-4-[(1-methylcyclopentanecarbonyl)amino]pyridine-2-carboxamide (Compound 83.4);

[0554] N-(1-cyano-1-methyl-ethyl)-4-(3-cyclohexylpropionylamino)pyridine-2-carboxamide (Compound 83.5);

[0555] 4-(2-{Bicyclo[2.2.1]hept-2-yl}acetylamino)-N-(1-cyano-1-methylethyl)pyridine-2-carboxamide (Compound 83.6);

[0556] N-(1-cyano-1-methyl-ethyl)-4-[[2-(1-methylcyclohexyl)acetyl]amino]pyridine-2-carboxamide (Compound 83.7);

[0557] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-2-cyclopropyl-pyrimidine-5-carboxamide (Compound 83.8);

[0558] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-3-isobutyl-isoxazole-5-carboxamide (Compound 83.9);

[0559] N-(1-cyano-1-methyl-ethyl)-4-[[2-(4,4-difluorocyclohexyl)acetyl]amino]pyridine-2-carboxamide (Compound 83.10);

[0560] 4-[(1-Benzylcyclopropanecarbonyl)amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 83.11);

[0561] N-(1-cyano-1-methyl-ethyl)-4-[3-(2-methoxy-4-pyridinyl)propionylamino]pyridine-2-carboxamide (Compound 83.13);

[0562] 4-[(5-tert-Butyl-2-methyl-pyrazole-3-carbonyl)amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 83.14);

[0563] N-(1-cyano-1-methyl-ethyl)-4-[(2-pyrazol-1-ylbenzoyl)amino]pyridine-2-carboxamide (Compound 83.15);

[0564] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl-6-(trifluoromethyl)pyridine-2-carboxamide (Compound 83.16);

[0565] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-3-oxo-4H-1,4-benzoxazine-7-carboxamide (Compound 83.17);

[0566] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-1-ethyl-indole-2-carboxamide (Compound 83.18);

[0567] N-(1-cyano-1-methyl-ethyl)-4-[[2-(2,2,2-trifluoroethyl)pyrazole-3-carbonyl]amino]pyridine-2-carboxamide (Compound 83.19);

[0568] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-3-phenyl-isoxazole-4-carboxamide (Compound 83.20);

[0569] 4-[(1-Benzylpyrazole-4-carbonyl)amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 83.21);

[0570] N-(1-cyano-1-methyl-ethyl)-4-[(2-methyl-5-phenyl-pyrazole-3-carbonyl)amino]pyridine-2-carboxamide (Compound 83.22);

[0571] N-(1-cyano-1-methyl-ethyl)-4-[[2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoyl]amino]pyridine-2-carboxamide (Compound 83.23);

[0572] N-(1-cyano-1-methyl-ethyl)-4-[(3-methyl-1-phenyl-pyrazole-4-carbonyl)amino]pyridine-2-carboxamide (Compound 83.24);

[0573] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-2-phenoxy-pyridine-3-carboxamide (Compound 83.25);

[0574] N-(1-cyano-1-methyl-ethyl)-4-[[2,5-dimethyl-1-(2-thienylmethyl)pyrrole-3-carbonyl]amino]pyridine-2-carboxamide (Compound 83.26);

[0575] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-5-(2-methoxyphenyl)isoxazole-3-carboxamide (Compound 83.27);

[0576] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-4-methyl-2-phenyl-thiazole-5-carboxamide (Compound 83.28);

[0577] 4-[(4-Acetylaminobenzoyl)amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 83.29);

[0578] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-1,3-benzothiazole-7-carboxamide (Compound 83.30);

[0579] N-(1-cyano-1-methyl-ethyl)-4-[3-(4-fluorophenyl)butyrylamino]pyridine-2-carboxamide (Compound 83.31);

[0580] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-1-methyl-2-oxo-quinoline-3-carboxamide (Compound 83.32);

[0581] N-tert-butyl-3-[[2-(2-hydroxycyclohexyl)acetyl]amino]benzamide (Compound 84);

[0582] N-tert-Butyl-6-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyrimidine-4-carboxamide (Compound 85);

[0583] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-cyano-2-methoxy-1-(methoxymethyl)ethyl]pyridine-2-carboxamide (Compound 86);

[0584] 4-[[2-(3-Amino-4-tert-butyl-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 87);

[0585] 4-[[2-(2-Amino-4-tert-butyl-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 88);

[0586] N-tert-butyl-4-[[2-(4-tert-butyl-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 89);

[0587] N-tert-butyl-4-[[2-(4-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 90);

[0588] N-tert-butyl-4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 91);

[0589] 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 92);

[0590] 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 92.1);

[0591] 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 92.2);

[0592] 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-[(1s,2s)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 92.3);

[0593] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 93);

[0594] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-[(2S)-2-hydroxycyclohexyl]pyridine-2-carboxamide (Compound 93.1);

[0595] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-[(2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 93.2);

[0596] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 93.3);

[0597] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 93.4);

[0598] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 93.5);

[0599] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methyl-1-phenyl-ethyl)pyridine-2-carboxamide (Compound 94); and salts and solvates of any of the foregoing.

[0600] Some compounds of general formula (I) are novel and therefore in another aspect of the present invention there is provided a compound of general formula (I) as defined above, provided that:

[0601] When X 1 N and X 2 CR 8 , especially when X 1 N and X 2 When CH, Z is -C(O)- and Y is a bond, R4 is not a 5- to 10-membered heteroaryl or heterocyclic ring connected to Y via a nitrogen atom; and

[0602] When X 1 and X 2 Both are CR 8 , and especially when X 1 and X 2 When both are CH, R 4 is phenyl having OH in the 2- or 3-position, and optionally having one or more further substituents as defined above; and

[0603] When X 1 CR 8 And X 2 For N, especially when X 1 is CH and X 2 When N is:

[0604] When Z is -C(O)-, Y is not a bond; and

[0605] When Z is -C(O)NH- and Y is a bond, R 4 is not a 12-membered heteroaryl ring system; and

[0606] When X 1 and X 2 Both are N, and when R 1 and R 2 One of them is H and R 1 and R 2 When the other is H or methyl, R 3 Unsubstituted or unsubstituted phenyl.

[0607] R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 Suitable values ​​for , Y and Z are as defined above.

[0608] In some particularly suitable novel compounds of the present invention, X 1 is N and X 2 Yes CR 8 , especially CH.

[0609] Examples of novel compounds according to the invention are:

[0610] N-tert-butyl-4-[[2-(2-hydroxyphenyl)acetyl]amino]pyridine-2-carboxamide (Compound 1);

[0611] N-(1,1-dimethylpropyl)-3-[[2-(2-hydroxyphenyl)acetyl]amino]benzamide (Compound 1.1);

[0612] N-(1-adamantyl)-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 1.2);

[0613] N-(1-adamantyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 1.3);

[0614] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-methoxy-1,1-dimethyl-propyl)pyridine-2-carboxamide (Compound 1.4);

[0615] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylpropyl)benzamide (Compound 1.5);

[0616] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide (Compound 1.6);

[0617] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclohexyl)pyridine-2-carboxamide (Compound 1.7);

[0618] N-[3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]-3-methyl-butyl]carbamic acid tert-butyl ester (Compound 1.8);

[0619] 3-[[2-(2-Hydroxyphenyl)acetyl]amino]-N-(2-methoxy-1,1-dimethyl-ethyl)benzamide (Compound 1.9);

[0620] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-cyclohexyl-pyridine-2-carboxamide (Compound 1.10);

[0621] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2);

[0622] N-tert-butyl-3-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.1);

[0623] N-tert-butyl-3-[[2-(3-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.2);

[0624] N-tert-butyl-3-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.3);

[0625] N-tert-butyl-3-[[2-(2,6-dihydroxyphenyl)acetyl]amino]benzamide (Compound 2.4);

[0626] N-tert-butyl-3-[3-(2-hydroxyphenyl)propionylamino]benzamide (Compound 2.5);

[0627] N-tert-butyl-3-[[2-(2-hydroxy-6-methoxy-phenyl)acetyl]amino]benzamide (Compound 2.6);

[0628] N-tert-butyl-3-[2-(2-hydroxyphenyl)propionylamino]benzamide (Compound 2.7);

[0629] N-tert-butyl-3-[[2-(2-hydroxy-3-methoxy-phenyl)acetyl]amino]benzamide (Compound 2.8);

[0630] N-tert-butyl-3-[[2-(3,5-difluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.9);

[0631] 3-[[2-(5-Bromo-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-benzamide (Compound 2.10);

[0632] N-tert-butyl-3-[[2-(2,3-difluoro-6-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.11);

[0633] N-tert-butyl-3-[[2-(4,5-difluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.12);

[0634] N-(1,1-dimethylpropyl)-3-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.13);

[0635] N-tert-butyl-3-[[2-(2-hydroxy-4-methoxy-phenyl)acetyl]amino]benzamide (Compound 2.14);

[0636] N-tert-butyl-3-[[2-(2-fluoro-6-hydroxy-phenyl)acetyl]amino]benzamide (Compound 2.15);

[0637] N-tert-butyl-3-[[2-(2,3-dihydroxyphenyl)acetyl]amino]benzamide (Compound 2.16);

[0638] N-tert-butyl-3-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]benzamide (Compound 2.17);

[0639] 3-[2-[3-(tert-Butylcarbamoyl)anilino]-2-oxo-ethyl]-4-hydroxy-benzoic acid methyl ester (Compound 2.18);

[0640] N-tert-butyl-3-[[2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetyl]amino]benzamide (Compound 2.19);

[0641] N-tert-butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3);

[0642] N-(1,1-dimethylpropyl)-4-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.1a);

[0643] N-tert-butyl-4-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.2a);

[0644] N-tert-butyl-4-[[2-(2-chloro-6-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.3a);

[0645] 4-[[2-(4-bromo-5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 3.4a);

[0646] 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide (Compound 3.5a);

[0647] 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide (Compound 3.6a);

[0648] N-tert-butyl-4-[2-(2,5-dibromo-3-fluoro-6-hydroxyphenyl)acetylamino]pyridine-2-carboxamide (Compound 3.7a);

[0649] N-tert-butyl-4-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 3.5b);

[0650] N-tert-butyl-4-[[2-(4-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.6b);

[0651] N-tert-butyl-4-[[2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 3.7b);

[0652] N-tert-butyl-4-[[2-(2-hydroxy-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.8b);

[0653] N-tert-butyl-4-[(6-hydroxyindane-1-carbonyl)amino]pyridine-2-carboxamide (Compound 3.9b);

[0654] N-tert-butyl-4-[(7-hydroxyindane-1-carbonyl)amino]pyridine-2-carboxamide (Compound 3.10b);

[0655] N-tert-butyl-4-[[2-(2,5-dibromo-3-chloro-6-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.11b);

[0656] N-tert-butyl-4-[[2-(3-hydroxyphenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.12b);

[0657] N-tert-butyl-4-[[2-(2-fluoro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.13b);

[0658] N-tert-butyl-4-[[2-(4-chloro-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.14b);

[0659] N-tert-butyl-4-[[2-(2-chloro-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.15b);

[0660] N-tert-butyl-4-[[2-(2-chloro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.16b);

[0661] N-tert-butyl-4-[[2-(3-chloro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 3.17b);

[0662] N-tert-butyl-3-[[2-(3-hydroxyphenyl)acetyl]amino]benzamide (Compound 4);

[0663] N-tert-butyl-3-[[2-(1H-indazol-3-yl)acetyl]amino]benzamide (Compound 4.1);

[0664] N-tert-butyl-3-[[2-(5-fluoro-1H-indol-3-yl)acetyl]amino]benzamide (Compound 4.2);

[0665] N-tert-butyl-3-[[2-(2-hydroxyphenyl)acetyl]amino]benzamide (Compound 4.3);

[0666] N-tert-butyl-4-[[2-(2-thienyl)acetyl]amino]pyridine-2-carboxamide (Compound 5);

[0667] 4-[[2-(2-adamantyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 5.1);

[0668] N-tert-butyl-4-[[2-(4-fluoro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.2);

[0669] N-tert-butyl-4-[[2-(5-chloro-2-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.3);

[0670] N-tert-butyl-4-[[2-(2-furyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.4);

[0671] N-tert-butyl-4-[[2-(3-chlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.5);

[0672] N-tert-butyl-4-[[2-(1H-indol-3-yl)acetyl]amino]pyridine-2-carboxamide (Compound 5.6);

[0673] N-tert-butyl-4-[[2-(o-tolyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.7);

[0674] N-tert-butyl-4-[[2-(3,4-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.8);

[0675] N-tert-butyl-4-[[2-(3-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.9);

[0676] N-tert-butyl-4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.10);

[0677] N-tert-butyl-4-[[2-(p-methylphenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.11);

[0678] N-tert-butyl-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.12);

[0679] N-tert-butyl-4-[[2-(4-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.13);

[0680] N-tert-butyl-4-[[2-(m-tolyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.14);

[0681] 4-[[2-(1,3-Benzoxazol-6-yl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 5.15);

[0682] N-tert-butyl-4-[[2-(2-chloro-3-pyridinyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.16);

[0683] N-tert-butyl-4-[[2-(2,6-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.17);

[0684] N-tert-butyl-4-[[2-(4-chloro-3-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.18);

[0685] N-tert-butyl-4-[[2-(3,5-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.19);

[0686] N-tert-butyl-4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.20);

[0687] N-tert-butyl-4-[[2-(3-chloro-4-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.21);

[0688] N-tert-butyl-4-(indane-1-carbonylamino)pyridine-2-carboxamide (Compound 5.22);

[0689] N-tert-butyl-4-[(2-quinoxalin-6-ylacetyl)amino]pyridine-2-carboxamide (Compound 5.23);

[0690] N-tert-butyl-4-[[2-(2-naphthyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.24);

[0691] N-tert-butyl-4-(2,3-dihydrobenzofuran-3-carbonylamino)pyridine-2-carboxamide (Compound 5.25);

[0692] N-tert-butyl-4-(6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-carbonylamino)pyridine-2-carboxamide (Compound 5.26);

[0693] N-tert-butyl-4-(1,2,3,4-tetrahydronaphthalene-1-carbonylamino)pyridine-2-carboxamide (Compound 5.27);

[0694] N-tert-butyl-4-[[2-(6-quinolinyl)acetyl]amino]pyridine-2-carboxamide (Compound 5.29);

[0695] N-tert-butyl-4-[[1-(3-chlorophenyl)cyclopropanecarbonyl]amino]pyridine-2-carboxamide (Compound 5.31);

[0696] N-tert-butyl-4-[[2-(2,3-dihydro-1,4-benzodioxin-6-yl)acetyl]amino]pyridine-2-carboxamide (Compound 5.32);

[0697] N-(1,1-dimethylprop-2-ynyl)-4-[(2-isochroman-1-ylacetyl)amino]pyridine-2-carboxamide (Compound 5.33);

[0698] 4-[[2-(4,4-difluorocyclohexyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 5.34);

[0699] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 5.35);

[0700] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)-1H-pyrazol-4-yl]acetyl]amino]pyridine-2-carboxamide (Compound 5.36);

[0701] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 5.37);

[0702] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 5.38);

[0703] 4-[[2-(2,3-dihydro-1,4-benzoxazin-4-yl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 5.39);

[0704] N-tert-butyl-4-[[2-(5-cyano-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 6);

[0705] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2,2-tetramethylpropyl)benzamide (Compound 7);

[0706] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylbutyl)benzamide (Compound 7.1);

[0707] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylbutyl)pyridine-2-carboxamide (Compound 7.2);

[0708] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-cyclohexyl-benzamide (Compound 7.3);

[0709] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-tetrahydropyran-4-yl-benzamide (Compound 7.4);

[0710] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2-trimethylpropyl)benzamide (Compound 7.5);

[0711] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2-trimethylpropyl)pyridine-2-carboxamide (Compound 7.6);

[0712] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-isopropyl-pyridine-2-carboxamide (Compound 7.7);

[0713] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)benzamide (Compound 7.8);

[0714] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 7.9);

[0715] 3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)benzamide (Compound 7.10);

[0716] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-tetrahydropyran-4-yl-pyridine-2-carboxamide (Compound 7.11);

[0717] 4-[2-(5-chloro-2-hydroxyphenyl)acetylamino]-N-[(1s,4s)-4-hydroxycyclohexyl]pyridine-2-carboxamide (Compound 7.12);

[0718] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-sec-butyl-pyridine-2-carboxamide (Compound 7.13);

[0719] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-hydroxy-1,1,2-trimethyl-propyl)pyridine-2-carboxamide (Compound 7.14);

[0720] N-(3-Bicyclo[1.1.1]pentyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 7.15);

[0721] 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide (Compound 7.16);

[0722] 3-[[3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzoyl]amino]piperidine-1-carboxylic acid tert-butyl ester (Compound 8);

[0723] 3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]piperidine-1-carboxylic acid tert-butyl ester (Compound 8.1);

[0724] 4-[[3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]benzoyl]amino]-4-methyl-piperidine-1-carboxylic acid tert-butyl ester (Compound 8.2);

[0725] (1r,5s,6s)-6-{4-[2-(5-chloro-2-hydroxyphenyl)acetylamino]pyridine-2-amido}-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester (Compound 8.3);

[0726] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-fluoro-benzamide (Compound 9);

[0727] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-methyl-benzamide (Compound 9.1);

[0728] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylpropyl)pyridine-2-carboxamide (Compound 9.2);

[0729] N-tert-butyl-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 10);

[0730] N-tert-butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-hydroxy-benzamide (Compound 11);

[0731] N-tert-butyl-3-[[2-(5-cyano-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 12);

[0732] 3-[2-[[2-(tert-Butylcarbamoyl)-4-pyridinyl]amino]-2-oxo-ethyl]-4-hydroxy-benzoic acid methyl ester (Compound 13);

[0733] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-hydroxy-benzamide (Compound 14);

[0734] N-tert-butyl-4-[[2-(2-hydroxy-5-methyl-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 15);

[0735] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-methoxy-benzamide (Compound 16);

[0736] N-tert-Butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-fluoro-benzamide (Compound 17);

[0737] N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-benzamide (Compound 18);

[0738] N-tert-butyl-4-[[2-(3-hydroxy-2-pyridinyl)acetyl]amino]pyridine-2-carboxamide (Compound 19);

[0739] N-tert-butyl-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 20);

[0740] N-tert-butyl-4-[[(1R) or (1S)-indane-1-carbonyl]amino]pyridine-2-carboxamide (Compound 21a);

[0741] N-tert-butyl-4-[[(1R) or (1S)-indane-1-carbonyl]amino]pyridine-2-carboxamide (Compound 21b);

[0742] N-tert-Butyl-4-[(2-phenylacetyl)amino]pyridine-2-carboxamide (Compound 22);

[0743] 4-(3,3-dimethylbutyrylamino)-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 22.1);

[0744] 4-[(2-Cyclopentylacetyl)amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 22.2);

[0745] 4-[[2-(3-chloro-4-pyridinyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 22.3);

[0746] 4-[[2-(4-Chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 23);

[0747] 4-[[2-(3-chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 23.1);

[0748] 4-[[2-(2-Chloro-5-fluoro-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 23.2);

[0749] N-tert-butyl-4-(indane-2-carbonylamino)pyridine-2-carboxamide (Compound 23.3);

[0750] N-tert-butyl-4-[[2-[2-(difluoromethoxy)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 23.4);

[0751] N-tert-butyl-4-[[2-[2-(difluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 23.5);

[0752] N-tert-butyl-4-[[2-(3,4-difluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.6);

[0753] N-tert-butyl-4-[[2-(3,5-difluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.7);

[0754] N-tert-butyl-4-[[2-(2,3-difluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.8);

[0755] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-tetrahydropyran-4-yl-pyridine-2-carboxamide (Compound 23.9);

[0756] N-(1-cyanocyclobutyl)-4-[[2-(6-quinolinyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.11);

[0757] N-tert-butyl-4-[[2-[2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 23.12);

[0758] 4-[[2-(2-bromophenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 23.13);

[0759] N-tert-butyl-4-[[2-(2-cyanophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.14);

[0760] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 23.15);

[0761] N-(4-cyanotetrahydropyran-4-yl)-4-[[2-(6-quinolinyl)acetyl]amino]pyridine-2-carboxamide (Compound 23.16);

[0762] 4-[[2-(2-Chloro-5-methoxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 24);

[0763] N-(3-Bicyclo[1.1.1]pentyl)-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 25);

[0764] -[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 25.1);

[0765] N-tert-butyl-4-[[2-(2-hydroxy-5-phenyl-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 26);

[0766] N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-4-(pyrrolidin-1-ylmethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 27);

[0767] N-tert-butyl-4-[[2-[4-[(tert-butylamino)methyl]-5-chloro-2-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 27.1);

[0768] N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-4-(morpholinomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 27.2);

[0769] N-tert-butyl-4-[[2-[5-chloro-4-[(3,3-difluoropyrrolidin-1-yl)methyl]-2-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 27.3);

[0770] N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxamide (Compound 28);

[0771] N-tert-butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-3-fluoro-pyridine-2-carboxamide (Compound 28.1);

[0772] 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide (Compound 30);

[0773] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 30.1);

[0774] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[2.1.1]hexyl)pyridine-2-carboxamide (Compound 30.2);

[0775] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyclopropyl-1-methyl-ethyl)pyridine-2-carboxamide (Compound 30.3);

[0776] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 30.3a);

[0777] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-methyl-3-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide (Compound 30.4);

[0778] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyano-3-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide (Compound 30.5);

[0779] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(2,2-difluorocyclopropyl)pyridine-2-carboxamide (Compound 30.6);

[0780] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 30.7);

[0781] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide (Compound 30.8);

[0782] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(3-fluoro-1-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide (Compound 30.9);

[0783] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(2-fluoro-1,1-dimethyl-ethyl)pyridine-2-carboxamide (Compound 30.10);

[0784] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(4-ethynyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 30.11);

[0785] 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyanocyclopentyl)pyridine-2-carboxamide (Compound 30.12);

[0786] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(2,2-difluoro-1,1-dimethyl-ethyl)pyridine-2-carboxamide (Compound 30.13);

[0787] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 31);

[0788] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclopentyl)pyridine-2-carboxamide (Compound 31.2);

[0789] 4-[2-(5-chloro-2-hydroxyphenyl)acetylamino]-N-[(1s,2s)-2-hydroxycyclohexyl]pyridine-2-carboxamide (Compound 31.3);

[0790] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2S)-2-hydroxycyclohexyl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2R)-2-hydroxycyclohexyl]pyridine-2-carboxamide (Compound 31.3a);

[0791] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-ethynyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 31.4);

[0792] N-[(6-amino-2-pyridinyl)methyl]-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 32);

[0793] 12-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]dodecanoic acid (Compound 32.1);

[0794] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-pyridylmethyl)pyridine-2-carboxamide (Compound 32.2);

[0795] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-pyridinylmethyl)pyridine-2-carboxamide (Compound 32.3);

[0796] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-pyridinylmethyl)pyridine-2-carboxamide (Compound 32.4);

[0797] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(2-hydroxyphenyl)methyl]pyridine-2-carboxamide (Compound 32.5);

[0798] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethyl-2-morpholino-ethyl)pyridine-2-carboxamide (Compound 32.6);

[0799] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-hydroxy-1,1-dimethyl-ethyl)pyridine-2-carboxamide (Compound 32.7);

[0800] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3,3-difluoro-4-piperidinyl)pyridine-2-carboxamide (Compound 32.8);

[0801] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1H-imidazol-2-yl)pyridine-2-carboxamide (Compound 32.9);

[0802] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2R)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 33);

[0803] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 34);

[0804] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 35);

[0805] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3R)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3S)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 35a);

[0806] -[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3R)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide or 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3S)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 35b);

[0807] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-hydroxy-4-methyl-cyclohexyl)pyridine-2-carboxamide as a 6:4 mixture of stereoisomers (Compound 35.1);

[0808] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1s,2r)-2-(hydroxymethyl)cyclohexyl]pyridine-2-carboxamide (Compound 35.2);

[0809] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1s,3r)-3-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 35.3);

[0810] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-1-methyl-ethyl]pyridine-2-carboxamide (Compound 35.4);

[0811] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-hydroxycyclohexyl)pyridine-2-carboxamide as a mixture of stereoisomers (Compound 35.6);

[0812] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-phenoxypropyl)pyridine-2-carboxamide (Compound 35.7);

[0813] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide (Compound 35.8);

[0814] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-methyl-1-(2-pyridinyl)ethyl]pyridine-2-carboxamide (Compound 35.9);

[0815] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-phenylpropyl)pyridine-2-carboxamide (Compound 35.10);

[0816] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[2-hydroxy-1-(2-pyridinyl)ethyl]pyridine-2-carboxamide (Compound 35.11);

[0817] 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(5-methoxy-2-pyridinyl)methyl]pyridine-2-carboxamide (Compound 35.12);

[0818] 3-[[4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]-3-methyl-butyric acid ethyl ester (Compound 35.13);

[0819] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-hydroxy-1,1-dimethyl-propyl)pyridine-2-carboxamide (Compound 35.14);

[0820] N-benzyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 35.15);

[0821] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-phenyl-pyridine-2-carboxamide (Compound 35.16);

[0822] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 35.17);

[0823] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 35.18);

[0824] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2R)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 35.19);

[0825] 3-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclohexyl)benzamide (Compound 35.20);

[0826] N-(1,1-dimethylprop-2-ynyl)-3-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 35.21);

[0827] N-cyclohexyl-3-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 35.22);

[0828] 3-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]benzamide (Compound 35.23);

[0829] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclohexyl)pyridine-2-carboxamide (Compound 35.24);

[0830] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide (Compound 35.25);

[0831] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)oxetan-3-yl]pyridine-2-carboxamide (Compound 35.26);

[0832] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-methoxy-1-methyl-ethyl)pyridine-2-carboxamide (Compound 35.27);

[0833] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1-hydroxycyclobutyl)methyl]pyridine-2-carboxamide (Compound 35.28);

[0834] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 36);

[0835] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1,2-dimethyl-propyl)pyridine-2-carboxamide (Compound 37);

[0836] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopentyl)pyridine-2-carboxamide (Compound 38);

[0837] N-(4-tert-Butylcyclohexyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 39);

[0838] N-tert-butyl-4-[[2-(2-chloro-3-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 40);

[0839] N-tert-butyl-4-[[2-(2-chloro-5-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 40.1);

[0840] N-(4-cyanotetrahydropyran-4-yl)-3-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]benzamide (Compound 41);

[0841] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[4-(2-hydroxyethyl)tetrahydropyran-4-yl]pyridine-2-carboxamide (Compound 42);

[0842] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1,1-dimethyl-3-(2,2,2-trifluoroethylamino)propyl]pyridine-2-carboxamide (Compound 43);

[0843] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[2.1.1]hexyl)pyridine-2-carboxamide (Compound 44);

[0844] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(2,2-dimethylpropionylamino)-1,1-dimethyl-propyl]pyridine-2-carboxamide (Compound 45);

[0845] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-hydroxy-1-methyl-ethyl)pyridine-2-carboxamide (Compound 46);

[0846] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 46a);

[0847] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 46b);

[0848] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-cyanotetrahydrofuran-3-yl)pyridine-2-carboxamide (Compound 47);

[0849] 2-[4-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]tetrahydropyran-4-yl]acetic acid methyl ester (Compound 47.1);

[0850] 4-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]tetrahydropyran-4-carboxylic acid methyl ester (Compound 47.2);

[0851] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-cyanoxetan-3-yl)pyridine-2-carboxamide (Compound 47.3);

[0852] 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide (Compound 48);

[0853] N-(4-cyanotetrahydropyran-4-yl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 48.1);

[0854] N-[3-(tert-Butylamino)-1,1-dimethyl-3-oxo-propyl]-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 49);

[0855] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(methylsulfonylamino)-1,1-dimethyl-propyl]pyridine-2-carboxamide (Compound 50);

[0856] N-(3-Acetylamino-1,1-dimethyl-propyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 51);

[0857] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[4-(hydroxymethyl)tetrahydropyran-4-yl]pyridine-2-carboxamide (Compound 53);

[0858] N-tert-butyl-4-[[2-[3-(1-hydroxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 54);

[0859] N-tert-Butyl-5-chloro-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 55);

[0860] N-tert-butyl-4-[[2-[5-chloro-2-[(4-methoxyphenyl)methoxy]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 56);

[0861] N-tert-butyl-4-[[(1S) or (1R)-4-chloro-7-hydroxy-indane-1-carbonyl]amino]pyridine-2-carboxamide and Example 57b: N-tert-butyl-4-[[(1S) or (1R)-4-chloro-7-hydroxy-indane-1-carbonyl]amino]pyridine-2-carboxamide (Compound 57a);

[0862] N-tert-butyl-4-[[(1S) or (1R)-4-chloro-7-hydroxy-indane-1-carbonyl]amino]pyridine-2-carboxamide and Example 57b: N-tert-butyl-4-[[(1S) or (1R)-4-chloro-7-hydroxy-indane-1-carbonyl]amino]pyridine-2-carboxamide (Compound 57b);

[0863] N-tert-butyl-4-[[2-(2-cyclopropylphenyl)acetyl]amino]pyridine-2-carboxamide (Compound 58);

[0864] 4-[[2-(3-Bromo-5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 59);

[0865] N-(4-fluoro-1-bicyclo[2.1.1]hexyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 60);

[0866] N-(1-cyano-2-hydroxy-1-methyl-ethyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 60.1);

[0867] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide (Compound 60.2);

[0868] N-tert-butyl-4-[[2-(5-chloro-2-hydroxy-3-isopropyl-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 61);

[0869] N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-3-(1-methoxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 62);

[0870] 4-[[2-(6-Quinolinyl)acetyl]amino]-N-tetrahydropyran-4-yl-pyridine-2-carboxamide (Compound 63);

[0871] 4-(Benzylcarbamoylamino)-N-tert-butyl-pyridine-2-carboxamide (Compound 64);

[0872] N-tert-butyl-4-(cyclohexylmethylcarbamoylamino)pyridine-2-carboxamide (Compound 64.1);

[0873] N-tert-butyl-4-(2-phenylethylcarbamoylamino)pyridine-2-carboxamide (Compound 64.2);

[0874] N-tert-butyl-4-[[(1R)-1-phenylethyl]carbamoylamino]pyridine-2-carboxamide (Compound 64.3);

[0875] N-tert-butyl-4-[[(1S)-1-phenylethyl]carbamoylamino]pyridine-2-carboxamide (Compound 64.4);

[0876] N-tert-butyl-4-[(2-chlorophenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 64.5);

[0877] N-tert-butyl-4-(1H-indol-3-ylcarbamoylamino)pyridine-2-carboxamide (Compound 64.6);

[0878] N-tert-butyl-4-[(3-chlorophenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 64.7);

[0879] N-tert-butyl-4-[(4-chlorophenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 64.8);

[0880] N-tert-butyl-4-[(2-hydroxyphenyl)carbamoylamino]pyridine-2-carboxamide (Compound 65);

[0881] N-tert-butyl-4-[(2-methoxyphenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 65.1);

[0882] N-tert-butyl-4-[(2-hydroxyphenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 65.2);

[0883] N-tert-butyl-4-[(3-hydroxyphenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 65.3);

[0884] N-tert-butyl-4-[(4-hydroxyphenyl)methylcarbamoylamino]pyridine-2-carboxamide (Compound 65.4);

[0885] N-tert-butyl-4-[[2-[2-hydroxy-5-(1-hydroxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 66);

[0886] N-tert-butyl-4-[[2-[2-hydroxy-5-[1-(2,2,2-trifluoroethylamino)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 67);

[0887] N-tert-butyl-4-[[2-[3-(cyanomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 68);

[0888] N-tert-butyl-4-[[2-[3-(methoxymethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 69);

[0889] N-tert-butyl-4-[[2-[2-hydroxy-5-(morpholinomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 70);

[0890] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-cyanotetrahydrofuran-3-yl)benzamide (Compound 71);

[0891] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclohexyl)benzamide (Compound 71.1);

[0892] 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 72);

[0893] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)-2-methoxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 73);

[0894] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylbut-2-ynyl)pyridine-2-carboxamide (Compound 73.1);

[0895] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)benzamide (Compound 74);

[0896] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]benzamide (Compound 74.1);

[0897] N-tert-butyl-4-[[2-[2-hydroxy-5-(3-hydroxypropyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 75);

[0898] 4-[[2-(5-Chloro-4-fluoro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide (Compound 76);

[0899] 4-[[2-(2,5-difluorophenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 77);

[0900] 4-[[2-(2,5-difluorophenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[2.1.1]hexyl)pyridine-2-carboxamide (Compound 77.1);

[0901] 4-[[2-(4-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 78);

[0902] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 78.1);

[0903] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 78.2);

[0904] 4-[(2-Chroman-4-ylacetyl)amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 79);

[0905] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(1-isopropyl-3,5-dimethyl-pyrazol-4-yl)acetyl]amino]pyridine-2-carboxamide (Compound 79.1);

[0906] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(1H-indazol-4-yl)acetyl]amino]pyridine-2-carboxamide (Compound 79.2);

[0907] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(1H-indol-7-yl)acetyl]amino]pyridine-2-carboxamide (Compound 79.3);

[0908] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)benzamide (Compound 80);

[0909] N-(1-cyano-1-methyl-ethyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 81);

[0910] N-(1-cyano-2-hydroxy-1-methyl-ethyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 81.1);

[0911] 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-isopropyl-pyridine-2-carboxamide (Compound 81.2);

[0912] N-(1,1-dimethylprop-2-ynyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 81.3);

[0913] N-(4-Fluoro-1-bicyclo[2.1.1]hexyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 81.4);

[0914] 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide (Compound 81.5);

[0915] N-tert-butyl-6-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyrimidine-4-carboxamide (Compound 82);

[0916] N-(1-cyano-1-methyl-ethyl)-4-(thiophene-3-carbonylamino)pyridine-2-carboxamide (Compound 83);

[0917] N-(1-cyano-1-methyl-ethyl)-4-[(2-cyclohexylacetyl)amino]pyridine-2-carboxamide (Compound 83.1);

[0918] N-(1-cyano-1-methyl-ethyl)-4-(cyclohexanecarbonylamino)pyridine-2-carboxamide (Compound 83.2);

[0919] N-(1-cyano-1-methyl-ethyl)-4-[(3,3-difluorocyclopentanecarbonyl)amino]pyridine-2-carboxamide (Compound 83.3);

[0920] N-(1-cyano-1-methyl-ethyl)-4-[(1-methylcyclopentanecarbonyl)amino]pyridine-2-carboxamide (Compound 83.4);

[0921] N-(1-cyano-1-methyl-ethyl)-4-(3-cyclohexylpropionylamino)pyridine-2-carboxamide (Compound 83.5);

[0922] 4-(2-{Bicyclo[2.2.1]hept-2-yl}acetylamino)-N-(1-cyano-1-methylethyl)pyridine-2-carboxamide (Compound 83.6);

[0923] N-(1-cyano-1-methyl-ethyl)-4-[[2-(1-methylcyclohexyl)acetyl]amino]pyridine-2-carboxamide (Compound 83.7);

[0924] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-2-cyclopropyl-pyrimidine-5-carboxamide (Compound 83.8);

[0925] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-3-isobutyl-isoxazole-5-carboxamide (Compound 83.9);

[0926] N-(1-cyano-1-methyl-ethyl)-4-[[2-(4,4-difluorocyclohexyl)acetyl]amino]pyridine-2-carboxamide (Compound 83.10);

[0927] 4-[(1-Benzylcyclopropanecarbonyl)amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 83.11);

[0928] N-(1-cyano-1-methyl-ethyl)-4-[3-(2-methoxy-4-pyridinyl)propionylamino]pyridine-2-carboxamide (Compound 83.13);

[0929] 4-[(5-tert-Butyl-2-methyl-pyrazole-3-carbonyl)amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 83.14);

[0930] N-(1-cyano-1-methyl-ethyl)-4-[(2-pyrazol-1-ylbenzoyl)amino]pyridine-2-carboxamide (Compound 83.15);

[0931] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-6-(trifluoromethyl)pyridine-2-carboxamide (Compound 83.16);

[0932] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-3-oxo-4H-1,4-benzoxazine-7-carboxamide (Compound 83.17);

[0933] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-1-ethyl-indole-2-carboxamide (Compound 83.18);

[0934] N-(1-cyano-1-methyl-ethyl)-4-[[2-(2,2,2-trifluoroethyl)pyrazole-3-carbonyl]amino]pyridine-2-carboxamide (Compound 83.19);

[0935] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-3-phenyl-isoxazole-4-carboxamide (Compound 83.20);

[0936] 4-[(1-Benzylpyrazole-4-carbonyl)amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 83.21);

[0937] N-(1-cyano-1-methyl-ethyl)-4-[(2-methyl-5-phenyl-pyrazole-3-carbonyl)amino]pyridine-2-carboxamide (Compound 83.22);

[0938] N-(1-cyano-1-methyl-ethyl)-4-[[2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoyl]amino]pyridine-2-carboxamide (Compound 83.23);

[0939] N-(1-cyano-1-methyl-ethyl)-4-[(3-methyl-1-phenyl-pyrazole-4-carbonyl)amino]pyridine-2-carboxamide (Compound 83.24);

[0940] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-2-phenoxy-pyridine-3-carboxamide (Compound 83.25);

[0941] N-(1-cyano-1-methyl-ethyl)-4-[[2,5-dimethyl-1-(2-thienylmethyl)pyrrole-3-carbonyl]amino]pyridine-2-carboxamide (Compound 83.26);

[0942] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-5-(2-methoxyphenyl)isoxazole-3-carboxamide (Compound 83.27);

[0943] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-4-methyl-2-phenyl-thiazole-5-carboxamide (Compound 83.28);

[0944] 4-[(4-Acetylaminobenzoyl)amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 83.29);

[0945] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-1,3-benzothiazole-7-carboxamide (Compound 83.30);

[0946] N-(1-cyano-1-methyl-ethyl)-4-[3-(4-fluorophenyl)butyrylamino]pyridine-2-carboxamide (Compound 83.31);

[0947] N-[2-[(1-cyano-1-methyl-ethyl)carbamoyl]-4-pyridinyl]-1-methyl-2-oxo-quinoline-3-carboxamide (Compound 83.32);

[0948] N-tert-butyl-3-[[2-(2-hydroxycyclohexyl)acetyl]amino]benzamide (Compound 84);

[0949] N-tert-Butyl-6-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyrimidine-4-carboxamide (Compound 85);

[0950] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-cyano-2-methoxy-1-(methoxymethyl)ethyl]pyridine-2-carboxamide (Compound 86);

[0951] 4-[[2-(3-Amino-4-tert-butyl-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 87);

[0952] 4-[[2-(2-Amino-4-tert-butyl-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Compound 88);

[0953] N-tert-butyl-4-[[2-(4-tert-butyl-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 89);

[0954] N-tert-butyl-4-[[2-(4-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 90);

[0955] N-tert-butyl-4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 91);

[0956] 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 92);

[0957] 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 92.1);

[0958] 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 92.2);

[0959] 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-[(1s,2s)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 92.3);

[0960] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide (Compound 93);

[0961] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-[(2S)-2-hydroxycyclohexyl]pyridine-2-carboxamide (Compound 93.1);

[0962] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-[(2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 93.2);

[0963] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 93.3);

[0964] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 93.4);

[0965] 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 93.5);

[0966] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methyl-1-phenyl-ethyl)pyridine-2-carboxamide (Compound 94); and salts and solvates of any of the foregoing.

[0967] The compounds of general formula (I) may be prepared as described below, and processes for their preparation form a further aspect of the invention.

[0968] The compound of formula (I) wherein Z is -C(O)- is prepared by reacting a compound of formula (II):

[0969]

[0970] Where R 1 , R2 , R 3 , R 5a and R 5b , X 1 and X 2 As defined in general formula (I);

[0971] By reacting with a compound of general formula (III):

[0972]

[0973] Where R 4 and Y is as defined in the general formula (I).

[0974] The reaction is suitably carried out in the presence of a coupling agent, and this method is particularly suitable for the case where X 1 and X 2 Each is N or CR independently 8 A compound of the general formula (I), wherein R 8 is a halo group, and Y is a bond or an alkylene group.

[0975] An example of a suitable coupling agent is a carbodiimide, such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) and a triazole, such as 1-hydroxy-7-azabenzotriazole (HOAt) or hydroxybenzotriazole (HOBT). Suitably, the reaction is carried out under basic conditions, such as in the presence of an amine, such as diisopropylethylamine (DIPEA), and in an organic solvent, such as DMF.

[0976] Alternatively, the coupling agent may be propylphosphonic anhydride (T3P). When T3P is used as the coupling agent, the reaction may be carried out under basic conditions, for example in the presence of an amine such as diisopropylethylamine (DIPEA) or triethylamine (TEA) and in an organic solvent such as dioxane.

[0977] Other known peptide coupling agents may also be used, such as O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TATU), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), and the like.

[0978] The compound of general formula (III) may be commercially available or may be prepared by methods known to those skilled in the art. 2 -The synthesis of the compound of the general formula (III) can be carried out by preparing the nitrile of the general formula (XXIII):

[0979]

[0980] Where R 4 As defined in general formula (I);

[0981] Reaction with an aqueous base, for example a metal hydroxide such as lithium hydroxide, followed by acidification, for example with hydrochloric acid, is carried out.

[0982] The reaction is suitably carried out in aqueous solution and heated to reflux temperature.

[0983] The nitrile of general formula (XXIII) can be prepared by reacting a compound of general formula (XXIV):

[0984]

[0985] Where R 4 As defined in formula (I) and R 27 is halogen, for example fluorine, chlorine or bromine, especially chlorine;

[0986] This is done by reaction with a cyanide salt, such as sodium cyanide.

[0987] The reaction can be carried out at a temperature of about 15 to 25°C, usually at room temperature, in an organic solvent such as N,N-dimethylformamide.

[0988] The compound of general formula (XXIV) can be prepared by halogenating the compound of general formula (XXV) with a halogenating agent:

[0989]

[0990] Where R 4 As defined in general formula (I).

[0991] The appropriate halogenating agent for the reaction depends on the desired halogen group R 27 For example, when R 27 When it is chlorine, the halogenating agent may be thionyl chloride. The reaction can be carried out at a temperature of about 15 to 25°C, usually at room temperature, in an organic solvent (eg dichloromethane).

[0992] Compounds of general formula (XXV) can be obtained by reducing compounds of general formula (III) wherein Y is a bond (ie, which has the formula:

[0993]

[0994] Where R 4 As defined in general formula (I).

[0995] The reduction may be carried out using any suitable reducing agent, for example borane-THF, and is suitably carried out at elevated temperature, for example 30-60°C, typically about 50°C.

[0996] In another method for preparing compounds of general formula (I), compounds of general formula (II) as defined above may be reacted with an acid chloride of general formula (IV):

[0997]

[0998] Where R 4 and Y is as defined in the general formula (I).

[0999] The reaction is suitably carried out under basic conditions, for example in the presence of an amine such as DIPEA.

[1000] This method is particularly suitable for compounds where Y is a bond or an alkylene group.

[1001] The acid chloride of the general formula (IV) may be commercially available or may be obtained by reacting a carboxylic acid of the general formula (III) with a chlorinating agent (eg, thionyl chloride).

[1002] The compounds of general formula (III) may be known and commercially available or may be prepared by methods known to those skilled in the art.

[1003] Alternatively, for a compound of formula (I) wherein Z is -C(O)NH-, the compound of formula (II) may be reacted with a compound of formula (XIV):

[1004] O=C=NYR 4 (XIV)

[1005] Where R 4 and Y is as defined in the general formula (I).

[1006] Suitably, the reaction is carried out in an anhydrous organic solvent (eg N,N-dimethylformamide) at elevated temperature, for example about 70 to 85°C.

[1007] Another method for preparing compounds of general formula (Ia) or (Ib) is by reacting a compound of general formula (II) with a compound of general formula (XIII):

[1008]

[1009] Where R 10 , R 11 and n is as defined in the general formula (Ia).

[1010] For example, to prepare 11a is Cl and R 11b The compound of formula (Ib) is H, and the compound of formula (XIII) may be 5-chloro-2(3H)-benzofuranone, which has the following structure:

[1011]

[1012] The reaction can be carried out in an organic solvent such as toluene, typically at an elevated temperature, for example about 90 to 120°C, such as about 100 to 110°C, and under pressure, for example in a sealed tube.

[1013] The compounds of general formula (XIII) and (XIV) may be known and commercially available or may be prepared by methods known to those skilled in the art.

[1014] The compound of general formula (II) can be prepared by converting the compound of general formula (VIII):

[1015]

[1016] Where R 5a , R 5b , X 1 and X 2 As defined in general formula (I);

[1017] Reaction with a compound of formula (VII) to form:

[1018]

[1019] Where R 1 , R 2 and R 3 As defined in general formula (I).

[1020] Suitably, the reaction is carried out in the presence of a coupling agent as described above for the reaction between compounds of general formula (II) and (III). TBTU is a particularly suitable coupling agent for this reaction, although EDCI and HOAt or HOBt may also be used.

[1021] In some cases, compounds of formula (VIII) may be protected as carbamates of formula (VI):

[1022]

[1023] Where R 5a , R 5b , X 1 and X 2 As defined in formula (I); and R 20 C 1-8 Alkyl or benzyl.

[1024] In this case, the reaction with a compound of the general formula (VII) gives a carbamate of the general formula (V):

[1025]

[1026] Where R 1 , R 2 , R 3 , R 5a , R 5b , X 1 and X 2 As defined in formula (I); and R 20 As defined in formula (VI).

[1027] The carbamate protecting group may be removed by hydrolysis, suitably acid hydrolysis, for example using hydrochloric acid, and may be carried out in an organic solvent such as dichloromethane.

[1028] The compounds of the general formulae (VI), (VII) and (VIII) are known and are commercially available or can be prepared by methods known to those skilled in the art.

[1029] For example, where X 2 The compound of the general formula (VIII) is C-Cl by replacing 2 The compound of formula (VIII) is CH and is prepared by reacting a chlorinating agent (eg N-chlorosuccinimide). Suitably, the reaction can be carried out in an organic solvent (eg N,N-dimethylformamide) at an elevated temperature (eg about 50 to 70°C).

[1030] Furthermore, R 1 is ethynyl and R 2 With R 2 The compounds of the general formula (VII) which together form a carbocyclic or heterocyclic ring can be prepared by reacting the compound of the general formula (XVII):

[1031]

[1032] Where R 2 With R 3 form a carbocyclic or heterocyclic ring, and R 21 C 3-8 Alkyl groups, such as tert-butyl;

[1033] Reaction with a compound of formula (XVIII), suitably in the presence of an aluminum catalyst and a base:

[1034]

[1035] Where R 23 Each independently is C 1-3Alkyl; then prepared using acid deprotection.

[1036] Suitable bases include strong bases such as n-butyllithium and a suitable acid for the deprotection step is hydrochloric acid, suitably in an organic solvent such as dioxane.

[1037] The compound of general formula (XVII) can be prepared by converting the compound of general formula (XIX):

[1038]

[1039] Where R 21 As defined in formula (XVII);

[1040] Prepared by reacting with a compound of general formula (XX):

[1041]

[1042] Where R 2 With R 3 Form a carbocyclic or heterocyclic ring.

[1043] Suitably, the reaction is catalysed using a titanium (IV) catalyst, for example titanium (IV) ethoxide.

[1044] Compounds of the general formulae (XIX) and (XX) are known and readily available.

[1045] An alternative method for preparing compounds of general formula (II) is by reducing compounds of general formula (IX), for example by hydrogenation over a palladium catalyst:

[1046]

[1047] Where R 1 , R 2 , R 3 , R 5a , R 5b , X 1 and X 2 As defined in general formula (I).

[1048] The hydrogenation is typically carried out in an alcohol solvent such as ethanol at a temperature of about 15 to 25° C., for example at room temperature.

[1049] The compound of general formula (IX) can be prepared by converting the compound of general formula (VIIIa):

[1050]

[1051] Where R 5a , R 5b , X 1 and X 2 As defined in general formula (I);

[1052] It is obtained by reacting with an amine of the general formula (VII).

[1053] The reaction may be carried out in the presence of a coupling agent, such as one of the coupling agents described above for the reaction between compounds of formula (II) and (III).

[1054] An alternative method for preparing compounds of general formula (I) is to convert compounds of general formula (X):

[1055]

[1056] Where X 1 , X 2 , Y, R 4 , R 5a and R 5b As defined in general formula (I);

[1057] Reaction with a compound of general formula (VII) as defined above.

[1058] This method is particularly suitable for 1 N or CR 8 A compound wherein R 8 is H or halogen, and / or X 2 N or CR 8 , where R 8 is H, OH or O(C 1-4 alkyl), and / or R 5a It is H or F.

[1059] Suitably, the reaction is carried out under basic conditions, for example in the presence of an amine (e.g. DIPEA or TEA), and in the presence of a coupling agent as described above for the reaction between compounds of formula (II) and (III). EDCI and HOAt or HOBt are suitable coupling agents for the reaction, as are HATU, TBTU and HBTU.

[1060] The compound of general formula (X) can be prepared by deprotecting the compound of general formula (XI):

[1061]

[1062] Where X 1 , X 2 , Y, R 4 , R 5a and R 5b As defined in formula (I); and R 25 C 1-8 Alkyl or benzyl.

[1063] Although other methods of deprotecting carboxylic acids are known in the art and / or discussed below, one example of a suitable deprotecting agent is boron tribromide.

[1064] When the target compound is R 4 is a compound of the general formula (I) substituted with OH, for example, a compound of the general formula (Ib), (Ic), (d) or (Ie) or a compound wherein R 10 and / or one or more R 11 The method of using boron tribromide for deprotection is particularly suitable for compounds of the general formula (Ia) wherein the group is OH. 4 The OH groups on the structural parts can be protected, such as OR 26 Group, where R 26 C 1-8 The protecting group can also be removed using boron tribromide. Similarly, boron tribromide deprotection is also suitable for preparing 1 and / or X 2 CR 8 A compound of the general formula (X), wherein R 8 For OH.

[1065] On the other hand, if the desired compound of formula (I) is a compound containing an alkoxy group, for example, wherein R 4 For example, O(C 1-6 alkyl) or wherein X 1 and / or X 2 C(OC 1-4 alkyl), then the deprotection is preferably carried out by hydrolysis, in particular alkaline hydrolysis, for example using an alkali metal hydroxide such as lithium hydroxide. This ensures that C(O)OR 25 The group hydrolyzes to C(O)OH without affecting the alkoxy substituents in the rest of the molecule.

[1066] The compound of general formula (XI) can be prepared by converting the compound of general formula (XII):

[1067]

[1068] Where X 1 and X 2 , R 5a and R 5b As defined in formula (I); and R 25 As defined in formula (XI);

[1069] With the compound of general formula (III) as defined above, or with the compound of general formula (IV) as defined above, or with the compound of general formula (XIII) (e.g. 5-chloro-2(3H)-benzofuranone) to obtain wherein R11a is chlorine and R 11b It is a compound of formula (Ib) wherein H is

[1070] The reaction with the compound of general formula (III) is suitably carried out under basic conditions, for example in the presence of an amine such as DIPEA or TEA, and in the presence of a coupling agent as described above for the reaction between compounds of general formula (II) and (III). EDCI and HOAt or HOBt are particularly suitable coupling agents.

[1071] The reaction with the compound of formula (IV) is generally carried out in an organic solvent such as dichloromethane.The compound of formula (IV) can be generated in situ by reacting the compound of formula (III) with thionyl chloride.

[1072] The reaction with the compound of general formula (XIII) may be carried out in an organic solvent such as toluene, typically at elevated temperature, for example about 90 to 120°C, such as about 100 to 110°C, and under pressure, for example in a sealed tube.

[1073] Compounds of general formula (XII) are known and are commercially available or can be prepared by methods known to those skilled in the art.

[1074] In another alternative method, a compound of formula (I) can be prepared by reacting a compound of formula (XV):

[1075]

[1076] Where X 1 , X 2 , Y, R 4 , R 5a and R 5b As defined in general formula (I), and R 22 is halogen, suitably chlorine or bromine;

[1077] Prepared by reaction with an amine of general formula (VII) as defined above and carbon monoxide.

[1078] The compound of general formula (XV) can be prepared by reacting a compound of general formula (XVI):

[1079]

[1080] Where X 1 , X 2 , R 5a and R 5b As defined in general formula (I), and R 22 As defined in formula (XV);

[1081] It can be prepared by reacting with a compound of the general formula (IV) as defined above or with a compound of the general formula (III) as defined above.

[1082] The reaction may be carried out under an inert atmosphere in an organic solvent such as N,N-dimethylformamide at a temperature of about 15 to 25°C, suitably at room temperature.

[1083] When a compound of formula (IV) is used, it can be generated in situ by reacting a compound of formula (III) with thionyl chloride.

[1084] Alternatively, the compound of general formula (XVI) may be reacted with a lactone of general formula (XIII).

[1085] Compounds of general formula (XVI) are well known and are either commercially available or can be prepared by methods familiar to those skilled in the art.

[1086] The compounds of general formula (I) can be prepared as protected derivatives. For example, wherein R 4 The compounds of general formula (I) having an OH substituent may be prepared by protecting the OH group (e.g., protected as C 1-6 The compounds of the general formula (I) are prepared by using an equivalent compound of the general formula (I) containing a substituted benzyloxy group, wherein the substituted benzyloxy group may be C 1-6 The protecting group may be present in the precursors of formula (III), (IV), (X), (XI), (XIII), (XIV) and (XV) and may be removed using an aqueous acid such as aqueous hydrochloric acid or by hydrogenation, for example under hydrogen pressure in the presence of a metal catalyst such as palladium on carbon.

[1087] Compounds of general formula (I) can also be converted into other compounds of general formula (I).

[1088] Where R 4 For one or more -O(C 1-6 Compounds of the general formula (I) or (Ia) having an aryl or heteroaryl ring system substituted with an alkyl) substituent can be converted to a compound in which -O(C 1-6 The method can be used to prepare compounds of formula (Ib), (Ic), (Id) and (Ie).

[1089] Where R 4 Compounds of formula (I) or (Ia) which are aryl or heteroaryl ring systems substituted with OH may also be prepared by combining an equivalent 4 NH 2The compounds of the general formula (I) of the substituted aryl or heteroaryl ring system are prepared by diazotization with nitrous acid (generated in situ from sodium nitrite and a strong acid such as sulfuric acid). The resulting diazonium salt is reacted with water in a reaction suitably catalyzed by copper (I) (e.g. in the form of copper (I) oxide) to give R 4 An OH substituent is formed on the group.

[1090] Where R 4 NH 2 The compounds of the general formula (I) or (Ia) with substituted aryl or heteroaryl ring systems can be prepared by reducing the R 4 The reduction is generally achieved by hydrogenation, suitably catalysed by palladium.

[1091] Where R 4 Compounds of formula (I) or (Ia) which are aryl or heteroaryl ring systems substituted with nitro groups can be prepared by nitration of equivalent compounds of formula (I), for example using concentrated nitric acid mixed with sulfuric acid. Alternatively, the nitration can be carried out at an earlier stage of the process. For example, the nitration can be carried out on compounds of formula (III) or formula (IV) and these nitrated derivatives can then be converted into compounds of formula (I).

[1092] The R 4 A compound of the general formula (I) having an aryl or heteroaryl group with a halide substituent is converted into a compound of the general formula (I), wherein the halide substituent is replaced by CN, C(O)R 6 、C(O)OR 6 、C(O)N(R 6 )(R 7 )、N(R 7 )C(O)R 6 , R 19 or C 1-6 alkyl, which is optionally substituted by one or more substituents selected from the group consisting of halogen, CN, nitro, cycloalkyl, OR 6 , SR 6 NR 6 R 7 、C(O)R 6 C(O)OR 6 、C(O)N(R 6 )(R 7 ) and N(R 7 )C(O)R 6 , where R 6 and R 7As defined above in general formula (I). If desired, the alkenyl group may be reduced to an alkyl group by further methods such as hydrogenation.

[1093] For example, where R 4 Compounds of the general formula (I) having a halogenated substituent can be converted into compounds wherein R 4 For analogs having a cyano substituent, the reaction is suitably catalyzed by a palladium / phosphine complex such as tetrakis(triphenylphosphine)palladium(0).

[1094] Where R 4 With C(O)R 6 Substituted compounds of formula (I) may be prepared by reacting an equivalent halogen substituted compound with 1-vinyloxyalkane or vinyloxysilane via palladium / phosphine catalysis. Suitably, the reaction with vinyloxyalkane may be carried out in the presence of a base such as triethylamine and at elevated temperature (e.g. about 90 to 120°C) under pressure (e.g. in a sealed tube). The reaction with vinyloxysilane may be carried out in the presence of zinc fluoride and in an anhydrous solvent such as N,N-dimethylformamide at elevated temperature (e.g. about 60 to 80°C) under pressure (e.g. in a sealed tube). If desired, the carbonyl group may be reduced to an OH group, for example using a hydride reducing agent such as sodium borohydride.

[1095] Similarly, where R 4 The compound of general formula (I) having a halogen substituent can be converted into a compound of general formula (XXII) by a palladium / phosphine catalytic reaction followed by catalytic hydrogenation. 4 CH 2 CH 2 -C(O)OR 6 Substituted compounds:

[1096]

[1097] Where R 6 As defined in general formula (I), but preferably other than hydrogen.

[1098] The reaction with the compound of general formula (XXII) can be carried out under nitrogen pressure in the presence of a base such as triethylamine and at elevated temperature, for example about 60 to 80°C.

[1099] The hydrogenation can be catalyzed by palladium or palladium on carbon.

[1100] The obtained R 6 Compounds that are not hydrogen can be converted by hydrolysis into 6 Compounds which are hydrogen are usually hydrolyzed by base, for example using aqueous alkali metal hydroxide, such as lithium hydroxide.

[1101] R 4 CH 2 CH 2 -C(O)OH substituted product of general formula (I) is reduced to obtain 4 CH 2 CH 2 -CH 2 OH substituted compounds of formula (I). Suitably, the acid may first be converted into a mixed anhydride using a suitable alkyl chloroformate reagent (e.g. methyl chloroformate) and then reduced in situ to the desired alcohol using a suitable reducing agent (e.g. sodium borohydride). The reaction may be carried out in the presence of a base such as triethylamine.

[1102] Where R 4 With C(O)OR 6 Substituents (where R 6 The compound of general formula (I) which is not H) can be composed of 4 The halogen-substituted compound of formula (I) is prepared by reacting carbon monoxide with a suitable alcohol in a palladium / phosphine catalytic reaction. The catalyst may be prepared from a precatalyst, suitably a third generation Buchwald precatalyst such as XantPhos. Carbon monoxide may be prepared by reacting formic acid with a reagent such as methanesulfonyl chloride and a base such as triethylamine. The C(O)OR 6 The group can be converted to C(O)OH by hydrolysis, for example base hydrolysis using an alkali metal hydroxide such as lithium hydroxide.

[1103] In a palladium catalyzed reaction, a compound of formula (XXa) or (XXb) can be used to convert R 4 The compound of formula (I) having a halogen substituent is converted into a compound wherein R 4 C 1-6 Alkyl-substituted compound of formula (I), wherein C 1-6 Alkyl is OR 6 or NR 6 R 7 Substitution, where R 6 and R 7 As defined in general formula (I):

[1104]

[1105] Where R 6 and R 7 As defined in the general formula (I), M + is a metal ion, suitably a potassium ion, and Q is C 1-6 Alkylene, suitably -CH 2 -.

[1106] Suitably, the reaction is carried out under mild basic conditions, for example in the presence of sodium carbonate, at an elevated temperature, such as about 70 to 90°C.

[1107] Where R 4 Compounds of the general formula (I) in which R is substituted with halogen can be converted to compounds in which R is substituted with halogen by reaction with a suitable arylboronic acid. 4 The compound of formula (I) is an aryl group substituted with an aryl group. The reaction is suitably catalyzed by a palladium / phosphine catalyst (e.g. 1,1′-bis(diphenylphosphino)ferrocenepalladium dichloride (II). Suitably, the reaction can be carried out in an organic solvent such as 1,4-dioxane and at an elevated temperature of, for example, about 90 to 120° C. and under pressurized conditions, for example, in a sealed tube.

[1108] Where R 4 Compounds of formula (I) which are phenyl groups can be alkylated using a Friedel Crafts type alkylation by reaction with a suitable alcohol or alkyl halide in the presence of a strong Lewis acid catalyst (e.g. sulfuric acid). The position of the alkylation will depend on the position of the other substituents in the ring. For example, when R 4 In the case of 2-fluoro-5-hydroxyphenyl, alkylation would occur at the 4-position as shown in Example 91.

[1109] In the compounds of formula (I), the replacement of halogen with methyl can be achieved via Suzuki-Miyaura coupling reaction (Grey et al., Tetrahedron Letters, 41 (32), 6237-6240; 2000); the configuration of nitrile can be achieved as described by Willardsen et al. in Journal of Medicinal Chemistry, 47 (16), 4089-4099; 2004. The configuration of esters and amides can be achieved by carbonylation, as described by Veryser et al. in React. Chem. Eng., 2016, 1, 142-146.

[1110] Where R 4 To be OR 6 In the compounds of the general formula (I) having a substituted aryl or heteroaryl ring system, R 4 The group can be halogenated by reaction with a halogenating agent, for example N-halosuccinimide or bromine.

[1111] The reaction with N-halosuccinimide is carried out in a polar organic solvent such as acetonitrile and at elevated temperature (e.g., about 50 to 70° C.). The reaction with bromine can occur in a solvent such as acetic acid and at reduced temperature (e.g., about −5 to 5° C.).

[1112] Where R 4 C(O)R 6’Substitute (where R 6’ C 1-6 The compound of the general formula (I) wherein R is alkyl or haloalkyl) can be converted to the compound of the general formula (I) by reacting with a compound of the following formula (XXI) under reducing conditions, such as in the presence of a borohydride (e.g. sodium triacetoxyborohydride), wherein R 4 C(R 6’ )-NR 6 R 7 Substitution, where R 6 and R 7 As defined in general formula (I):

[1113]

[1114] Where R 6 and R 7 As defined in general formula (I). The reaction can be carried out in an organic solvent, such as a halogenated solvent (such as dichloroethane or dichloromethane), in the presence of a suitable acid (such as acetic acid) catalyst, and the reaction temperature can be about 15 to 25°C, usually room temperature.

[1115] Where R 4 The compound of formula (I) substituted with a haloalkyl group can be converted into a compound wherein R 4 Analogs substituted with cyanoalkyl. The reaction is suitably carried out at a temperature of about 15 to 80°C. In some cases, the reaction may require room temperature. The reaction solvent may be an aqueous solvent, typically a mixture of water and an organic solvent such as dichloromethane.

[1116] Make R 4 The reaction of the mutual conversion of the substituent groups on can also be carried out in the early stage of the method. For example, the compound of formula (III), (IV), (VI), (X), (XI) or (XV) can also be mutually converted in the same manner as the compound of formula (I).

[1117] In which R 1 is C(O)OH or R 1 or R 3 is substituted by C(O)OH or R 4 In compounds having a substituent comprising a C(O)OH group, the C(O)OH group may be reduced to an OH group using any suitable method. Hydride reducing agents such as lithium aluminum hydride are particularly suitable.

[1118] In the case of a primary or secondary amino group N(R) 2In the compounds of the general formula (I) in which the alkyl group is substituted, the amino group can be converted into a group -N(R)-C(O)-alkyl (wherein R is a group R 6 , R 12 or R 15 , depending on the position of the amino group in the molecule).

[1119] The primary and secondary amines in these compounds can be converted to the group -N(R)-C(O)O-alkyl by reaction with a carboxylic anhydride. The process can be reversed to produce the primary and secondary amines by treating the compound containing the alkyloxycarbonylamino substituent with an acid or with boron tribromide.

[1120] Where R 3 N(R 15 )S(O) 2 R 14 or N(R 15 )S(O) 2 R 16 The compound of the general formula (I) can be prepared by replacing R 3 N(R 15 ) 2 The compound of general formula (I) and sulfonyl halide WS (O) 2 R 14 or WS(O) 2 R 16 Reaction, wherein W is a halide, especially a chloride, and R 14 , R 15 and R 16 As defined above.

[1121] Where R 1 , R 3 or R 4 A compound of formula (I) comprising C(O)OR' (wherein R' is suitably R 6 , R 7 , R 12 or R 15 ) can be converted to a C(O)N(R')-containing group by reaction with a suitable amine in the presence of a coupling agent. 2 of compounds.

[1122] Other interconversions of various substituent groups can be carried out by methods familiar to those skilled in the art.

[1123] The compounds of the present invention are usually administered as part of a pharmaceutical composition. Therefore, the present invention further provides a pharmaceutical composition comprising general formula (I), (Iz), (Iy), (Ix), (Ia), (Ib), (Ic), (Id) or (Ie) and a pharmaceutically acceptable excipient.

[1124] The pharmaceutical compositions may be formulated for oral, rectal, nasal, bronchial (inhalation), topical (including dermal, transdermal, eye drop, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration and may be prepared by any methods well known in the pharmaceutical art.

[1125] The composition can be prepared by combining the active agent defined above with an excipient. Generally speaking, the preparation is prepared by uniformly and closely combining the active agent with a liquid carrier or a subdivided solid carrier or both, and then molding the product if necessary. The present invention also relates to a method for preparing a pharmaceutical composition, which comprises combining or combining a compound of formula (I) with a pharmaceutically acceptable carrier or medium.

[1126] The formulations of the present invention for oral administration may be in the form of discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active agent; powders or granules; solutions or suspensions of the active agent in an aqueous liquid or a non-aqueous liquid; or oil-in-water liquid emulsions or water-in-oil liquid emulsions; or boluses, and the like.

[1127] In compositions for oral administration (e.g., tablets and capsules), the term "acceptable carrier" includes carriers such as common excipients, such as binders, for example, syrup, gum arabic, gelatin, sorbitol, gum tragacanth, polyvinylpyrrolidone (povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose and starch; fillers and carriers, for example, corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid; and lubricants, such as magnesium stearate, sodium stearate and other metal stearates, stearyl glyceride, stearic acid, silicone oil, talc, waxes, oils and colloidal silica. Flavoring agents such as peppermint, wintergreen oil, cherry flavor and the like may also be used. It may be desirable to add colorants to make the dosage form easily recognizable. Tablets may also be coated by methods well known in the art.

[1128] Tablets are optionally prepared by compression or molding with one or more auxiliary agents. Compressed tablets can be prepared by compressing an active agent in a free-flowing form, such as a powder or granules, in a suitable machine, optionally mixed with a binder, lubricant, inert diluent, preservative, surfactant or dispersant. Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. Tablets can be optionally coated or scored, and can be formulated to provide a slow or controlled release of an active agent.

[1129] Other suitable formulations for oral administration include lozenges comprising the active agent in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active agent in an inert basis such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active agent in a suitable liquid carrier.

[1130] For topical application to the skin, the compounds of general formula (I) may be formulated into creams, ointments, jellies, solutions or suspensions etc. Cream or ointment formulations useful for the drug are conventional formulations known in the art, for example, as described in standard textbooks of pharmacology such as the British Pharmacopoeia.

[1131] Aerosol preparations can be used for topical administration to the lungs. Aerosol preparations typically include active ingredients suspended or dissolved in a suitable aerosol propellant, such as a chlorofluorocarbon (CFC) or a hydrofluorocarbon (HFC). Suitable CFC propellants include trichloromonofluoromethane (propellant 11), dichlorotetrafluoromethane (propellant 114), and dichlorodifluoromethane (propellant 12). Suitable HFC propellants include tetrafluoroethane (HFC-134a) and heptafluoropropane (HFC-227). Propellants typically account for 40%-99.5% of the total inhalation composition weight, for example: 40%-90%. The preparation may include excipients, including cosolvents (e.g., ethanol) and surfactants (e.g., lecithin, trioleic acid sorbitan ester, etc.). Other possible excipients include polyethylene glycol, polyvinyl pyrrolidone, glycerol, etc. Aerosol formulations are packaged in cans and delivered by means of a metering valve (for example supplied by Bespak, Valois or 3M or by Aptar, Coster or Vari) to deliver a suitable dose.

[1132] Non-pressurized formulations such as aqueous solutions or suspensions can also be used to achieve local administration to the lungs. These can be administered by means of a nebulizer, for example, which can be hand-held and portable or can be used at home or in hospitals (can also be non-portable). The formulation can contain excipients such as water, buffers, tension adjusters, pH adjusters, surfactants and co-solvents. Suspensions and aerosol formulations (whether pressurized or not) usually contain the compound of the invention in fine powder form, such as D 50 The particle size distribution can be D 10 , D 50 With D 90 The value represents the particle size distribution D 50 The median value is defined as the particle size in micrometers when the distribution is cut in half. The values ​​measured from the laser particle size analyzer will be more accurately described as volume distributions, so the D obtained using this procedure is 50 The value is more meaningful in terms of Dv 50The Dv value used in this article refers to the particle size distribution measured by a laser particle size analyzer. Similarly, the Dv value used by the laser particle size analyzer in this context 10 With D 90 The value is the average Dv 10 With Dv 90 value, and respectively means in D 10 The 10% distribution particle size below the value, and the D 90 The 90% distribution particle size is below the value.

[1133] Dry powder formulations may also be used for local administration to the lungs. Dry powder formulations will contain the compounds of the present disclosure in fine powder form, typically with a mass mean diameter (MMAD) of 1-10 μm or D 50 The particle size distribution of the compound of the present invention is 0.5-10 μm, for example, about 1-5 μm. The powder of the compound of the present invention in fine powder form can be prepared by a micronization process or a similar fine grinding method. A jet jet mill can be used for micronization, such as those manufactured by Hosokawa Alpine. A laser particle size analyzer (e.g., Malvern Mastersizer 2000S instrument) can be used to measure the resulting particle size distribution. The formulation usually contains a topically acceptable diluent, such as lactose, glucose or mannitol (preferably lactose), and the particle size is usually relatively large, for example, the mass mean diameter (MMAD) is 50 μm or more, for example, 100 μm or more or D 50 The term "lactose" as used herein refers to lactose-containing components, including α-lactose monohydrate, β-lactose monohydrate, α-lactose anhydrate, β-lactose anhydrate and amorphous lactose. The lactose component can be processed by micronization, sieving, grinding, compression, agglomeration or spray drying. It also includes various commercially available lactose forms, such as (inhalation grade lactose; DFE Pharma), 70 (sieved lactose for dry powder inhalers; Meggle), (DFE Pharma) and (Sieve inhalation grade lactose; DFE Pharma) and other products. In one embodiment, the lactose component is selected from α-lactose monohydrate, α-lactose anhydrate and amorphous lactose, preferably, the lactose is α-lactose monohydrate.

[1134] The dry powder formulation may also include other excipients. Thus in one embodiment, the dry powder formulation according to the present disclosure includes magnesium stearate or calcium stearate. The formulation may have excellent chemical and / or physical stability, especially when the formulation also includes lactose.

[1135] Dry powder formulations are typically delivered using a dry powder inhaler (DPI) device. Examples of dry powder delivery systems include and Examples of other dry powder delivery systems include ECLIPSE, NEXT, ROTAHALER, HANDIHALER, AEROLISER, CYCLOHALER, BREEZHALER / NEOHALER, MONODOSE, FLOWCAPS, TWINCAPS, X-CAPS, TURBOSPIN, ELPENHALER, MIATHALER, TWISTHALER, NOVOLIZER, PRESSAIR, ELLIPTA, ORIEL dry powder inhaler, MICRODOSE, PULVINAL, EASYHALER, ULTRAHALER, TAIFUN, PULMOJET, OMNIHALER, GYROHALER, TAPER, CONIX, XCELOVAIR, and PROHALER.

[1136] In one embodiment, the compound of formula (I) is provided as a micronized dry powder formulation, for example containing a suitable grade of lactose.

[1137] Therefore, one aspect of the present invention is to provide a pharmaceutical composition comprising a compound of formula (I) in granular form and granular lactose, said composition optionally comprising magnesium stearate.

[1138] In one embodiment, the compound of formula (I) is provided in the form of a micronized dry powder formulation, which contains a suitable grade of lactose and magnesium stearate, filled into a device such as DISKUS. Suitably, the device is a multi-dose device, for example, the formulation is filled into a blister for a multiple unit dose device such as DISKUS.

[1139] In another embodiment, the compound of formula (I) is provided as a micronized dry powder formulation, for example containing a suitable grade of lactose, filled into a hard shell capsule for use in a single dose device, for example AEROLISER.

[1140] In another embodiment, the compound of formula (I) is provided as a micronized dry powder formulation, comprising a suitable grade of lactose and magnesium stearate, filled into a hard shell capsule for use in a single dose device, such as AEROLISER.

[1141] In another embodiment, there is provided a compound of formula (I) in a fine powder form for inhalation, wherein the powder is D 50The fine particles of 0.5-10 μm, for example, about 1-5 μm, are obtained by fine grinding rather than jet mill micronization, such as spray drying, spray freezing, microfluidization, high pressure homogenization, supercritical fluid crystallization, ultrasonic crystallization or a combination of these methods, or other suitable particle formation methods known in the art can be used to produce fine particles with an aerodynamic particle size of 0.5-10 μm. The particle size distribution produced can be measured using a laser particle size analyzer (e.g., Malvern Mastersizer 2000S instrument). The particles can contain only the compound or be combined with other suitable excipients that are helpful for processing. The fine particles produced can form a final formulation for delivery to humans or optionally further formulated with other suitable excipients to facilitate delivery in an acceptable dosage form.

[1142] The compounds of the invention can also be administered rectally, for example in the form of suppositories or enemas, including aqueous or oily solutions and suspensions and emulsions and foams. The compositions are prepared by standard methods well known to those skilled in the art. For example, suppositories can be prepared by mixing the active ingredient with a conventional suppository base (e.g., cocoa butter or other glycerides). In this case, the drug is mixed with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will therefore melt in the rectum to release the drug. The substances are cocoa butter and polyethylene glycol.

[1143] Normally, for compositions intended for topical application to the eye in the form of eye drops or eye ointment, the total amount of compounds of formula (I) will be from about 0.0001 to less than 4.0% (w / w).

[1144] Preferably, for topical ocular administration, the composition administered according to formula (I) will be formulated into solutions, suspensions, emulsions and other dosage forms. Aqueous solutions are generally preferred because they are easy to prepare and the patient can easily apply such compositions by dropping one or two drops of solution into the affected eye. However, the composition may also be a suspension, a viscous or semi-viscous gel or other solid or semi-solid composition. For compounds that are poorly soluble in water, a suspension may be preferred.

[1145] Another method of administration to the eye is by intravitreal injection of a solution or suspension of a compound of formula (I). In addition, the compounds of formula (I) may be delivered using ocular implants or inserts.

[1146] The composition according to formula (I) may also include various other ingredients, including but not limited to tonicity agents, buffers, surfactants, stabilizing polymers, preservatives, co-solvents and viscosity building agents. Suitable pharmaceutical compositions of formula (I) include compounds of the invention formulated with tonicity agents and buffers. Pharmaceutical compositions of formula (I) may further optionally include surfactants and / or demulcents and / or stabilizing polymers.

[1147] Various tonicity agents can be used to adjust the tonicity of the composition, preferably adjusting the ophthalmic composition to the tonicity of natural tears. For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, monosaccharides such as dextrose, fructose, galactose, and / or simple polyols such as sugar alcohols, mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol, and hydrogenated starch hydrolysates can be added to the composition to approach physiological tonicity. The amount of tonicity agent will depend on the specific agent added. However, the tonicity agent content of the composition will generally be sufficient to give the final composition an ophthalmologically acceptable osmotic pressure (generally about 150-450 mOsm, preferably 250-350 mOsm, and optimally about 290 mOsm). In general, the content of the tonicity agent of the present invention will be present in the range of 2 to 4% w / w. Preferred tonicity agents of the present invention include simple sugars or sugar alcohols, such as D-mannitol.

[1148] A suitable buffer system (e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid) may be added to the composition to prevent pH drift under storage conditions. The specific concentration will depend on the pharmaceutical agent used. However, it is preferred to select a buffer that can maintain the target pH in the range of pH 5 to 8, more preferably at a target pH of pH 5 to 7.

[1149] Surfactants may be optionally used to deliver higher concentrations of the compound of formula (I). The function of the surfactant is to dissolve the compound and stabilize colloidal dispersions, such as micellar solutions, microemulsions, emulsions and suspensions. Examples of surfactants that are optionally used include polysorbates, poloxamers, polyosyl 40 stearate, polyoxylated castor oil, tyloxapol, Triton and sorbitan monolaurate. Preferred surfactants used in the present invention have a hydrophilicity / lipophilicity / balance "HLB" in the range of 12.4 to 13.2 and are ophthalmically acceptable, such as Triton X114 and tyloxapol.

[1150] Other agents that may be added to ophthalmic compositions of compounds of formula (I) are demulcents that act as stabilizing polymers. The stabilizing polymers should be ionic / charged examples, preferably for topical ocular use, more specifically polymers with negative charges on their surface, thus exhibiting physical stability with a zeta potential (-) of 10-50 mV, and capable of forming a dispersion in water (i.e., water soluble). Preferred stabilizing polymers of the present invention are polyelectrolytes, or if there is more than one, polyelectrolytes from the family of cross-linked polyacrylates, such as carbomers and Pemulen (R), specifically Carbomer 974p (polyacrylic acid), 0.1-0.5% w / w.

[1151] Other compounds may also be added to the ophthalmic composition of the compound of formula (I) to increase the viscosity of the carrier. Examples of viscosity enhancers include, but are not limited to, polysaccharides, such as hyaluronic acid and its salts, chondroitin sulfate and its salts, dextran, various polymers of the cellulose family; vinyl polymers; and acrylic polymers.

[1152] Topical ophthalmic products are usually packaged in multiple doses and therefore require preservatives to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methylparaben, propylparaben, phenylethyl alcohol, disodium edetate, sorbic acid, polyquaternium-1 or other agents known to those skilled in the art. These preservatives are usually used in an amount of 0.001 to 1.0% w / v. The unit dose composition of formula (I) is sterile, but is usually not preservative. Therefore, such compositions usually do not contain a preservative.

[1153] Parenteral formulations are generally sterile.

[1154] A medical practitioner or other skilled artisan will be able to determine appropriate dosages of compounds of Formula (I), (Ia) or (Ib), and therefore the amount of the compound to be included in any particular pharmaceutical formulation, whether in unit dosage form or otherwise.

[1155] The compounds of general formula (I) may be used in combination with one or more other active agents useful in the treatment or prevention of respiratory diseases and disorders.

[1156] Such additional active agents may be included in the above-mentioned pharmaceutical compositions, but alternatively, they may also be administered separately, either simultaneously or earlier or later than the compound of general formula (I).

[1157] Therefore, another aspect of the present invention is to provide a product comprising a compound of general formula (I) and another active agent for the treatment or prevention of respiratory disorders, which product is used as a combined preparation for simultaneous, sequential or separate use in the treatment of diseases or disorders affected by TMEM16A regulation, especially respiratory diseases or disorders, such as one of the above-mentioned diseases and disorders.

[1158] Also provided is a combination of a compound of formula (I) and another active agent for treating or preventing respiratory disorders as a combined preparation for simultaneous, sequential or separate use in treating a disease or disorder affected by TMEM16A regulation, in particular a respiratory disease or disorder, such as one of the above-mentioned diseases and disorders.

[1159] Suitable additional active agents that may be included in the pharmaceutical compositions or combined preparations of compounds of general formula (I) include:

[1160] β2 adrenergic receptor agonists, such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, indacaterol, terbutaline, orciprenaline, bitolterol mesylate, pirbuterol, olodaterol, vilanterol and abediterol;

[1161] Antihistamines, such as histamine H 1 receptor antagonists, such as loratadine, cetirizine, desloratadine, levocetirizine, fexofenadine, astemizole, astemizole, and chlorpheniramine, or H 4 Receptor antagonist; dornase alpha;

[1162] Corticosteroids, such as prednisone, corticosterone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, mometasone furoate and fluticasone furoate;

[1163] Leukotriene antagonists, such as montelukast and zafirlukast;

[1164] Anticholinergic compounds, in particular muscarinic antagonists, for example ipratropium, tiotropium, glycopyrrolate, aclidinium and umeclidinium;

[1165] CFTR repair therapies (e.g., CFTR potentiators, modifiers, or amplifiers), such as Ivacaftor, QBW251, VX659, VX445, VX561 / CPT-656, VX152, VX440, GLP2737, GLP2222, GLP2451, PTI438, PT1801, PTI808, FDL-169, and FDL-176, and CFTR modifiers, such as Lumacaftor and Tezacaftor;

[1166] ENaC modulators, particularly ENaC inhibitors;

[1167] antibiotic;

[1168] Airway moisturizers (osmolytes), such as hypertonic saline and mannitol and

[1169] Mucolytic agents, such as N-acetylcysteine.

[1170] When the additional active agent is an ENaC modulator, it may be an ENaC inhibitor, such as amiloride, VX-371, AZD5634, QBW276, SPX-101, BI443651 and ETD001. Other suitable ENaC blockers are described in our applications WO 2017 / 221008, WO 2018 / 096325, PCT / GB2018 / 052982 and GB1808093.7, and any of the exemplified compounds of these applications may be used in combination with the compound of formula (I). Compounds particularly suitable for use in combination with the compound of formula (I) include compounds having cations selected from:

[1171] 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)ethyl]-6-(4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}piperidine-1-carbonyl)-1,3-diethyl-1H-1,3-benzodiazol-3-ium;

[1172] 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-6-{[2-(4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}piperidin-1-yl)ethyl]carbamoyl}-1,3-diethyl-1H-1,3-benzodiazol-3-ium;

[1173] 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-5-[4-({bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}methyl)piperidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium;

[1174] 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-6-[(3R)-3-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}pyrrolidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium;

[1175] 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-6-[(3S)-3-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}pyrrolidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium;

[1176] 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-1,3-diethyl-6-{[(1r,4r)-4-{bis[(2S,3R,4R,SR)-2,3,4,5,6-pentahydroxyhexyl]amino}cyclohexyl]carbamoyl}-1H-1,3-benzodiazol-3-ium;

[1177] 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-1,3-diethyl-6-{[(1s,4s)-4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}cyclohexyl]carbamoyl}-1H-1,3-benzodiazol-3-ium;

[1178] and suitable anions such as halide, sulfate, nitrate, phosphate, formate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate or p-toluenesulfonate.

[1179] The present invention is illustrated by the following non-limiting examples and accompanying drawings, in which:

[1180] Figure 1 is an example trace from the whole-cell patch clamp (Qpatch) TMEM16A potentiator assay used in Biological Example 95 and illustrates the methods used in the assay. Figure 1 In the figure: S is saline; V is medium; #1 is test compound concentration #1; #2 is test compound concentration 2; #3 is test compound concentration 3; #4 is test compound concentration 4; #5 is test compound concentration 5; R is reference. The arrow in the V column indicates the baseline current, I BL The arrows in columns #1, #2, #3, #4, #5 and R represent [#1] ,I [#2] ,I [#3] ,I [#4] ,I [#5] and I [Ref] , which are the peak currents of test compound concentrations #1 to #5 and the reference during the incubation period. Example

[1181] The invention is illustrated by the following examples.

[1182] General conditions:

[1183] Mass spectra were performed on LC-MS systems using electrospray ionization, these were run using a Waters Acquity uPLC system or a Shimadzu LCMS-2010EV system with a Waters PDA and ELS detector. [M+H]+ means monoisotopic molecular weight.

[1184] NMR spectra were recorded on a Bruker Avance III HD 500 MHz, Bruker Avance III HD 250 MHz or a SmartProbe 400 MHz Avance III HD Nanobay with a 5 mm Broad Band Inverse probe, using the solvent as an internal deuterium lock. Unless otherwise stated, spectra were recorded at room temperature and referenced using the solvent peak.

[1185]

[00136] Referring to the following examples, compounds of the preferred embodiments were synthesized using the methods described herein or other methods known in the art.

[1186] Where appropriate, conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation and chromatography can be used to separate and purify the various raw materials, intermediates and compounds of the preferred embodiments. Unless otherwise indicated, all raw materials are obtained from commercial suppliers and can be used without further purification. Salts can be prepared from compounds by known salt-forming methods.

[1187] By Purify compounds by flash column chromatography on normal phase silica gel using an appropriate SNAP cartridge and gradient. Alternatively, use an Isolera system with an appropriate SNAP C18 cartridge and reverse phase eluent. Compounds were purified on reverse phase silica gel using the Isolera system or by preparative HPLC where otherwise stated.

[1188] Preparative HPLC using acidic pH, early elution method

[1189] Purification was performed on a Gilson LC system using a Waters Sunfire C18 column (30 mm x 100 mm, 10 μM; temperature: RT) with a gradient of 10-95% B (A = water containing 0.1% formic acid; B = acetonitrile containing 0.1% formic acid) over 14.44 minutes, then 95% B for 2.11 minutes, an injection volume of 1500 μL, a flow rate of 40 mL / min, and UV spectra were recorded at 215 nm using a Gilson detector.

[1190] Preparative HPLC using acidic pH, standard elution method

[1191] Purification by preparative HPLC (acidic pH, standard elution method) was performed on a Gilson LC system using a Waters Sunfire C18 column (30 mm x 100 mm, 10 μM; temperature: RT) with a gradient of 30-95% B (A = water containing 0.1% formic acid; B = acetonitrile containing 0.1% formic acid) over 11 minutes, then 95% B for 2.11 minutes, with an injection volume of 1500 μL and a flow rate of 40 mL / min, UV spectra were recorded at 215 nm using a Gilson detector.

[1192] Preparative HPLC using basic pH, early elution method

[1193] Purification by preparative HPLC (basic pH, early elution method) was carried out on a Gilson LC system using a Waters Xbridge C18 column (30 mm x 100 mm, 10 μM; temperature: RT) and a gradient of 10-95% (A = water containing 0.2% ammonium hydroxide; B = acetonitrile containing 0.2% ammonium hydroxide) over 14.44 minutes, then 95% B for 2.11 minutes, with an injection volume of 1500 μL and a flow rate of 40 mL / min, UV spectra were recorded at 215 nm using a Gilson detector.

[1194] Preparative HPLC using basic pH, standard elution method

[1195] Purification by preparative HPLC (basic pH, standard elution method) was performed on a Gilson LC system using a Waters Xbridge C18 column (30 mm x 100 mm, 10 μM; temperature: RT) with a gradient of 30-95% (A = water containing 0.2% ammonium hydroxide; B = acetonitrile containing 0.2% ammonium hydroxide) over 11 minutes, then 95% B for 2.11 minutes, with an injection volume of 1500 μL and a flow rate of 40 mL / min, UV spectra were recorded at 215 nm using a Gilson detector.

[1196] If not otherwise stated, analytical HPLC conditions were as follows:

[1197] Method A

[1198] Column: Phenomenex Kinetix-XB C18 2.1 x 100 mm, 1.7 μm

[1199] Column temperature 40℃

[1200] Eluent: A: H20 0.1% formic acid, B: acetonitrile, 0.1% formic acid

[1201] Flow rate: 0.6mL / min

[1202] Gradient: 0-5.3 min 5-100% B, 5.3-5.8 min 100% B, 5.8-5.82 min 100-5% B, 5.82-7.00 min 5% B

[1203] Method B

[1204] Column: Waters CSH TM C182.1x 100mm 1.7μm

[1205] Column temperature 40℃

[1206] Eluent: A: 2 mM ammonium bicarbonate, buffered to pH 10, B: acetonitrile

[1207] Flow rate: 0.6mL / min

[1208] Gradient: 0-5.3 min 5-100% B, 5.3-5.8 min 100% B, 5.8-5.82 min 100-5% B, 5.82-7.00 min 5% B

[1209] Method C

[1210] Column: Waters BEH TM C18 2.1x 100mm 1.7μm

[1211] Column temperature 40℃

[1212] Eluent: A: 2 mM ammonium bicarbonate, buffered to pH 10, B: acetonitrile

[1213] Flow rate: 0.6mL / min

[1214] Gradient: 0-5.3 min 5-100% B, 5.3-5.8 min 100% B, 5.8-5.82 min 100-5% B, 5.82-7.00 min 5% B

[1215] Method D

[1216] Column: Waters Atlantis dC18 2.1 x 100mm 3μm

[1217] Column temperature 40℃

[1218] Eluent: A: H20 + 0.1% formic acid, B: acetonitrile + 0.1% formic acid

[1219] Flow rate: 0.6mL / min

[1220] Gradient: 0-5 min 5-100% B, 5-5.4 min 100% B, 5.4-5.42 min 100-5% B, 5.42-7.00 min 5% B

[1221] Method E

[1222] Column: Kinetex Core-Shell C182.1x 50mm 5μm

[1223] Column temperature 40℃

[1224] Eluent: A: H20 + 0.1% formic acid, B: acetonitrile + 0.1% formic acid

[1225] Flow rate: 1.2mL / min

[1226] Gradient: 0-1.20 min 5-100% B, 1.20-1.30 min 100% B, 1.30-1.31 min 100-5% B

[1227] Method F

[1228] Column: Phenomenex Gemini-NX C18 2x 50mm 3μm

[1229] Column temperature 40℃

[1230] Eluent: A: 2 mM ammonium bicarbonate, buffered to pH 10, B: acetonitrile

[1231] Flow rate: 1mL / min

[1232] Gradient: 0-1.80 min 1-100% B, 1.80-2.10 min 100% B, 2.10-2.30 min 100-1% B

[1233] The following examples are intended to illustrate the present invention and should not be construed as limiting it. Temperatures are given in degrees Celsius. If not otherwise mentioned, all evaporations are carried out under vacuum, preferably between about 15 mm Hg and 100 mm Hg (=20-133 mbar). The structures of final products, intermediates and starting materials are confirmed by standard analytical methods, such as microanalysis and spectral characteristics, such as MS, IR and NMR. Abbreviations used are those conventional in the art. If not defined, these terms have their commonly accepted meanings.

[1234] abbreviation

[1235] aq. containing water

[1236] br Width

[1237] d Doublet

[1238] dd double peaks

[1239] DCM Dichloromethane

[1240] DIPEA Diisopropylethylamine

[1241] DMF N,N-Dimethylformamide

[1242] EDCl 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

[1243] EtOAc Ethyl acetate

[1244] HOAt 1-Hydroxy-7-azabenzotriazole

[1245] HATU 2-(7-Aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate

[1246] HPLC High Pressure Liquid Chromatography

[1247] MeCN Acetonitrile

[1248] MeOH Methanol

[1249] MS mass spectrometry

[1250] m multiplet

[1251] min

[1252] mL milliliters

[1253] m / z mass-to-charge ratio

[1254] NCS N-Chlorosuccinimide

[1255] NMR Nuclear Magnetic Resonance

[1256] PTFE Polytetrafluoroethylene

[1257] Rt retention time

[1258] s Single peak

[1259] t Triple Peak

[1260] TBME tert-butyl methyl ether

[1261] TBTU N,N,N',N'-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate

[1262] TEA Triethylamine

[1263] TFA Trifluoroacetic acid

[1264] THF Tetrahydrofuran

[1265] 1,2-Propylphosphonic anhydride

[1266] Preparation of Examples

[1267] Example 1

[1268] N-tert-Butyl-4-[[2-(2-hydroxyphenyl)acetyl]amino]pyridine-2-carboxamide

[1269]

[1270] Step 1: 4-[[2-(2-methoxyphenyl)acetyl]amino]pyridine-2-carboxylic acid methyl ester

[1271]

[1272] To a solution of 2-(2-methoxyphenyl)acetic acid (218 mg, 1.31 mmol) in DMF (4 mL) were added HOAt (179 mg, 1.31 mmol), EDCI (328 mg, 1.71 mmol), DIPEA (574 μL, 3.29 mmol) and methyl 4-aminopyridine-2-carboxylate (200 mg, 1.31 mmol), and the mixture was stirred at room temperature for 6 hours and 15 minutes. The resulting mixture was partitioned with H 2 O (30 mL) and DCM (30 mL), and the two phases were separated. The aqueous phase was further extracted with DCM (30 mL), and the combined organic extracts were washed with brine and purified by Na 2 SO 4 Dry, filter, and concentrate in vacuo. The crude product is purified by silica gel chromatography eluting with EtOAc in heptane to afford the title compound as a light yellow gum.

[1273] 1H NMR (500MHz, chlorine-proof-d) δ8.58 (d, J=5.5Hz, 1H), 8.10 (s, 1H), 7.92 (dd, J=5.5, 2.2Hz, 1H), 7.84 (d, J=2.1Hz, 1H) , 7.37-7.32 (m, 1H), 7.29 (dd, J=7.4, 1.5Hz, 1H), 7.04-6.97 (m, 2H), 3.98 (s, 3H), 3.97 (s, 3H), 3.75 (s, 2H).

[1274] LC-MS (Method E): Rt 0.96 min; MS m / z 301.1 = [M+H]+ (99% @ 215 nm)

[1275] Step 2: 4-[[2-(2-Hydroxyphenyl)acetyl]amino]pyridine-2-carboxylic acid

[1276]

[1277] A solution of methyl 4-[[2-(2-methoxyphenyl)acetyl]amino]pyridine-2-carboxylate (step 1) (119 mg, 0.4 mmol) in DCM (1.2 mL) was cooled to 0 °C and washed with 1 M BBr 3 The reaction mixture was treated with DCM (2.38 mL, 2.38 mmol) over 15 min and stirred at 0 °C for 1 h. After warming to room temperature, the reaction was further stirred for 19 h. Another portion of 1 M BBr was added at room temperature. 3 of DCM (1.19 mL, 1.19 mmol) was added and stirring was continued for another 72 h. Water (25 mL) was slowly added to the reaction mixture and the biphasic solution was then concentrated under vacuum to give the title compound as a brown solid.

[1278] 1H NMR (500 MHz, methanol-d4) δ 8.68-8.60 (m, 2H), 8.39 (dd, J=6.7, 2.4 Hz, 1H), 7.18 (dd, J=7.7, 1.6 Hz, 1H), 7.15-7.10 (m, 1H), 6.85-6.79 (m, 2H), 3.84 (s, 2H). (Compound purity 85%).

[1279] LC-MS (Method E): Rt 0.74 min; MS m / z 273.0 = [M+H]+ (92% @ 215 nm)

[1280] Step 3: N-tert-butyl-4-[[2-(2-hydroxyphenyl)acetyl]amino]pyridine-2-carboxamide

[1281] A solution of 4-[[2-(2-hydroxyphenyl)acetyl]amino]pyridine-2-carboxylic acid (step 2) (138 mg, 0.43 mmol) in DMF (1.5 mL) was treated with EDCI (107 mg, 0.56 mmol), HOAt (59 mg, 0.43 mmol), DIPEA (113 μL, 0.65 mmol) and 2-methylpropan-2-amine (45 μL, 0.43 mmol). The reaction mixture was stirred at room temperature for 21 hours and then concentrated under vacuum. The crude residue was purified by preparative HPLC (acidic pH, early elution method) and the product containing fractions were freeze-dried to give the title compound as a white solid.

[1282] 1H NMR (500MHz, DMSO-d6) δ10.65 (s, 1H), 9.49 (s, 1H), 8.43 (d, J = 5.5Hz, 1H), 8.18 (d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7.82 (dd, J = 5.5, 2.2Hz, 1H), 7 .13 (dd, J=7.5, 1.5Hz, 1H), 7.07 (td, J=7.8, 1.7Hz, 1H), 6.79 (dd, J=8.0, 0.9Hz, 1H), 6.75 (td, J=7.4, 1.1Hz, 1H), 3.65 (s, 2H), 1.39 (s, 9H).

[1283] LC-MS (Method A): Rt 2.86 min; MS m / z 328.2 = [M+H]+ (100% @ 215 nm)

[1284] Example 1.1

[1285] N-(1,1-dimethylpropyl)-3-[[2-(2-hydroxyphenyl)acetyl]amino]benzamide

[1286]

[1287] Step 1: Methyl 3-[[2-(2-methoxyphenyl)acetyl]amino]benzoate

[1288]

[1289] 2-(2-Methoxyphenyl)acetic acid (1.09 g, 6.62 mmol) in DMF (1.5 mL) was treated with HOAt (900 mg, 6.62 mmol), EDCI (1.65 g, 8.6 mmol), DIPEA (2.89 mL, 16.54 mmol) and methyl 3-aminobenzoate (1.0 g, 6.62 mmol). The mixture was stirred at room temperature for 3.5 h. The resulting mixture was partitioned with H2 O (30 mL) and DCM (30 mL), the two phases were separated. The aqueous phase was further extracted with DCM (30 mL), the combined organic extracts were washed with brine, 2 SO 4 Dry, filter, and concentrate under vacuum.The crude product is purified by silica gel chromatography eluting with EtOAc in heptane to give the title compound as a beige crystalline solid.

[1290] 1H NMR (500MHz, DMSO-d6) δ10.28 (s, 1H), 8.30 (t, J=1.8Hz, 1H), 7.86-7.80 (m, 1H), 7.62 (dt, J=7.7, 1.2Hz, 1H), 7.44 (t, J=7 .9Hz, 1H), 7.28-7.19 (m, 2H), 6.98 (d, J=7.9Hz, 1H), 6.90 (td, J=7.4, 0.9Hz, 1H), 3.84 (s, 3H), 3.76 (s, 3H), 3.64 (s, 2H).

[1291] LC-MS (Method E): Rt 1.10 min; MS m / z 300.0 = [M+H]+ (100% @ 215 nm)

[1292] Step 2: 3-[[2-(2-Hydroxyphenyl)acetyl]amino]benzoic acid

[1293]

[1294] A solution of methyl 3-[[2-(2-methoxyphenyl)acetyl]amino]benzoate (step 1) (1.21 g, 4.04 mmol) in DCM (15 mL) was cooled to 0 °C and treated with 1 M BBr over 15 min. 3 The mixture was treated with DCM (16.17 mL, 16.17 mmol). After the addition was complete, the mixture was stirred at 0 °C for 1 hour and then at room temperature for 19 hours. Water (50 mL) was slowly added to the mixture and the DCM was concentrated in vacuo. The aqueous residue was extracted with EtOAc (2 x 50 mL), and the combined organic extracts were washed with brine (15 mL), filtered through Na 2 SO 4 The recovered material was suspended in DCM (7.5 mL), cooled to 0 °C and washed with 1 M BBr 3The mixture was stirred for 1 hour at 0 ° C and then at room temperature for 4 hours. Water (100 mL) was slowly added to the reaction mixture and the DCM was concentrated under vacuum. The resulting mixture was extracted with EtOAc (2 x 100 mL), the combined organic extracts were washed with brine (15 mL), and the mixture was precipitated with Na 2 SO 4 Dry, filter, and concentrate in vacuo to give the title compound as a straw colored solid.

[1295] 1H NMR (500MHz, DMSO-d6) δ12.89 (s, 1H), 10.22 (s, 1H), 9.47 (s, 1H), 8.24 (t, J=1.7Hz, 1H), 7.86-7.80 (m, 1H), 7.60 (dt, J=7.7, 1.2Hz, 1H), 7.41 (t , J=7.9Hz, 1H), 7.14 (dd, J=7.5, 1.4Hz, 1H), 7.07 (td, J=7.8, 1.7Hz, 1H), 6.80 (dd, J=8.0, 0.9Hz, 1H), 6.75 (td, J=7.4, 1.1Hz, 1H), 3.61 (s, 2H).

[1296] LC-MS (Method E): Rt 0.93 min; MS m / z 272.1 = [M+H]+ (92% @ 215 nm)

[1297] Step 3: N-(1,1-dimethylpropyl)-3-[[2-(2-hydroxyphenyl)acetyl]amino]benzamide

[1298] To a solution of 3-[[2-(2-hydroxyphenyl)acetyl]amino]benzoic acid (step 2) (70 mg, 0.24 mmol) in DMF (1 mL) was added EDCI (59 mg, 0.31 mmol), HOAt (32 mg, 0.24 mmol), DIPEA (62.2 μL, 0.36 mmol) and 2-methylbutan-2-amine (36.1 μL, 0.31 mmol) and the mixture was stirred at room temperature for 17 hours. The resulting mixture was partitioned between water (5 mL) and DCM (5 mL), the organic layer was collected using a hydrophobic frit and concentrated under vacuum. The residue was purified via preparative HPLC (acidic pH, early elution method) and the product fractions were lyophilized overnight to give the title compound as an off-white powder.

[1299] 1H NMR (500MHz, DMSO-d6) δ10.15 (s, 1H), 9.49 (s, 1H), 7.89 (t, J=1.8Hz, 1H), 7.80-7.74 (m, 1 H), 7.54 (s, 1H), 7.40 (dt, J=7.7, 1.2Hz, 1H), 7.33 (t, J=7.9Hz, 1H), 7.14 (dd, J=7.5, 1.6H z, 1H), 7.06 (td, J=7.8, 1.7Hz, 1H), 6.80 (dd, J=8.0, 1.0Hz, 1H), 6.75 (td, J=7.4, 1.1Hz, 1 H), 3.60 (s, 2H), 1.77 (q, J=7.5Hz, 2H), 1.30 (s, 6H), 0.80 (t, J=7.5Hz, 3H). LC-MS (Method A): Rt 2.96min; MS m / z 341.2=[M+H]+(99%@215nm).

[1300] The compounds of the examples listed in the table below (Table 1) were prepared analogously to Example 1 by replacing 2-(2-methoxyphenyl)acetic acid (step 1) and methyl 4-aminopyridine-2-carboxylate (step 1) with appropriate commercially available acids and amines and by replacing 2-methylpropan-2-amine (step 3) with appropriate amines.

[1301]

[1302]

[1303]

[1304] Example 1.6

[1305] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide

[1306]

[1307] To a solution of 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid (Example 31 Step 1) (800 mg, 2.61 mmol), 1-methylcyclobutylamine hydrochloride (381 mg, 3.13 mmol) and TEA (800 μL, 5.74 mmol) in DMF (15 mL) was added HATU (1.19 g, 3.13 mmol), and the mixture was stirred at room temperature overnight. The resulting mixture was concentrated under vacuum, and the residue was dissolved in EtOAc and washed with 1 M aqueous HCl, NaHCO 3The organic extract was washed with aqueous solution, brine and 1M NaOH solution. 2 SO 4 The crude product was purified by silica gel chromatography using heptane containing 50-100% ethyl acetate to produce a pale yellow foam. The separated material was recrystallized by dissolving in methanol (15 mL) and heating to reflux until all solids dissolved, the mixture was slowly cooled to room temperature, and the resulting crystals were filtered to obtain a light yellow solid of the title compound.

[1308] 1H NMR (500MHz, DMSO-d6) δ10.67 (s, 1H), 9.81 (s, 1H), 8.47 (s, 1H), 8.45 (d, J = 5.5Hz, 1H), 8.15 (d, J = 1.9Hz, 1H), 7.82 (dd, J = 5.5, 2.2Hz, 1H), 7.22 (d, J =2.7Hz, 1H), 7.12 (dd, J = 8.6, 2.7Hz, 1H), 6.80 (d, J = 8.6Hz, 1H), 3.67 (s, 2 H), 2.42-2.36(m, 2H), 2.02-1.96(m, 2H), 1.84-1.77(m, 2H), 1.47(s, 3H).

[1309] LC-MS (Method A): Rt 3.24 min; MS m / z 374.3 / 376.3 = [M+H]+ (100% @ 215 nm)

[1310] Example 1.10

[1311] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-cyclohexyl-pyridine-2-carboxamide

[1312]

[1313] Step 1: 4-[[2-(5-Chloro-2-methoxy-phenyl)acetyl]amino]-N-cyclohexyl-pyridine-2-carboxamide

[1314]

[1315] A solution of 4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid (Example 8.1 Step 2) (3.0 g, 9.07 mmol), cyclohexylamine (1.25 mL, 10.89 mmol), EDCI (2.09 g, 10.89 mmol), HOAt (1.48 g, 10.89 mmol) and DIPEA (3.17 mL, 18.15 mmol) in DMF (30 mL) was stirred at room temperature for 19.5 hours. The resulting mixture was concentrated under vacuum and the residue was partitioned between EtOAc (200 mL) and water (200 mL). The organic portion was separated and the aqueous layer was extracted again with EtOAc (2 x 100 mL). The combined organic extracts were washed with water (2 x 100 mL), brine (2 x 100 mL) and purified by Na 2 SO 4 .4 4 3 4 5 6 7 8 9 10 12 14 16 18 19 20 21 23 24 28 29 30 40 41 42 43 45 46 47 48 48 49 50 50 51 52 53 48 49 51 51 50 2 SO 4 Drying and concentration in vacuo afforded the title compound as a red / brown solid.

[1316] 1H NMR (500MHz, DMSO-d6) δ10.69 (s, 1H), 8.47 (d, J = 5.5Hz, 1H), 8.38 (d, J = 8.6Hz, 1H), 8.18 (d, J = 2.1Hz, 1H), 7.81 (dd, J = 5.5, 2.2Hz, 1H), 7. 35-7.27(m,2H),7.05-6.98(m,1H),3.76(s,3H),3.71(s,2H),1.85-1 .67(m, 4H), 1.64-1.53(m, 1H), 1.45-1.27(m, 4H), 1.25-1.03(m, 2H).

[1317] LC-MS (Method E): Rt 1.26 min; MS m / z 402.0 / 404.1 = [M+H]+ (89% @ 215 nm)

[1318] Step 2: 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-cyclohexyl-pyridine-2-carboxamide

[1319] 1M BBr 34-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-N-cyclohexyl-pyridine-2-carboxamide (step 1) (3.2 g, 7.09 mmol) in DCM (50 mL) was added to a stirred suspension of 4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-N-cyclohexyl-pyridine-2-carboxamide (step 1) (3.2 g, 7.09 mmol) in DCM (50 mL) at 0°C. After addition, the ice bath was removed and the reaction was stirred at room temperature for 2 hours. The reaction was quenched by the slow addition of water (-70 mL) and the mixture was partially concentrated under vacuum to remove volatile solvents. EtOAc (200 mL) was added followed by water (100 mL), the organic portion was separated, the aqueous layer was extracted with EtOAc (100 mL), and the combined organics were washed with saturated NaHCO 3 (2 x 150 mL), brine (100 mL), and Na 2 SO 4 The crude product was purified by reverse phase chromatography on C18 using 10-100% MeCN in water and 0.1% formic acid as eluent to give a dark brown / orange solid. The solid was dissolved in a minimum volume of boiling MeCN (-100 mL) and allowed to stand overnight. The resulting crystals were collected by vacuum filtration and dried in a vacuum oven at 40°C for 5 hours to give the title compound as light beige needles.

[1320] 1H NMR (500MHz, DMSO-d6) δ10.68 (br s, 1H), 9.81 (br s, 1H), 8.46 (d, J = 5.5Hz, 1H), 8.38 (d, J = 8.6Hz, 1H), 8.18 (d, J = 2.1Hz, 1H), 7 .82 (dd, J=5.5, 2.2Hz, 1H), 7.21 (d, J=2.7Hz, 1H), 7.12 (dd, J=8.6, 2.7Hz, 1H ), 6.80 (d, J=8.6Hz, 1H), 3.83-3.70 (m, 1H), 3.66 (s, 2H), 1.85-1.75 (m, 2H), 1.75-1.65(m, 2H), 1.63-1.54(m, 1H), 1.45-1.25(m, 4H), 1.21-1.07(m, 1H).

[1321] LC-MS (Method A): Rt 3.46 min; MS m / z 388.2 / 390.1 = [M+H]+ (100% @ 215 nm)

[1322] Example 2

[1323] N-tert-Butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzamide

[1324]

[1325] Step 1a: tert-Butyl N-[3-(tert-butylcarbamoyl)phenyl]carbamate

[1326]

[1327] Commercially available 3-(tert-butoxycarbonylamino)benzoic acid (2.5 g, 10.54 mmol) in DMF (40 mL) was treated with HOAt (1.43 g, 10.54 mmol), EDCI (2.63 g, 13.7 mmol), TEA (1.9 mL, 13.7 mmol) and 2-methylpropan-2-amine (1.44 mL, 13.7 mmol) and stirred at room temperature for 2 hours. The resulting mixture was diluted with water (100 mL) and filtered to collect the resulting white suspension. The filter cake was washed with water (3 x 15 mL) and oven dried to give the title compound as an off-white solid.

[1328] 1H NMR (500 MHz, methanol-d4) δ 7.78-7.70 (m, 1H), 7.52-7.46 (m, 1H), 7.38-7.28 (m, 2H), 1.53 (s, 9H), 1.45 (s, 9H).

[1329] LC-MS (Method E): Rt 1.17 min; MS m / z 293.0 = [M+H]+ (100% @ 215 nm)

[1330] Step 1b: 3-Amino-N-tert-butyl-benzamide hydrochloride

[1331]

[1332] Tert-butyl N-[3-(tert-butylcarbamoyl)phenyl]carbamate (step 1a) (5.3 g, 18.13 mmol) was suspended in 1,4-dioxane (20 mL) and then 4M HCl in dioxane (9.59 mL, 271.92 mmol) was added. After stirring at room temperature for 24 hours, the resulting mixture was concentrated under vacuum and azeotroped with methanol. The resulting foam was dried in a vacuum oven at 40°C for another 3 hours to give the title compound as a light orange foam.

[1333] 1H NMR(500MHz, DMSO-d6)δ10.25(br s, 2H), 7.91 (s, 1H), 7.76 (d, J=7.1Hz, 1H), 7.71-7.68 (m, 1H), 7.50 (t, J=7.8Hz, 1H), 7.47-7.43 (m, 1H), 1.37 (s, 9H).

[1334] LC-MS (Method E): Rt 0.73 min; MS m / z 193.1 = [M+H]+ (99% @ 215 nm)

[1335] Step 2: 2-(5-Chloro-2-methoxy-phenyl)acetic acid

[1336]

[1337] To a cooled (-10°C) stirred solution of 2-(2-methoxyphenyl)acetic acid (2.0 g, 12.04 mmol) in THF (34.8 mL) was added sulfonyl chloride (1.37 mL, 16.85 mmol) dropwise over 15 minutes and stirring was continued for 1 hour. The reaction was quenched with ice-cold water (34.8 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were purified by Na 2 SO 4 Drying and concentration in vacuo afforded the title compound as a pink solid.

[1338] 1H NMR (250MHz, DMSO-d6) δ 12.24 (s, 1H), 7.30 (d, J=2.7Hz, 2H), 6.99 (d, J=8.8Hz, 1H), 3.76 (s, 3H), 3.51 (s, 2H).

[1339] LC-MS (Method E): Rt 1.01min; No characteristic mass ions were observed for MS m / z

[1340] Step 3: N-tert-butyl-3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]benzamide

[1341]

[1342] To 2-(5-chloro-2-methoxy-phenyl)acetic acid (step 2) (114 mg, 0.57 mmol) in DMF (3 mL) was added HOAt (77 mg, 0.57 mmol), EDCI (142 mg, 0.74 mmol), DIPEA (248 μL, 1.42 mmol) and 3-amino-N-tert-butyl-benzamide hydrochloride (step 1b) (130 mg, 0.57 mmol). The reaction mixture was stirred at room temperature for 1 hour, the resulting mixture was partitioned between water (8 mL) and DCM (8 mL) and the phases were separated using a PTFE-sintered phase separator. The organic layer was concentrated under vacuum and the crude product was purified by silica gel chromatography eluting with EtOAc in heptane and the product fractions were placed under vacuum to give the title compound as a white solid.

[1343] 1H NMR (500 MHz, chloroform-d) δ 7.76-7.64 (m, 3H), 7.41-7.37 (m, 1H), 7.36-7.31 (m, 1H), 7.30-7.26 (m, 2H), 6.88 (d, J = 8.6 Hz, 1H), 5.97 (br. s, 1H), 3.92 (s, 3H), 3.68 (s, 2H), 1.45 (s, 9H).

[1344] LC-MS (Method E): Rt 1.20 min; MS m / z 375.0 / 377.0 = [M+H]+ (94% @ 215 nm)

[1345] Step 4: N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzamide

[1346] A solution of N-tert-butyl-3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]benzamide (step 3) (3.83 g, 10.2 mmol) in DCM (80 mL) was cooled to 0 °C and 1 M BBr 3 The mixture was diluted with water (10 mL) and the volatile solvents were removed in vacuo to give a gummy residue. The residue was dissolved in EtOAc (60 mL) and saturated sodium bicarbonate (60 mL) and stirred for 1 hour to ensure complete dissolution. The biphasic mixture was separated and the organic portion was washed with saturated sodium bicarbonate solution (80 mL), brine (80 mL), and Na 2 SO 4 The product was dried and concentrated under vacuum to give a thick beige oil. The crude product was purified by silica gel chromatography using heptanes containing 0-100% EtOAc to produce a white foam. The material was azeotroped with MeCN (2x 80 mL) and then dissolved in boiling MeCN (~30 mL) and allowed to cool to room temperature. After 3 hours, the resulting crystalline solid was collected by filtration and recrystallized again from boiling MeCN (40 mL) to give the title compound as a white crystalline solid.

[1347] 1H NMR (500MHz, DMSO-d6) δ10.22 (s, 1H), 9.81 (s, 1H), 7.90 (t, J = 1.7Hz, 1H), 7.78-7.72 (m, 1H), 7.69 (s, 1H), 7.42 (dt, J = 7.8, 1.1Hz , 1H), 7.33 (t, J=7.9Hz, 1H), 7.20 (d, J=2.7Hz, 1H), 7.10 (dd, J=8.6, 2.7Hz, 1H), 6.80 (d, J=8.6Hz, 1H), 3.61 (s, 2H), 1.36 (s, 9H).

[1348] LC-MS (Method A): Rt 3.19 min; MS m / z 361.1 / 363.2 = [M+H]+ (100% @ 215 nm)

[1349] The compounds of the following examples (Table 2) were prepared in analogy to Example 2 by replacing 2-(5-chloro-2-methoxy-phenyl)acetic acid (Step 2) with the appropriate commercially available acid.

[1350]

[1351]

[1352]

[1353]

[1354]

[1355]

[1356] Example 3

[1357] N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1358]

[1359] Step 1: 4-amino-N-tert-butyl-pyridine-2-carboxamide

[1360]

[1361] To a mixture of 4-aminopyridine-2-carboxylic acid (8.0 g, 57.92 mmol), TBTU (22.32 g, 69.5 mmol) and TEA (24.22 mL, 173.76 mmol) in DMF (100 mL) was added 2-methylpropan-2-amine (7.30 mL, 69.5 mmol), the resulting mixture was stirred at room temperature for 22 hours, then concentrated under vacuum. The crude material was purified by silica gel chromatography, eluting with 3.5 M methanolic ammonia in DCM, the product fractions were combined, and concentrated under vacuum to give a pale yellow solid of the title compound.

[1362] 1H NMR (500 MHz, methanol-d4) δ 7.99 (d, J = 5.6 Hz, 1H), 7.23 (d, J = 2.2 Hz, 1H), 6.62 (dd, J = 5.6, 2.4 Hz, 1H), 1.45 (s, 9H).

[1363] LC-MS (Method F): Rt 1.47 min; MS m / z 194.3 = [M+H]+ (100% @ 215 nm)

[1364] Step 2: N-tert-butyl-4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1365]

[1366] A solution of 2-(5-chloro-2-methoxy-phenyl)acetic acid (2.26 g, 11.27 mmol) in thionyl chloride (8.13 mL, 92.21 mmol) was heated at 70 °C for 30 min. After cooling to room temperature, excess thionyl chloride was removed in vacuo and azeotroped with toluene. The resulting residue was dissolved in DCM (5 mL) and added to a solution of 4-amino-N-tert-butyl-pyridine-2-carboxamide (step 1) (2.0 g, 10.25 mmol) and DIPEA (2.15 mL, 12.29 mmol) in DCM (25 mL). The mixture was stirred at room temperature for 1 h, then diluted with water (50 mL) and extracted with DCM. The combined organic extracts were washed with brine (50 mL), purified by Na 2 SO 4 Dry and concentrate in vacuo. The crude residue is purified by silica gel chromatography eluting with 0-50% EtOAc in heptane to give the title compound as a light orange powder.

[1367] 1H NMR (500MHz, chloroform-d) δ8.39 (d, J=5.6Hz, 1H), 8.20 (dd, J=5.6, 2.2Hz, 1H), 8.10 (br s, 1H), 7.98 (br s, 1H), 7.56 (d, J=2.1Hz, 1H), 7.29-7.26 (m, 2H), 6.89 (d, J=9.5Hz, 1H), 3.94 (s, 3H), 3.70 (s, 2H), 1.47 (s, 9H).

[1368] LC-MS (Method E): Rt 1.21 min; MS m / z 376.1 / 378.1 = [M+H]+ (92% @ 215 nm)

[1369] Step 3: N-tert-butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1370] To a solution of N-tert-butyl-4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (step 2) (2.7 g, 6.82 mmol, 95%) in DCM (10 mL) at 0 °C was added dropwise 1 M BBr 3 The mixture was stirred for 1 h at 4 °C for 1 hr at 4 °C. The mixture was stirred for 1 h at 4 °C for 1 hr at 4 °C. The mixture was stirred for 1 h at 4 °C for 1 hr at 4 °C. The mixture was stirred for 2 ... 3 The organic portion was separated and washed with Na 2 SO 4 The product was dried and concentrated under vacuum. The crude residue was purified by silica gel chromatography eluting with 0-70% EtOAc in heptane to give the product as an orange powder. This was further purified by reverse phase chromatography eluting with 0-100% MeCN in water and 0.1% formic acid to give the product as a colorless powder. The product was recrystallized from MeCN to give the title compound and a second crop of the product was isolated by adding water dropwise to the MeCN filtrate and then heating and cooling the mixture. IH NMR (500MHz, DMSO-d6) δ10.69 (br s, 1H), 9.82 (br s, IH), 8.44 (d, J=5.5Hz, 1H), 8.17 (d, J=1.9Hz, 1H), 8.03 (s, 1H), 7.82 (dd, J=5.5, 2.2Hz, 1H), 7. 22 (d, J=2.7Hz, 1H), 7.12 (dd, J=8.6, 2.7Hz, 1H), 6.80 (d, J=8.6Hz, 1H), 3.67 (s, 2H), 1.40 (s, 9H).

[1371] LC-MS (Method A): Rt 3.28 min; MS m / z 362.1 / 364.1 = [M+H]+ (99% @ 215 nm)

[1372] The compounds of the examples listed in the table below (Table 3a) were prepared analogously to Example 3 by replacing 2-methylpropan-2-amine (step 1) with a suitable amine and by replacing 2-(5-chloro-2-methoxy-phenyl)acetic acid (step 2) with a suitable commercially available acid.

[1373]

[1374]

[1375] Example 3.5b

[1376] N-tert-Butyl-4-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1377]

[1378] Step 1: N-tert-butyl-4-[[2-[2-methoxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1379]

[1380] To a solution of 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3, step 1) (70 mg, 0.36 mmol), TEA (127 μL, 0.72 mmol) and 2-[2-methoxy-5-(trifluoromethyl)phenyl]acetic acid (102 mg, 0.43 mmol) in 1,4-dioxane (1 mL) was added 50% A solution of 50 μL (948 μL, 0.8 mmol) in EtOAc was added and the reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was partitioned between water (25 mL) and EtOAc (25 mL). The organic layer was separated, washed with water (20 mL), and purified by Na 2 SO 4 Dry and concentrate under vacuum.The crude residue is purified by silica gel chromatography eluting with EtOAc in heptane to give the title compound as a light yellow solid.

[1381] 1H NMR (500MHz, DMSO-d6) δ10.75 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.17 (d, J = 2.1Hz, 1H), 8.03 (s, 1H), 7.80 ( dd, J=5.5, 2.2Hz, 1H), 7.69-7.61 (m, 2H), 7.18 (d, J=8.5Hz, 1H), 3.83 (s, 3H), 3.81 (s, 2H), 1.40 (s, 9H).

[1382] LC-MS (Method E): Rt 1.23 min; MS m / z 410.0 = [M+H]+ (93% @ 215 nm)

[1383] Step 2: N-tert-butyl-4-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1384] The title compound was prepared in analogy to Example 3, Step 3, from N-tert-butyl-4-[[2-[2-methoxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Step 2).

[1385] 1H NMR (500MHz, DMSO-d6) δ11.32-9.82 (m, 2H), 8.44 (d, J=5.5Hz, 1H), 8.17 (d, J=2.0Hz, 1H), 8.03 (s, 1H), 7.82 (dd, J=5 .5, 2.2Hz, 1H), 7.54 (d, J=2.0Hz, 1H), 7.45 (dd, J=8.5, 2.1Hz, 1H), 6.95 (d, J=8.4Hz, 1H), 3.76 (s, 2H), 1.40 (s, 9H).

[1386] LC-MS (Method A): Rt 3.41 min; MS m / z 396.2 = [M+H]+ (100% @ 215 nm)

[1387] The compounds of the examples listed below (Table 3b) were prepared in analogy to Example 3.5b by replacing 2-[2-methoxy-5-(trifluoromethyl)phenyl]acetic acid (step 1) with the appropriate commercially available acid.

[1388] Table 3b

[1389]

[1390]

[1391]

[1392]

[1393]

[1394] Example 4

[1395] N-tert-Butyl-3-[[2-(3-hydroxyphenyl)acetyl]amino]benzamide

[1396]

[1397] A mixture of 3-amino-N-tert-butyl-benzamide hydrochloride (Example 2 Step 1b) (50 mg, 0.22 mmol), EDCI (50 mg, 0.26 mmol), HOAt (36 mg, 0.26 mmol), DIPEA (0.09 mL, 0.52 mmol) in DCM (1.25 mL) was treated with 2-(3-hydroxyphenyl)acetic acid (33 mg, 0.22 mmol) and stirred at room temperature for 1 hour. The resulting mixture was diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The combined organics were passed through a PTFE phase separator and concentrated under vacuum. The crude product was purified by preparative HPLC (acidic pH, early elution method) and the product fractions were concentrated and dried under vacuum to give the title compound as a white solid.

[1398] 1H NMR (500MHz, methanol-d4) δ7.90 (t, J=1.8Hz, 1H), 7.72 (s, 1H), 7.69 (ddd, J=8.0, 2.1, 1.1Hz, 1H), 7.49-7.45 (m, 1H ), 7.39 (t, J=7.9Hz, 1H), 7.19-7.13 (m, 1H), 6.87-6.81 (m, 2H), 6.73-6.68 (m, 1H), 3.63 (s, 2H), 1.46 (s, 9H).

[1399] LC-MS (Method B): Rt 2.56 min; MS m / z 344.3 = [M+NH 3 ]+(99%@215nm)

[1400] The compounds of the following examples (Table 4) were prepared in analogy to Example 4 by replacing 2-(3-hydroxyphenyl)acetic acid with the appropriate commercially available acid.

[1401] Table 4

[1402]

[1403]

[1404]

[1405] Example 5

[1406] N-tert-Butyl-4-[[2-(2-thienyl)acetyl]amino]pyridine-2-carboxamide

[1407]

[1408] A solution of 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3, Step 1) (50 mg, 0.26 mmol), 2-(2-thienyl)acetic acid (37 mg, 0.26 mmol) and TEA (0.09 mL, 0.52 mmol) in 1,4-dioxane (2 mL) was heated with 50% The solution (617 μ L, 0.97 mmol) in EtOAc is processed, and stirred 1 hour at room temperature under an inert atmosphere. The mixture obtained is diluted with EtOAc (10 mL), and washed with water (10 mL). The organic part is separated and concentrated under vacuum, purified by preparative HPLC (acidic pH, standard elution method), and freeze-dried product fractions, the white solid of title compound is obtained.

[1409] 1H NMR (500MHz, DMSO-d6) δ10.80 (s, 1H), 8.46 (d, J = 5.5Hz, 1H), 8.19 (d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7. 80 (dd, J=5.5, 2.2Hz, 1H), 7.41 (dd, J=5.0, 1.4Hz, 1H), 7.03-6.94 (m, 2H), 3.95 (s, 2H), 1.40 (s, 9H)

[1410] LC-MS (Method A): Rt 3.19 min; MS m / z 318.2 = [M+H]+ (99% @ 215 nm).

[1411] Example 5.1

[1412] 4-[[2-(2-Adamantyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide

[1413]

[1414] A solution of 2-(2-adamantyl)acetic acid (40 mg, 0.21 mmol) in thionyl chloride (160 μL, 1.82 mmol) was heated at 70° C. for 30 minutes, excess thionyl chloride was removed under vacuum (azeotropic drying with DCM), and the residue was treated with a mixture of 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3, Step 1) (40 mg, 0.21 mmol) and DIPEA (43 μL, 0.25 mmol) in DCM (1.5 mL) and stirred at room temperature for 1 hour. The resulting mixture was partitioned between water (5 mL) and DCM (5 mL). The phases were separated via a PTFE-sintered separator, the organic layer was concentrated under vacuum, the crude product was purified by preparative HPLC (acidic pH, standard elution method), and the product fractions were concentrated under vacuum to give the title compound as a white crystalline solid.

[1415] 1H NMR (500MHz, DMSO-d6) δ10.50 (s, 1H), 8.42 (d, J = 5.5Hz, 1H), 8.19 (d, J = 2.0Hz, 1H), 8.02 (s, 1H), 7.79 (dd, J = 5.5, 2.2Hz, 1H), 2.54-2.51 (m, 2H), 2 .27-2.19(m, 1H), 1.94-1.87(m, 2H), 1.87-1.83(m, 1H), 1.83-1.77(m, 3H ), 1.77-1.71(m, 2H), 1.71-1.65(m, 4H), 1.54-1.49(m, 2H), 1.39(s, 9H).

[1416] LC-MS (Method A): Rt 4.29 min; MS m / z 370.3 = [M+H]+ (100% @ 215 nm)

[1417] Similar to Example 5 (using ) or Example 5.1 (using thionyl chloride), the compounds of the following examples (Table 5) were prepared from 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3, Step 1) and a suitable commercially available acid.

[1418]

[1419]

[1420]

[1421]

[1422]

[1423]

[1424]

[1425]

[1426] Example 5.33

[1427] N-(1,1-dimethylprop-2-ynyl)-4-[(2-isochroman-1-ylacetyl)amino]pyridine-2-carboxamide

[1428]

[1429] The title compound was prepared in analogy to Example 5.1 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-isochroman-1-ylacetic acid.

[1430] 1H NMR (500MHz, DMSO-d6) δ10.60 (s, 1H), 8.49 (d, J=5.5Hz, 1H), 8.33 (s, 1H), 8.22 (d, J= 2.0Hz, 1H), 7.87 (dd, J=5.5, 2.2Hz, 1H), 7.19 (tdd, J=12.4, 9.2, 5.5Hz, 4H), 5.19 (dd , J=10.0, 3.1Hz, 1H), 4.08-4.01 (m, 1H), 3.72 (ddd, J=11.4, 9.0, 4.1Hz, 1H), 3.21 (s, 1H), 3.09 (dd, J=14.6, 3.4Hz, 1H), 2.92-2.84 (m, 1H), 2.75-2.67 (m, 2H), 1.65 (s, 6H).

[1431] LC-MS (Method A): Rt 3.22 min; MS m / z 378.3 = [M+H]+ (100% @ 215 nm)

[1432] Example 5.34

[1433] 4-[[2-(4,4-difluorocyclohexyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide

[1434]

[1435] The title compound was prepared in analogy to Example 5.1 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-(4,4-difluorocyclohexyl)acetic acid.

[1436] 1H NMR (500MHz, DMSO-d6) δ10.52 (s, 1H), 8.46 (d, J = 5.5Hz, 1H), 8.30 (s, 1H), 8.20 (d, J = 2.0Hz, 1H), 7.80 (dd, J = 5.5, 2.2Hz, 1H), 3.21 (s, 1H), 2.34 (d, J=7.1Hz, 2H), 2.05-1.90 (m, 3H), 1.90-1.82 (m, 1H), 1.82-1.75 (m, 3H), 1.64 (s, 6H), 1.32-1.18 (m, 2H).

[1437] LC-MS (Method A): Rt 3.26 min; MS m / z 364.3 = [M+H]+ (97% @ 215 nm)

[1438] Example 5.35

[1439] N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1440]

[1441] The title compound was prepared in analogy to Example 5 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-[4-(trifluoromethyl)phenyl]acetic acid.

[1442] 1H NMR (500MHz, DMSO-d6) δ10.84 (s, 1H), 8.47 (d, J = 5.5Hz, 1H), 8.31 (s, 1H), 8.19 (d, J = 2.0Hz, 1H), 7.82 (dd , J=5.5, 2.2Hz, 1H), 7.70 (d, J=8.1Hz, 2H), 7.56 (d, J=8.1Hz, 2H), 3.86 (s, 2H), 3.20 (s, 1H), 1.64 (s, 6H).

[1443] LC-MS (Method A): Rt 3.53 min; MS m / z 390.2 = [M+H]+ (100% @ 215 nm)

[1444] Example 5.36

[1445] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)-1H-pyrazol-4-yl]acetyl]amino]pyridine-2-carboxamide

[1446]

[1447] Step 1: 2-[3-(Trifluoromethyl)-1H-pyrazol-4-yl]acetic acid

[1448]

[1449] Periodic acid (278 mg, 1.22 mmol) was added to MeCN (4.5 mL) and stirred at room temperature for 20 minutes. 2-[3-(trifluoromethyl)-1H-pyrazol-4-yl]ethanol (100 mg, 0.56 mmol) in MeCN (0.93 mL) was added to this solution and the mixture was cooled to 0 ° C. Pyridinium chlorochromate (8 mg, 0.04 mmol) was added, the mixture was gradually warmed to room temperature and stirred for 90 hours, and the resulting mixture was diluted with excess water, acidified with 3M sulfuric acid, and quenched with saturated sodium thiosulfate aqueous solution. After 3 days, the mixture was filtered and washed with water to obtain a light yellow solid of the title compound.

[1450] 1H NMR (400MHz, DMSO-d6) δ13.44 (s, 1H), 12.38 (s, 1H), 7.85 (s, 1H), 3.53 (s, 2H).

[1451] LC-MS (Method E): Rt 0.77 min; MS m / z 195.0 = [M+H]+ (95% @ 215 nm)

[1452] Step 2: N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)-1H-pyrazol-4-yl]acetyl]amino]pyridine-2-carboxamide

[1453] The title compound was prepared in analogy to Example 5 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-[3-(trifluoromethyl)-1H-pyrazol-4-yl]acetic acid (Step 1).

[1454] 1H NMR (400MHz, DMSO-d6) δ13.50 (s, 1H), 10.74 (s, 1H), 8.48 (d, J=5.5Hz, 1H), 8.32 (s, 1H), 8.20 (d , J=2.1Hz, 1H), 7.91 (s, 1H), 7.80 (dd, J=5.5, 2.1Hz, 1H), 3.73 (s, 2H), 3.21 (s, 1H), 1.64 (s, 6H).

[1455] LC-MS (Method A): Rt 2.69 min; MS m / z 380.2 = [M+H]+ (100% @ 215 nm)

[1456] Example 5.37

[1457] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1458]

[1459] The title compound was prepared in analogy to Example 5 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-[3-(trifluoromethyl)phenyl]acetic acid.

[1460] 1H NMR (500MHz, DMSO-d6) δ10.84 (s, 1H), 8.48 (d, J=5.5Hz, 1H), 8.31 (s, 1H), 8.19 (d, J=2.0Hz, 1H), 7.83 (dd, J=5. 5, 2.2Hz, 1H), 7.72-7.69(m, 1H), 7.66-7.61(m, 2H), 7.61-7.55(m, 1H), 3.88(s, 2H), 3.21(s, 1H), 1.64(s, 6H).

[1461] LC-MS (Method A): Rt 3.51 min; MS m / z 390.2 = [M+H]+ (100% @ 215 nm)

[1462] Example 5.38

[1463] N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1464]

[1465] The title compound was prepared in analogy to Example 5 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-[2-(trifluoromethyl)phenyl]acetic acid.

[1466] 1H NMR (500MHz, DMSO-d6) δ10.84 (s, 1H), 8.48 (d, J = 5.5Hz, 1H), 8.32 (s, 1H), 8.18 (d, J = 2.0Hz, 1H), 7.80 (dd, J = 5.5, 2.2Hz , 1H), 7.73 (d, J=7.8Hz, 1H), 7.67 (t, J=7.6Hz, 1H), 7.52 (dd, J=18.5, 7.7Hz, 2H), 4.01 (s, 2H), 3.21 (s, 1H), 1.64 (s, 6H).

[1467] LC-MS (Method A): Rt 3.53 min; MS m / z 390.2 = [M+H]+ (100% @ 215 nm)

[1468] Example 5.39

[1469] 4-[[2-(2,3-dihydro-1,4-benzoxazin-4-yl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide

[1470]

[1471] The title compound was prepared in analogy to Example 5 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-(2,3-dihydro-1,4-benzoxazin-4-yl)acetic acid.

[1472] 1H NMR (500MHz, DMSO-d6) δ10.65 (s, 1H), 8.48 (d, J = 5.5Hz, 1H), 8.31 (s, 1H), 8.20 (d, J = 2.1Hz, 1H), 7.86 (dd, J = 5.5, 2.2Hz, 1H), 6.74-6.67(m, 2H), 6.59-6.52(m, 2H), 4.26-4.21(m, 2H), 4.17(s, 2H), 3.52-3.47(m, 2H), 3.21(s, 1H), 1.64(s, 6H).

[1473] LC-MS (Method A): Rt 3.32 min; MS m / z 379.2 = [M+H]+ (90% @ 215 nm)

[1474] Example 6

[1475] N-tert-Butyl-4-[[2-(5-cyano-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1476]

[1477] Step 1: 4-[[2-(5-Bromo-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide

[1478]

[1479] 2-(5-Bromo-2-methoxy-phenyl)acetic acid (348 mg, 1.42 mmol) in thionyl chloride (1.25 mL, 14.2 mmol) was stirred at 70 °C under an inert atmosphere for 1 hour, the resulting solution was cooled to room temperature and concentrated under vacuum (azeotropy with toluene and DCM). The dry acid chloride was dissolved in anhydrous DCM (10 mL) and added dropwise to a solution of 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3 Step 1) (274 mg, 1.42 mmol) and DIPEA (0.5 mL, 2.84 mmol) in anhydrous DCM (10 mL). The reaction mixture was stirred at room temperature under an inert atmosphere. After 1 hour, the mixture was diluted with DCM (25 mL) and washed with water (2 x 25 mL). The organic extract was purified by Na 2 SO 4 The resulting crude oil was purified by silica gel chromatography, eluting with EtOAc in heptane, and the column was rinsed with methanol. The eluent was collected and concentrated under vacuum to give a beige solid, which was again purified by silica gel chromatography, eluting with DCM containing 0-10% MeOH, and the product fractions were concentrated under vacuum and dried in a vacuum oven at 40°C for 2 hours to give the title compound.

[1480] 1H NMR (500MHz, DMSO-d6) δ10.70 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.17 (d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7.80 (dd, J=5.5, 2.2Hz, 1H), 7.47-7.38(m, 2H), 7.01-6.92(m, 1H), 3.74(s, 3H), 3.71(s, 2H), 1.40(s, 9H).

[1481] LC-MS (Method A): Rt 3.62 min; MS m / z 420.2, 422.2 = [M+H]+ (100% @ 215 nm)

[1482] Step 2: N-tert-butyl-4-[[2-(5-cyano-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1483]

[1484] A solution of 4-[[2-(5-bromo-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (step 1) (75 mg, 0.18 mmol) in DMF (2 mL) was degassed with nitrogen for 5 minutes before the addition of tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.02 mmol). The mixture was purged with nitrogen for an additional 5 minutes and then treated with zinc cyanide (27 mg, 0.23 mmol) and the resulting mixture was stirred at 100° C. for 16 hours. Another portion of zinc cyanide (27 mg, 0.23 mmol) and tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.02 mmol) were added and the mixture was purged with nitrogen and stirring was continued at 100° C. for an additional 24 hours. The mixture was diluted with EtOAc (20 mL) and washed with water (20 mL), NaHCO 3 (sat.) aqueous solution (20 mL) and brine (20 mL). 2 SO 4 Dry and concentrate under vacuum. The crude material was purified by silica gel chromatography eluting with EtOAc in heptane and the product fractions were concentrated under vacuum and dried in a vacuum oven to give the title compound as a yellow solid.

[1485] 1H NMR (500MHz, chloroform-d) δ8.40 (d, J=5.6Hz, 1H), 8.39 (br.s, 1H), 8.20 (dd, J=5.6, 2.2Hz, 1H), 8.04 (s, 1H), 7.75-7.69 (m, 1 H), 7.63 (dd, J=8.6, 2.1Hz, 1H), 7.58 (d, J=2.0Hz, 1H), 6.99 (d, J=8.6Hz, 1H), 3.95 (s, 3H), 3.77 (s, 2H), 1.47 (s, 9H).

[1486] LC-MS (Method E): Rt 1.13 min; MS m / z 367.1 = [M+H]+ (95% @ 215 nm)

[1487] Step 3: N-tert-butyl-4-[[2-(5-cyano-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1488]

[1489] To a solution of N-tert-butyl-4-[[2-(5-cyano-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (step 2) (20 mg, 0.05 mmol) in DCM (2 mL) was added 1 M BBr 3DCM (164 μL, 0.16 mmol) was added and the resulting mixture was stirred under an inert atmosphere for 2 h. Additional 1 M BBr 3 1M BBr 3 10% ethanol (10% ethanol) was added to 1% ethanol (10% ethanol) and the mixture was stirred at room temperature under nitrogen for 24 hours. The mixture was diluted with DCM (20 mL) and washed with water (2 x 20 mL). The organic portion was purified by Na 2 SO 4 Dry and concentrate in vacuo. The crude product is purified by C18 reverse phase chromatography eluting with 0-100% MeCN in water and 0.1% formic acid and the product fractions are freeze dried to give the title compound as a white solid.

[1490] 1H NMR(500MHz, DMSO-d6)δ10.78(br s, 1H), 10.75 (s, 1H), 10.90-10.60 (m, 2H), 8.44 (d, J=5.5Hz, 1H), 8.16 (d, J=1.9Hz, 1H), 8.03 (s, 1H), 7.81 (dd, J=5 .5, 2.2Hz, 1H), 7.63 (d, J=2.1Hz, 1H), 7.57 (dd, J=8.4, 2.2Hz, 1H), 6.93 (d, J=8.4Hz, 1H), 3.72 (s, 2H), 1.40 (s, 9H).

[1491] LC-MS (Method A): Rt 2.84 min; MS m / z 353.3 = [M+H]+ (94% @ 215 nm)

[1492] Example 7

[1493] 3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2,2-tetramethylpropyl)benzamide

[1494]

[1495] Step 1: 3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]benzoic acid methyl ester

[1496]

[1497] A solution of 2-(5-chloro-2-methoxy-phenyl)acetic acid (1200 mg, 5.98 mmol), EDCI (1376 mg, 7.18 mmol), HOAt (814 mg, 5.98 mmol), DIPEA (2.61 mL, 14.95 mmol) and methyl 3-aminobenzoate (904 mg, 5.98 mmol) in DMF (5 mL) was stirred at room temperature for 17 hours, and the reaction mixture was diluted with water (35 mL) and extracted with EtOAc (2 x 40 mL). The combined organic fractions were washed with water (2 x 40 mL) and purified by Na 2 O 4 '-trifluoroacetic acid (40 mL). 2 SO 4 Dry and concentrate in vacuo. The crude material was purified by silica gel chromatography eluting with 10-70% EtOAc in heptane and the product fractions were concentrated in vacuo to afford the title compound as an off-white solid.

[1498] 1H NMR (500MHz, DMSO-d6) δ10.32 (s, 1H), 8.29 (t, J=1.8Hz, 1H), 7.82 (ddd, J=8.1, 2.1, 1.0Hz, 1H), 7.63 (dt, J=7.7, 1.2Hz, 1H), 7.45 (t, J=7.9Hz, 1H), 7.32-7.28 (m, 2H), 7.05-6.95 (m, 1H), 3.84 (s, 3H), 3.76 (s, 3H), 3.66 (s, 2H).

[1499] LC-MS (Method E): Rt 1.21 min; MS m / z 334.1 / 336.1 = [M+H]+ (96% @ 215 nm)

[1500] Step 2: 3-[[2-(5-Chloro-2-methoxy-phenyl)acetyl]amino]benzoic acid

[1501]

[1502] 2M LiOH (7.71 mL, 15.42 mmol) was added to a solution of methyl 3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]benzoate (step 1) (1751 mg, 5.14 mmol) in THF (8 mL). The reaction mixture was stirred at room temperature for 7 hours and the resulting mixture was concentrated under vacuum, diluted with water (8 mL) and acidified to pH 2 with 2M aqueous HCl. The precipitate formed was collected by vacuum filtration and washed with Et 2 O (2 x 20 mL) and the solid was dried in a vacuum oven at 40 °C for 3 h to afford the title compound as a light beige solid.

[1503] 1H NMR (500MHz, DMSO-d6) δ10.32 (s, 1H), 8.23 ​​(s, 1H), 7.87-7.74 (m, 1H), 7.61 (d, J=7.7Hz, 1 H), 7.41 (t, J=7.9Hz, 1H), 7.31-7.27 (m, 2H), 7.03-6.95 (m, 1H), 3.76 (s, 3H), 3.66 (s, 2H).

[1504] LC-MS (Method E): Rt 1.07 min; MS m / z 320.1 / 322.1 = [M+H]+ (100% @ 215 nm)

[1505] Step 3: 3-[[2-(5-Chloro-2-methoxy-phenyl)acetyl]amino]-N-(1,1,2,2-tetramethylpropyl)benzamide

[1506]

[1507] A solution of 3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]benzoic acid (step 2) (70 mg, 0.22 mmol), EDCI (50 mg, 0.26 mmol), HOAt (36 mg, 0.26 mmol), DIPEA (0.11 mL, 0.66 mmol) and 2,3,3-trimethylbutan-2-amine hydrochloride (33 mg, 0.22 mmol) in DMF (0.5 mL) was stirred at room temperature for 3 hours. The resulting mixture was diluted with EtOAc (5 mL) and water (5 mL), the aqueous layer was extracted with EtOAc (5 mL), the combined organic extracts were washed with water (5 mL), brine (5 mL), and purified by Na 2 SO 4 Dry and concentrate under vacuum.The crude residue was purified by preparative HPLC (acidic pH, early elution method) and the product fractions were concentrated under vacuum to give the title compound as an off-white powder.

[1508] 1H NMR (500MHz, DMSO-d6) δ10.19 (s, 1H), 7.85 (s, 1H), 7.74 (dt, J=6.8, 2.1Hz, 1H), 7.37-7.32 (m, 2H), 7. 32-7.26 (m, 2H), 7.09 (s, 1H), 7.02-6.98 (m, 1H), 3.76 (s, 3H), 3.65 (s, 2H), 1.39 (s, 6H), 0.97 (s, 9H).

[1509] LC-MS (Method E): Rt 1.32 min; MS m / z 417.2 / 419.2 = [M+H]+ (97% @ 215 nm)

[1510] Step 4: 3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2,2-tetramethylpropyl)benzamide

[1511] To a cooled (0 °C) solution of 3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-N-(1,1,2,2-tetramethylpropyl)benzamide (step 3) (53 mg, 0.13 mmol) in DCM (0.5 mL) was added 1 M BBr 3 DCM (0.38 mL, 0.38 mmol) was added and the mixture was stirred at room temperature for 1 hour. The resulting mixture was diluted with water (5 mL) and extracted with EtOAc (2 x 8 mL). The combined organic extracts were purified by Na 2 SO 4 Dry and concentrate under vacuum.The crude residue was purified by preparative HPLC (acidic pH, early elution method) and the product fractions were concentrated under vacuum to give the title compound as an off-white powder.

[1512] 1H NMR (500MHz, DMSO-d6) δ10.19 (s, 1H), 9.81 (br s, 1H), 7.86 (s, 1H), 7.75 (dt, J=6.6, 2.2Hz, 1H), 7.38-7.31 (m, 2H), 7.20 (d, J=2.7Hz, 1H), 7.13-7.05 (m, 2H), 6.80 (d, J=8.6Hz, 1H), 3.61 (s, 2H), 1.39 (s, 6H), 0.97 (s, 9H).

[1513] LC-MS (Method D): Rt 4.52 min; MS m / z 403.2 / 405.2 = [M+H]+ (100% @ 215 nm).

[1514] The compounds of the following examples (Table 6) were prepared analogously to Example 7 from the appropriate amino ester and acid (Step 1) and by replacing 2,3,3-trimethylbutan-2-amine hydrochloride (Step 3) with the appropriate commercially available amine. / TEA was used for the amide coupling step.

[1515]

[1516]

[1517]

[1518]

[1519]

[1520] Example 8

[1521] 3-[[3-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]benzoyl]amino]piperidine-1-carboxylic acid tert-butyl ester

[1522]

[1523] Step 1: 3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-piperidinyl)benzamide

[1524]

[1525] The title compound was prepared in analogy to Example 7 by substituting tert-butyl 3-aminopiperidine-1-carboxylate for 2,3,3-trimethylbutan-2-amine hydrochloride (step 3).

[1526] 1H NMR (500MHz, DMSO-d6) δ10.22 (s, 1H), 8.15 (d, J=7.9Hz, 1H), 7.98 (s, 1H), 7.82-7.70 (m, 1H), 7.50-7.46 (m, 1H), 7.36 (t, J=7.9Hz, 1H), 7.20 (d, J=2.7Hz, 1H), 7.11 (dd, J=8.6, 2.7 Hz, 1H), 6.80 (d, J=8.6Hz, 1H), 3.88-3.80 (m, 1H), 3.61 (s, 2H), 3.02-2.95 (m, 1H), 2.88- 2.80 (m, 1H), 2.48-2.42 (m, 2H), 1.90-1.77 (m, 1H), 1.74-1.59 (m, 1H), 1.54-1.37 (m, 2H).

[1527] LC-MS (Method A): Rt 1.66 min; MS m / z 388.2 / 390.2 = [M+H]+ (96% @ 215 nm)

[1528] Step 2: tert-Butyl 3-[[3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]benzoyl]amino]piperidine-1-carboxylate

[1529] To a solution of 3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-piperidinyl)benzamide (step 1) (19 mg, 0.05 mmol) in THF (0.5 mL) was added BOC anhydride (12 mg, 0.06 mmol) and the resulting mixture was stirred at room temperature for 3 hours. Additional BOC anhydride (12 mg, 0.06 mmol) was added and stirring was continued for another hour. The reaction mixture was concentrated under vacuum and the crude product was purified by silica gel chromatography eluting with EtOAc in heptane to give the title compound as an off-white powder.

[1530] 1H NMR (500MHz, DMSO-d6) δ10.26 (br s, 1H), 9.81 (br s, 1H), 8.24 (d, J=7.0Hz, 1H), 7.99 (s, 1H), 7.83-7.74 (m, 1H), 7.49 (d, J=7.8Hz , 1H), 7.37 (m, 1H), 7.20 (d, J=2.7Hz, 1H), 7.11 (dd, J=8.6, 2.7Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 4.05-3.67 (m, 3H), 3.61 (s, 2H), 3.03-2.70 (m, 2H), 1.91-1.81 (m, 1H), 1.76-1.67 (m, 1H), 1.60-1.46 (m, 1H), 1.45-1.31 (m, 10H). LC-MS (Method A): Rt 3.41 min; MS m / z 488.3 / 490.4 = [M+H]+ (99% @ 215 nm)

[1531] Example 8.1

[1532] tert-Butyl 3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]piperidine-1-carboxylate

[1533]

[1534] Step 1: 4-[[2-(5-Chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid methyl ester

[1535]

[1536] 2-(5-Chloro-2-methoxy-phenyl)acetic acid (24.19 g, 120.59 mmol) was suspended in thionyl chloride (103.68 mL, 1427.48 mmol) and heated at 70 °C for 1.5 hours. After cooling to room temperature, the mixture was concentrated under vacuum, and the residue was then dissolved in DCM (135 mL) and concentrated again. The resulting brown viscous oil was dissolved in DCM (135 mL) and added dropwise to a cooled (ice bath) suspension of methyl 4-aminopyridine-2-carboxylate (17.9 g, 117.65 mmol) and DIPEA (30.82 mL, 176.47 mmol) in DCM (225 mL). The reaction mixture was allowed to warm to room temperature and stirred overnight. The resulting mixture was diluted with water (180 mL) and stirred for 10 minutes. The organic portion was separated and purified by anhydrous Na 2 SO 4 Dry, filter, and concentrate in vacuo. The residue is purified by silica gel chromatography eluting with EtOAc to give the title compound as an orange glassy solid.

[1537] 1H NMR (500MHz, DMSO-d6) δ10.72 (s, 1H), 8.54 (d, J = 5.5Hz, 1H), 8.30 (d, J = 1.9Hz, 1H), 7.77 (dd, J =5.5, 2.2Hz, 1H), 7.32-7.29(m, 2H), 7.02-6.99(m, 1H), 3.86(s, 3H), 3.75(s, 3H), 3.71(s, 2H).

[1538] LC-MS (Method E): Rt 1.04 min; MS m / z 335.0 / 337.0 = [M+H]+ (98% @ 215 nm)

[1539] Step 2: 4-[[2-(5-Chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid

[1540]

[1541] To a solution of methyl 4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate (step 1) (95%, 38.09 g, 108.1 mmol) in THF (200 mL) was added 2M aqueous lithium hydroxide hydrate (162.15 mL, 324.29 mmol) and the resulting mixture was stirred at room temperature for 1 hour. The volatile organics were removed under vacuum and the aqueous residue was cooled (ice bath) and treated with slowly added 3M aqueous HCl (150 mL). The resulting suspension was filtered, washed with water (3 x 200 mL), diethyl ether (2 x 250 mL), suction dried and then further dried in a high vacuum oven at 40 °C to give the title compound as a beige solid.

[1542] 1H NMR (500MHz, DMSO-d6) δ10.78 (s, 1H), 8.53 (d, J = 5.6Hz, 1H), 8.27 (d, J = 2.0Hz, 1H), 7.81 (dd, J=5.6, 2.2Hz, 1H), 7.34-7.28 (m, 2H), 7.04-6.98 (m, 1H), 3.75 (s, 3H), 3.72 (s, 2H).

[1543] LC-MS (Method E): Rt 0.88 min; MS m / z 320.9 / 323.0 = [M+H]+ (97% @ 215 nm)

[1544] Step 3: 3-[[4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]piperidine-1-carboxylic acid tert-butyl ester

[1545]

[1546] A solution of 4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid (step 2) (70 mg, 0.22 mmol), EDCI (50 mg, 0.26 mmol), HOAt (36 mg, 0.26 mmol), DIPEA (0.08 mL, 0.44 mmol) and tert-butyl 3-aminopiperidine-1-carboxylate (27.2 μL, 0.26 mmol) in DMF (0.5 mL) was stirred at room temperature for 20 hours, the resulting mixture was diluted with EtOAc (5 mL) and water (5 mL), the aqueous layer was extracted with EtOAc (5 mL), the combined organic extracts were washed with water (5 mL), brine (5 mL), purified by chromatography on a column chromatography elution column, and the resulting mixture was purified by HPLC. 2 SO 4 Dry and concentrate under vacuum.The residue was purified by preparative HPLC (acidic pH, early elution method) to give the title compound as an off-white solid.

[1547] 1H NMR (500MHz, DMSO-d6) δ10.71 (br s, 1H), 8.52 (br s, 1H), 8.46 (m, 1H), 8.19 (brs, 1H), 7.87-7.79 (m, 1H), 7.35-7.26 (m, 2H), 7.08-6.93 (m, 1H), 3.87-3.78 (m, 1H), 3.75(s, 3H), 3.71(s, 2H), 3.17-2.83(m, 2H), 1.87-1.77(m, 1H), 1.77-1.58(m, 2H), 1.57-1.20(m, 10H).

[1548] LC-MS (Method E): Rt 1.28 min; MS m / z 503.3 / 505.2 = [M+H]+ (93% @ 215 nm)

[1549] Steps 4 and 5: tert-butyl 3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]piperidine-1-carboxylate

[1550] The title compound was prepared in analogy to Example 8 from tert-butyl 3-[[4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]piperidine-1-carboxylate (step 3).

[1551] 1H NMR (500MHz, DMSO-d6) δ10.71 (br s, 1H), 9.83 (br s, 1H), 8.61-8.40 (m, 2H), 8.20 (s, 1H), 7.83 (dd, J=5.5, 2.0Hz, 1H), 7.21 (d, J=2.7Hz, 1H), 7.12 (dd, J=8.6, 2.7Hz, 1H), 6.80 (d, J=8.6H z, 1H), 3.90-3.76 (m, 2H), 3.66 (s, 2H), 3.57-3.49 (m, 1H), 3.11-2.80 (m, 1H), 1.87-1.76 (m, 1H), 1.75-1.57 (m, 2H), 1.45-1.27 (m, 10H).

[1552] LC-MS (Method A): Rt 3.51 min; MS m / z 489.3 / 491.3 = [M+H]+ (99% @ 215 nm)

[1553] The compounds of the examples listed below (Table 7) were prepared analogously to Example 8 starting from the appropriate aryl acid and by replacing tert-butyl 3-aminopiperidine-1-carboxylate (Example 8, Step 1) with the appropriate commercially available amine.

[1554]

[1555] Example 9

[1556] N-tert-Butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-fluoro-benzamide

[1557]

[1558] Step 1: 3-Amino-N-tert-butyl-4-fluoro-benzamide

[1559]

[1560] To a solution of 3-amino-4-fluoro-benzoic acid (205 mg, 1.32 mmol) in DCM (5 mL) were added 2-methylpropan-2-amine (306 μL, 2.91 mmol), DIPEA (0.92 mL, 5.29 mmol) and HATU (553 mg, 1.46 mmol) in sequence, and the mixture was shaken at room temperature overnight. The resulting mixture was washed with 2M HCl (5 mL) and saturated NaHCO 3 The resulting mixture was washed with 4% paraformaldehyde (5 mL) and the organic phase was separated by passing through a hydrophobic frit and concentrated in vacuo. Purification by flash chromatography on silica gel eluting with 0-100% EtOAc in heptane afforded the title compound as an off-white solid.

[1561] 1H NMR (500 MHz, chloroform-d) δ 7.25-7.19 (m, 1H), 6.99-6.95 (m, 2H), 5.82 (s, 1H), 3.82 (s, 2H), 1.45 (s, 9H).

[1562] LC-MS (Method E): Rt 0.95 min; MS m / z 211.1 = [M+H]+ (97% @ 215 nm)

[1563] Step 2: N-tert-Butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-fluoro-benzamide

[1564] A suspension of 3-amino-N-tert-butyl-4-fluoro-benzamide (step 1) (105 mg, 0.5 mmol) and 5-chloro-3H-benzofuran-2-one (84 mg, 0.5 mmol) in toluene (3 mL) was heated to 110° C. for 4 days in a sealed tube. After cooling to room temperature, the mixture was concentrated under vacuum and the crude residue was purified by preparative HPLC (acidic pH, early elution method) to give the title compound as an off-white powder.

[1565] 1H NMR (500MHz, MeOD) δ8.28 (dd, J=7.4, 2.1Hz, 1H), 7.56-7.49 (m, 1H), 7.24-7.18 (m, 2H), 7. 10 (dd, J=8.6, 2.6Hz, 1H), 6.81 (d, J=8.6Hz, 1H), 3.74 (s, 2H), 1.43 (s, 9H). LC-MS (Method A): Rt 3.18min; MS m / z 379.1 / 381.1=[M+H]+(97%@215nm)

[1566] Example 9.1

[1567] N-tert-Butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-methyl-benzamide

[1568]

[1569] The title compound was prepared in analogy to Example 9 by substituting 3-amino-5-methyl-benzoic acid for 3-amino-4-fluoro-benzoic acid (step 1).

[1570] 1H NMR (500 MHz, methanol-d4) δ 7.67 (s, 1H), 7.50 (s, 1H), 7.28 (s, 1H), 7.19 (d, J = 2.6 Hz, 1H), 7.08 (dd, J = 8.6, 2.6 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 3.67 (s, 2H), 2.36 (s, 3H), 1.44 (s, 9H). LC-MS (method A): Rt 3.32 min; MS m / z 375.2 / 377.2 = [M+H]+ (99% @ 215 nm).

[1571] Example 9.2

[1572] 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylpropyl)pyridine-2-carboxamide

[1573]

[1574] Step 1: 4-amino-N-(1,1-dimethylpropyl)pyridine-2-carboxamide

[1575]

[1576] To a mixture of 2-methylbutan-2-amine (1.69 mL, 14.48 mmol), TBTU (1023 mg, 3.19 mmol) and TEA (0.81 mL, 5.79 mmol) was added 4-aminopyridine-2-carboxylic acid (400 mg, 2.9 mmol) and the mixture was stirred at room temperature for 5 hours.

[1577] The resulting mixture was partitioned between water (40 mL) and DCM (40 mL), the phases were separated, the organic portion was concentrated in vacuo, and the crude product was purified by C18 reverse phase chromatography using MeCN in HCl. 2 O and 0.1% ammonium hydroxide to give the title compound as a white solid.

[1578] 1H NMR (500MHz, DMSO-d6) δ7.97 (d, J=5.6Hz, 1H), 7.92 (s, 1H), 7.17 (d, J=2.3Hz, 1H), 6.56 (dd , J=5.6, 2.4Hz, 1H), 6.32 (s, 2H), 1.74 (q, J=7.5Hz, 2H), 1.31 (s, 6H), 0.80 (t, J=7.5Hz, 3H).

[1579] LC-MS (Method F): Rt 1.55 min; MS m / z 208.3 = [M+H]+ (100% @ 215 nm)

[1580] Step 2: 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylpropyl)pyridine-2-carboxamide

[1581] The title compound was prepared in analogy to Example 9 (step 2) from 4-amino-N-(1,1-dimethylpropyl)pyridine-2-carboxamide and 5-chloro-3H-benzofuran-2-one.

[1582] 1 H NMR (500 MHz, methanol-d 4)δ8.42 (d, J=5.6Hz, 1H), 8.13-8.08 (m, 1H), 7.91 (dd, J=5.5, 2.2Hz, 1H), 7.19 (d, J=2.6Hz, 1H), 7.09 (dd, J=8 .6, 2.6Hz, 1H), 6.77 (d, J=8.6Hz, 1H), 3.71 (s, 2H), 1.86 (q, J=7.5Hz, 2H), 1.42 (s, 6H), 0.91 (t, J=7.5Hz, 3H).

[1583] LC-MS (Method A): Rt 3.50 min; MS m / z 376.0 / 378.0 = [M+H]+ (98% @ 215 nm).

[1584] Example 10

[1585] N-tert-Butyl-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1586]

[1587] Step 1: N-tert-butyl-4-[[2-(5-tert-butyl-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1588]

[1589] The title compound was prepared in analogy to Example 4 from 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3, Step 1) and commercially available 2-(5-tert-butyl-2-methoxy-phenyl)acetic acid.

[1590] 1H NMR (500MHz, chloroform-d) δ 8.45 (br s, 1H), 8.38 (d, J = 5.7Hz, 1H), 8.29 (d, J = 5.3Hz, 1H), 8.16 (br s, 1H), 7.57 (s, 1H), 7.34 (dd, J=8.6, 2.5Hz, 1H), 7.28 (d, J=2.5Hz, 1H), 6 .92(d, J=8.6Hz, 1H), 3.98(s, 3H), 3.75(s, 2H), 1.48(s, 9H), 1.30(s, 9H).

[1591] LC-MS (Method E): Rt 1.31 min; MS m / z 398.2 = [M+H]+ (85% @ 215 nm)

[1592] Step 2: N-tert-butyl-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1593] The title compound was prepared in analogy to Example 3 (step 3) from N-tert-butyl-4-[[2-(5-tert-butyl-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide.

[1594] 1H NMR (500MHz, methanol-d4) δ8.42 (d, J=5.5Hz, 1H), 8.09 (d, J=1.8Hz, 1H), 7.91 (dd, J=5.5, 2.2Hz, 1H), 7.21 (d, J=2.5Hz, 1H), 7.15 (dd, J=8.4, 2.5Hz, 1H), 6.75 (d, J=8.4Hz, 1H), 3.72 (s, 2H), 1.47 (s, 9H), 1.28 (s, 9H).

[1595] LC-MS (Method A): Rt 3.81 min; MS m / z 384.3 = [M+H]+ (97% @ 215 nm)

[1596] Embodiment 11

[1597] N-tert-Butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-hydroxy-benzamide

[1598]

[1599] Step 1: 5-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-2-methoxy-benzoic acid methyl ester

[1600]

[1601] A mixture of 5-chloro-3H-benzofuran-2-one (75 mg, 0.44 mmol) and 5-amino-2-methoxy-benzoic acid methyl ester (81 mg, 0.44 mmol) in toluene (2 mL) was stirred in a sealed tube at 100 °C for 2 hours. The resulting mixture was cooled to room temperature, toluene was added, and the suspension was filtered, washed with toluene, and the solid was dried under vacuum to give the title compound as an off-white solid.

[1602] 1H NMR (500MHz, chloroform-d) δ7.79 (s, 1H), 7.77 (d, J=2.8Hz, 1H), 7.72 (dd, J=9.0, 2.8Hz, 1H), 7.14 (dd, J=8.6, 2.6Hz, 1 H), 7.08 (d, J=2.6Hz, 1H), 6.93 (d, J=9.0Hz, 1H), 6.90 (d, J=8.6Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.67 (s, 2H).

[1603] LC-MS (Method E): Rt 1.05 min; MS m / z 350.0 / 351.9 = [M+H]+ (98% @ 215 nm)

[1604] Step 2: 5-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-2-methoxy-benzoic acid

[1605]

[1606] To a solution of 5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-methoxy-benzoic acid methyl ester (step 1) (105 mg, 0.29 mmol) in 1,4-dioxane (2 mL) was added 2M aqueous LiOH (0.29 mL, 0.59 mmol), the mixture was shaken at room temperature for 5 hours, another equivalent of 2M aqueous LiOH (0.15 mL, 0.29 mmol) was added, and shaking was continued for 1 hour. The dioxane was removed under vacuum, and the resulting mixture was acidified to pH 1 with 1M HCl (1 mL). The mixture was extracted with EtOAc (2 x 5 mL), and the combined extracts were purified by Na 2 SO 4 Drying and concentration in vacuo afforded the title compound as an off-white solid.

[1607] 1H NMR(500MHz, DMSO-d6)δ12.60(br s, 1H), 10.05 (s, 1H), 9.79 (s, 1H), 7.89 (d, J=2.7Hz, 1H), 7.70 (dd, J=9.0, 2.8Hz, 1H), 7.19 (d, J=2.7Hz, 1H), 7.10 (dd, J=8.6, 2.7Hz, 1H), 7.07 (d, J=9.1Hz, 1H), 6.80 (d, J=8.6Hz, 1H), 3.77 (s, 3H), 3.57 (s, 2H).

[1608] LC-MS (Method E): Rt 0.99 min; MS m / z 336.0 / 338.0 = [M+H]+ (99% @ 215 nm)

[1609] Step 3: N-tert-Butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-methoxy-benzamide

[1610]

[1611] The title compound was prepared in analogy to Example 1, Step 3, from 5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-methoxy-benzoic acid (Step 2).

[1612] 1H NMR (500MHz, DMSO-d6) δ10.13 (s, 1H), 9.80 (s, 1H), 7.90 (d, J=2.8Hz, 1H), 7.85 (s, 1H), 7.74 (dd, J=8.9, 2.8Hz, 1H), 7.18 (d, J =2.7Hz, 1H), 7.09 (dd, J=8.6, 2.7Hz, 1H), 7.07 (d, J=9.0Hz, 1H), 6.79 (d, J=8.6Hz, 1H), 3.86 (s, 3H), 3.56 (s, 2H), 1.36 (s, 9H).

[1613] LC-MS (Method A): Rt 3.34 min; MS m / z 391.2 / 393.2 = [M+H]+ (99% @ 215 nm)

[1614] Step 4: N-tert-butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-hydroxy-benzamide

[1615] The title compound was prepared in analogy to Example 3, Step 3, from N-tert-butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-methoxy-benzamide (Step 3).

[1616] 1H NMR (500MHz, DMSO-d6) δ11.50 (br.s, 1H), 9.94 (s, 1H), 9.82 (s, 1H), 8.24 (s, 1H), 7.98-7.88 (m, 1H), 7.60-7.53 (m, 1H), 7 .19 (d, J=2.6Hz, 1H), 7.10 (dd, J=8.6, 2.7Hz, 1H), 6.83 (d, J=8.7Hz, 1H), 6.80 (d, J=8.6Hz, 1H), 3.56 (s, 2H), 1.38 (s, 9H).

[1617] LC-MS (Method A): Rt 3.29 min; MS m / z 377.2 / 379.2 = [M+H]+ (95% @ 215 nm)

[1618] Example 12

[1619] N-tert-Butyl-3-[[2-(5-cyano-2-hydroxy-phenyl)acetyl]amino]benzamide

[1620]

[1621] Step 1: 3-[[2-(5-Bromo-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-benzamide

[1622]

[1623] The title compound was prepared in analogy to Example 4 from 3-amino-N-tert-butyl-benzamide hydrochloride (Example 2, step 1b) and 2-(5-bromo-2-methoxy-phenyl)acetic acid.

[1624] 1H NMR (500MHz, DMSO-d6) δ10.19 (s, 1H), 7.89 (s, 1H), 7.74 (d, 1H), 7.70 (s, 1H), 7.44-7.40 (m, 3H), 7.33 (t, J=7.9Hz, 1H), 6.99-6.92 (m, 1H), 3.76 (s, 3H), 3.65 (s, 2H), 1.36 (s, 9H).

[1625] LC-MS (Method A): Rt 3.41 min; MS m / z 419.2, 421.2 = [M+H]+ (100% @ 215 nm)

[1626] Step 2-3: N-tert-butyl-3-[[2-(5-cyano-2-hydroxy-phenyl)acetyl]amino]benzamide

[1627] The title compound was prepared in analogy to Example 6 steps 2 and 3 from 3-[[2-(5-bromo-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-benzamide (step 1).

[1628] 1H NMR (500MHz, DMSO-d6) δ10.76 (br.S, 1H), 10.23 (s, 1H), 7.89 (t, J=1.8Hz, 1H), 7.80-7.72 (m, 1H), 7.70 (s, 1H), 7.61 (d, J=2 .1Hz, 1H), 7.56 (dd, J=8.4, 2.2Hz, 1H), 7.42 (d, J=7.8Hz, 1H), 7.33 (m, 1H), 6.93 (d, J=8.4Hz, 1H), 3.66 (s, 2H), 1.36 (s, 9H).

[1629] LC-MS (Method A): Rt 2.66 min; MS m / z 352.2 = [M+H]+ (98% @ 215 nm)

[1630] Embodiment 13

[1631] 3-[2-[[2-(tert-Butylcarbamoyl)-4-pyridinyl]amino]-2-oxo-ethyl]-4-hydroxy-benzoic acid methyl ester

[1632]

[1633] Step 1: 4-[[2-(5-Bromo-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide

[1634]

[1635] A solution of 4-[[2-(5-bromo-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Example 6, Step 1) (500 mg, 1.19 mmol) in DCM (25 mL) was treated with 1 M BBr 3 The resulting mixture was diluted with DCM (50 mL) and washed with water (25 mL x 2). The organic extract was purified by Na 2 SO 4 Dry and concentrate in vacuo. The crude solid is purified by C18 reverse phase chromatography eluting with 0-100% MeCN in water and 0.1% formic acid to afford the title compound as a light yellow solid.

[1636] 1H NMR (500MHz, DMSO-d6) δ10.69 (s, 1H), 9.86 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.17 (d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7.81 (dd, J=5.5, 2.2Hz, 1H), 7.34 (d, J=2.5Hz, 1H), 7.24 (dd, J=8.6, 2.6Hz, 1H), 6.76 (d, J=8.6Hz, 1H), 3.67 (s, 2H), 1.40 (s, 9H).

[1637] LC-MS (Method A): Rt 3.34 min; MS m / z 406.1 / 408.1 = [M+H]+ (90% @ 215 nm)

[1638] Step 2: 3-[2-[[2-(tert-Butylcarbamoyl)-4-pyridinyl]amino]-2-oxo-ethyl]-4-hydroxy-benzoic acid methyl ester

[1639] All reagents were charged to a Coware apparatus (carbon monoxide generation system) according to the following procedure; sodium carbonate (53 mg, 0.50 mmol), 4-[[2-(5-bromo-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (step 1) (75 mg, 0.16 mmol), XantPhos Pd-G3 (third generation (G3) Buchwald precatalyst) (8 mg, 0.01 mmol) and toluene (2 mL) were added to chamber A. The reaction mixture was degassed for 5 minutes and MeOH (0.25 mL) was added. Toluene (2 mL) containing formic acid (19 μL, 0.50 mmol) was added to chamber B, followed by methanesulfonyl chloride (39 μL, 0.50 mmol). Both chambers were sealed and TEA (139 μL, 0.99 mmol) was added to chamber B to generate carbon monoxide. This Coware equipment was heated 75 ℃ for 7 hours, the mixture that obtains is concentrated under vacuum, is dissolved among the EtOAc (20mL), and washs with water (2x 20mL).Under vacuum, concentrate organic part, and purify with preparation HPLC (acidic pH, early stage elution method).Separate this product fraction and freeze drying, obtain the off-white solid of title compound.

[1640] 1H NMR (500MHz, DMSO-d6) δ10.78(br s, 1H), 10.55(br s, 1H), 8.44 (d, J=5.5Hz, 1H), 8.17 (d, J=2.0Hz, 1H), 8.03 (s, 1H), 7.83-7.80 (m, 2H), 7. 74 (dd, J=8.5, 2.2Hz, 1H), 6.88 (d, J=8.5Hz, 1H), 3.79 (s, 3H), 3.72 (s, 2H), 1.40 (s, 9H).

[1641] LC-MS (Method A): Rt 2.94 min; MS m / z 386.3 = [M+H]+ (95% @ 215 nm)

[1642] Embodiment 14

[1643] N-tert-Butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-hydroxy-benzamide

[1644]

[1645] Step 1: 3-[[2-(5-Chloro-2-methoxy-phenyl)acetyl]amino]-4-methoxy-benzoic acid methyl ester

[1646]

[1647] The title compound was prepared in analogy to Example 6 (step 1) from 3-amino-4-methoxy-benzoic acid methyl ester and 2-(5-chloro-2-methoxy-phenyl)acetic acid.

[1648] 1H NMR (500MHz, chloroform-d) δ8.98 (m, 1H), 8.28 (s, 1H), 7.77 (dd, J=8.6, 2.1Hz, 1H), 7.31 (d, J=2.6Hz, 1H), 7.24 ( dd, J=8.7, 2.6Hz, 1H), 6.86 (dd, J=8.7, 6.1Hz, 2H), 3.90 (s, 3H), 3.90 (s, 3H), 3.86 (s, 3H), 3.71 (s, 2H).

[1649] LC-MS (Method E): Rt 1.20 min; MS m / z 364.1 / 366.1 = [M+H]+ (72% @ 215 nm)

[1650] Step 2: 3-[[2-(5-Chloro-2-methoxy-phenyl)acetyl]amino]-4-methoxy-benzoic acid

[1651]

[1652] To a solution of 3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-4-methoxy-benzoic acid methyl ester (step 1) (301 mg, 0.83 mmol) in 1,4-dioxane (4 mL) was added 2M aqueous LiOH (1.24 mL, 2.48 mmol), the mixture was shaken at room temperature overnight, the dioxane was removed under vacuum, and the resulting mixture was acidified to pH 1 with 1M HCl. The mixture was washed with EtOAc (2 x 5 mL), the aqueous phase was concentrated under vacuum, the resulting solid was sonicated with MeOH (20 mL), the suspension was filtered, washed with additional MeOH (5 mL), and the combined filtrates were concentrated under vacuum to give an off-white solid.

[1653] 1H NMR (500MHz, DMSO-d6) δ9.26 (s, 1H), 8.56 (s, 1H), 7.68 (dd, J=8.5, 2.1Hz, 1H), 7.35-7.20 ( m, 3H), 7.13 (d, J=8.6Hz, 1H), 7.03 (d, J=8.5Hz, 1H), 3.92 (s, 3H), 3.82 (s, 2H), 3.80 (s, 3H).

[1654] LC-MS (Method E): Rt 1.08 min; MS m / z 350.1 / 352.1 = [M+H]+ (85% @ 215 nm)

[1655] Step 3: N-tert-Butyl-3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-4-methoxy-benzamide

[1656]

[1657] To a solution of 3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-4-methoxy-benzoic acid (step 2) (201 mg, 0.57 mmol) in DMF (2 mL) was added EDCI (110 mg, 0.57 mmol), HOAt (78 mg, 0.57 mmol), DIPEA (251 μL, 1.44 mmol) and 2-methylpropan-2-amine (79 μL, 0.75 mmol). The reaction mixture was shaken at room temperature overnight and then partitioned between DCM (6 mL) and water (6 mL). The organic layer was collected using a hydrophobic frit and concentrated under vacuum and chromatographed on silica gel eluting with EtOAc in heptane to give the title compound as a colorless glass.

[1658] 1H NMR (500MHz, chloroform-d) δ8.63 (d, J=2.2Hz, 1H), 8.36 (s, 1H), 7.64 (dd, J=8.6, 2.3Hz, 1H), 7.30 (d, J=2.6Hz, 1H), 7.25 (dd , J=8.8, 2.6Hz, 1H), 6.87 (dd, J=10.9, 8.7Hz, 2H), 5.99 (s, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 3.70 (s, 2H), 1.43 (s, 9H).

[1659] LC-MS (Method E): Rt 1.20 min; MS m / z 405.1 / 407.1 = [M+H]+ (62% @ 215 nm)

[1660] Step 4: N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-hydroxy-benzamide

[1661] The title compound was prepared in analogy to Example 3, Step 3, from N-tert-butyl-3-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-4-methoxy-benzamide (Step 3).

[1662] 1H NMR (500MHz, methanol-d4) δ8.23 (d, J=2.2Hz, 1H), 7.48 (s, 1H), 7.39 (dd, J=8.4, 2.2Hz, 1H), 7.24 (d, J=2.6Hz, 1H), 7.11 (dd, J=8.6, 2.6Hz, 1H), 6.86 (d, J=8.4Hz, 1H), 6.82 (d, J=8.6Hz, 1H), 3.72 (s, 2H), 1.43 (s, 9H).

[1663] LC-MS (Method A): Rt 2.93 min; MS m / z 377.3 / 379.2 = [M+H]+ (99% @ 215 nm).

[1664] Embodiment 15

[1665] N-tert-Butyl-4-[[2-(2-hydroxy-5-methyl-phenyl)acetyl]amino]pyridine-2-carboxamide

[1666]

[1667] Step 1: N-tert-butyl-4-[[2-(2-methoxy-5-methyl-phenyl)acetyl]amino]pyridine-2-carboxamide

[1668]

[1669] To a solution of 4-[[2-(5-bromo-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Example 6, step 1) (200 mg, 0.48 mmol) and potassium carbonate (132 mg, 0.95 mmol) in diglyme (5 mL) was added Pd(dppf) 2 Cl 2 (17 mg, 0.02 mmol), then 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborane in THF (50%, 0.16 mL, 0.57 mmol) was added. The resulting mixture was degassed with nitrogen for 5 minutes and then stirred at 100°C in a pressure tube for 16 hours. The resulting mixture was diluted with EtOAc (25 mL) and washed with water (2 x 25 mL) and brine (2 x 25 mL). The organic portion was purified by Na 2 SO 4 Dry, concentrate under vacuum and chromatograph on silica gel eluting with EtOAc in heptane.Concentrate product fractions under vacuum to give the title compound as a beige solid.

[1670] 1H NMR (500MHz, DMSO-d6) δ10.65 (s, 1H), 8.43 (d, J = 5.5Hz, 1H), 8.18 (d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7.81 (dd, J = 5 .5, 2.2Hz, 1H), 7.06-7.01 (m, 2H), 6.86 (d, J=8.2Hz, 1H), 3.71 (s, 3H), 3.65 (s, 2H), 2.23 (s, 3H), 1.40 (s, 9H).

[1671] LC-MS (Method E): Rt 1.22 min; MS m / z 356.2 = [M+H]+ (97% @ 215 nm)

[1672] Step 2: N-tert-butyl-4-[[2-(2-hydroxy-5-methyl-phenyl)acetyl]amino]pyridine-2-carboxamide

[1673] The title compound was prepared in analogy to Example 3 (step 3) from N-tert-butyl-4-[[2-(2-methoxy-5-methyl-phenyl)acetyl]amino]pyridine-2-carboxamide (step 1).

[1674] 1H NMR (500MHz, DMSO-d6) δ10.63 (s, 1H), 9.25 (s, 1H), 8.43 (d, J = 5.5Hz, 1H), 8.18 (d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7.82 (dd, J = 5.5 , 2.2Hz, 1H), 6.94 (d, J=1.9Hz, 1H), 6.87 (dd, J=8.1, 1.9Hz, 1H), 6.68 (d, J=8.1Hz, 1H), 3.61 (s, 2H), 2.18 (s, 3H), 1.40 (s, 9H).

[1675] LC-MS (Method A): Rt 3.19 min; MS m / z 342.3 = [M+H]+ (100% @ 215 nm)

[1676] Example 16

[1677] N-tert-Butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-4-methoxy-benzamide

[1678]

[1679] The title compound was prepared in analogy to Example 11, Steps 1-3, from 3-amino-4-methoxy-benzoic acid methyl ester and 5-chloro-3H-benzofuran-2-one.

[1680] 1H NMR (500MHz, methanol-d4) δ8.36 (d, J=2.1Hz, 1H), 7.51 (dd, J=8.6, 2.2Hz, 1H), 7.24 (d, J=2.6Hz, 1H), 7.12 (dd , J=8.6, 2.6Hz, 1H), 7.03 (d, J=8.6Hz, 1H), 6.83 (d, J=8.6Hz, 1H), 3.91 (s, 3H), 3.72 (s, 2H), 1.43 (s, 9H).

[1681] LC-MS (Method A): Rt 3.18 min; MS m / z 391.2 / 393.2 = [M+H]+ (95% @ 215 nm)

[1682] Embodiment 17

[1683] N-tert-Butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-fluoro-benzamide

[1684]

[1685] Step 1-2: 5-[[2-(5-Chloro-2-methoxy-phenyl)acetyl]amino]-2-fluoro-benzoic acid

[1686]

[1687] The title compound was prepared in analogy to Example 7, steps 1 and 2, from 5-amino-2-fluoro-benzoate and 2-(5-chloro-2-methoxy-phenyl)acetic acid.

[1688] 1H NMR(500MHz, DMSO-d6)δ13.25(br s, 1H), 10.29 (s, 1H), 8.14 (dd, J=6.6, 2.8Hz, 1H), 7.83-7.76 (m, 1H), 7.32-7.28 ( m, 2H), 7.25 (dd, J=10.5, 9.0Hz, 1H), 7.03-6.98 (m, 1H), 3.77 (s, 3H), 3.65 (s, 2H).

[1689] LC-MS (Method E): Rt 1.04 min; MS m / z 338.0, 340.1 = [M+H]+ (95% @ 215 nm)

[1690] Step 3: N-tert-Butyl-5-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-2-fluoro-benzamide

[1691]

[1692] To a mixture of 5-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-2-fluoro-benzoic acid (step 2) (100 mg, 0.28 mmol), TBTU (108 mg, 0.34 mmol) and TEA (0.08 mL, 0.56 mmol) in DMF (1.5 mL) was added 2-methylpropan-2-amine (35 μL, 0.34 mmol) and the mixture was stirred at room temperature for 3 hours. The resulting mixture was concentrated under vacuum and the residue was partitioned between water (10 mL) and DCM (10 mL), the organic phase was separated and concentrated under vacuum and the crude product was purified by silica gel chromatography eluting with EtOAc in heptane to give the title compound as a white solid.

[1693] 1H NMR (500MHz, DMSO-d6) δ10.21 (s, 1H), 7.83 (s, 1H), 7.73 (dd, J=6.3, 2.7Hz, 1H), 7.65 (ddd, J=8.8, 4.4, 2.8Hz, 1H), 7. 32-7.29 (m, 1H), 7.29-7.27 (m, 1H), 7.17 (t, J=9.4Hz, 1H), 7.02-6.98 (m, 1H), 3.76 (s, 3H), 3.63 (s, 2H), 1.34 (s, 9H).

[1694] LC-MS (Method E): Rt 1.22 min; MS m / z 393.2, 395.1 = [M+H]+ (99% @ 215 nm)

[1695] Step 4: N-tert-Butyl-5-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-2-fluoro-benzamide

[1696] The title compound was prepared in analogy to Example 7, Step 4, from N-tert-butyl-5-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-2-fluoro-benzamide (Step 3).

[1697] 1H NMR (500MHz, DMSO-d6) δ10.21 (s, 1H), 9.84 (s, 1H), 7.83 (s, 1H), 7.73 (dd, J=6.3, 2.7Hz, 1H), 7.66 (ddd, J=8.9, 4 .4, 2.8Hz, 1H), 7.24-7.13 (m, 2H), 7.11 (dd, J=8.6, 2.7Hz, 1H), 6.80 (d, J=8.6Hz, 1H), 3.59 (s, 2H), 1.34 (s, 9H).

[1698] LC-MS (Method A): Rt 3.30 min; MS m / z 379.2 / 381.1 = [M+H]+ (99% @ 215 nm)

[1699] Embodiment 18

[1700] N-tert-Butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-benzamide

[1701]

[1702] Step 1: 3-Amino-N-tert-butyl-5-fluoro-benzamide

[1703] The title compound was prepared in analogy to Example 9, Step 1, from 3-amino-5-fluoro-benzoic acid.

[1704] 1H NMR (500 MHz, chloroform-d) δ 6.85-6.80 (m, 1H), 6.69 (dt, J = 9.1, 1.8 Hz, 1H), 6.45 (dt, J = 10.2, 2.2 Hz, 1H), 5.81 (s, 1H), 3.89 (s, 2H), 1.45 (s, 9H).

[1705] LC-MS (Method E): Rt 0.96 min; MS m / z 211.1 = [M+H]+ (100% @ 215 nm)

[1706] Step 2-3: N-tert-butyl-3-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-benzamide

[1707] The title compound was prepared in analogy to Example 3 Steps 2 and 3 from 3-amino-N-tert-butyl-5-fluoro-benzamide (Step 1).

[1708] 1H NMR (500MHz, DMSO-d6) δ10.41 (s, 1H), 9.81 (s, 1H), 7.81 (s, 1H), 7.75 (dt, J=11.2, 2.0Hz, 1H), 7.66 (s, 1H), 7.32- 7.24 (m, 1H), 7.20 (d, J=2.7Hz, 1H), 7.11 (dd, J=8.6, 2.7Hz, 1H), 6.80 (d, J=8.6Hz, 1H), 3.62 (s, 2H), 1.36 (s, 9H).

[1709] LC-MS (Method A): Rt 3.34 min; MS m / z 379.1 / 381.1 = [M+H]+ (97% @ 215 nm)

[1710] Embodiment 19

[1711] N-tert-Butyl-4-[[2-(3-hydroxy-2-pyridinyl)acetyl]amino]pyridine-2-carboxamide

[1712]

[1713] Step 1: N-tert-butyl-4-[[2-(3-methoxy-2-pyridinyl)acetyl]amino]pyridine-2-carboxamide

[1714]

[1715] The title compound was prepared in analogy to Example 5 from 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3, Step 1) and 2-(3-methoxy-2-pyridinyl)acetic acid.

[1716] 1H NMR (500MHz, DMSO-d6) δ10.75 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.18 (d, J = 2.1Hz, 1H), 8.07 (dd, J = 4.7, 1.3Hz, 1H), 8.03 (s, 1H), 7.80 (dd, J=5.5, 2.2Hz, 1H), 7.42 (dd, J=8.3, 1.2Hz, 1H), 7.30 (dd, J=8.3, 4.7Hz, 1H), 3.88 (s, 2H), 3.81 (s, 3H), 1.40 (s, 9H).

[1717] LC-MS (Method A): Rt 2.11 min; MS m / z 343.2 = [M+H]+ (100% @ 215 nm)

[1718] Step 2: N-tert-butyl-4-[[2-(3-hydroxy-2-pyridinyl)acetyl]amino]pyridine-2-carboxamide

[1719] The title compound was prepared in analogy to Example 7, Step 4, from N-tert-butyl-4-[[2-(3-methoxy-2-pyridinyl)acetyl]amino]pyridine-2-carboxamide (Step 1).

[1720] 1H NMR (500MHz, DMSO-d6) δ10.73 (s, 1H), 10.01 (br s, 1H), 8.44 (d, J=5.5Hz, 1H), 8.18 (d, J=2.1Hz, 1H), 8.03 (s, 1H), 7.95 (dd, J=4.4, 1 .6Hz, 1H), 7.81 (dd, J=5.5, 2.2Hz, 1H), 7.20-7.09 (m, 2H), 3.84 (s, 2H), 1.40 (s, 9H).

[1721] LC-MS (Method A): Rt 1.60 min; MS m / z 329.1 = [M+H]+ (98% @ 215 nm)

[1722] Embodiment 20

[1723] N-tert-Butyl-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1724]

[1725] Step 1: N-tert-butyl-4-[[2-(5-fluoro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1726]

[1727] A solution of 2-(5-fluoro-2-methoxy-phenyl)acetic acid (57 mg, 0.31 mmol) in thionyl chloride (246 μL, 2.79 mmol) was heated at 70°C for 1 hour. Excess thionyl chloride was removed under vacuum and azeotroped with DCM. The residue was added to a mixture of 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3 Step 1) (60 mg, 0.31 mmol) and DIPEA (65 μL, 0.37 mmol) in DCM (30 mL), and the mixture was stirred at room temperature. After 1 hour, the mixture was partitioned between water (25 mL) and DCM (25 mL). The organic layer was separated and purified by Na 2 SO 4 Dry, filter, and concentrate in vacuo. Purify the crude residue by silica gel chromatography eluting with EtOAc in heptane, then freeze-dry the product fractions to give the title compound as a white solid.

[1728] 1H NMR (500MHz, DMSO-d6) δ10.68 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.17 (d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7.81 (dd, J = 5.5, 2.2Hz, 1H), 7.12 (dd, J=9.2, 3.2Hz, 1H), 7.08 (td, J=8.6, 3.2Hz, 1H), 6.98 (dd, J=9.0, 4.6Hz, 1H), 3.74 (s, 3H), 3.71 (s, 2H), 1.40 (s, 9H).

[1729] LC-MS (Method E): Rt 1.16 min; MS m / z 360.1 = [M+H]+ (98% @ 215 nm)

[1730] Step 2: N-tert-butyl-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1731] To a solution of N-tert-butyl-4-[[2-(5-fluoro-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide (step 1) (54.1 mg, 0.15 mmol) in DCM (1.3 mL) was slowly added 1 M BBr 3The reaction was stirred at room temperature for 2.5 hours and then concentrated under vacuum. The residue was partitioned between H 2 The organic portion was separated between 4% CO 2 (10 mL) and EtOAc (10 mL) and concentrated under vacuum. The crude product was purified by preparative HPLC (acidic pH, early elution method) to give the title compound as a white solid.

[1732] 1H NMR (500MHz, DMSO-d6) δ10.67 (s, 1H), 9.52 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.18 (d, J = 2.1Hz, 1H), 8.03 (s, 1H), 7.82 (dd, J = 5.5 , 2.2Hz, 1H), 7.01 (dd, J=9.4, 3.2Hz, 1H), 6.91 (td, J=8.6, 3.2Hz, 1H), 6.77 (dd, J=8.8, 4.9Hz, 1H), 3.67 (s, 2H), 1.40 (s, 9H).

[1733] LC-MS (Method A): Rt 3.01 min; MS m / z 346.1 = [M+H]+ (98% @ 215 nm)

[1734] Embodiment 21

[1735] Racemic N-tert-butyl-4-[[-indane-1-carbonyl]amino]pyridine-2-carboxamide

[1736]

[1737] A mixture of 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3 Step 1) (100 mg, 0.52 mmol) and indane-1-carboxylic acid (84 mg, 0.52 mmol) in 1,4-dioxane (1 mL) was stirred with 50% The solution was treated with EtOAc (616 μL, 1.03 mmol) and TEA (181 μL, 1.03 mmol) and stirred at room temperature for 1.5 hours. The resulting mixture was diluted with EtOAc (20 mL) and water (20 mL), the organic portion was separated, and the mixture was purified by Na 2 SO 4 After drying, filtering, and concentrating in vacuo, the crude product was purified by silica gel chromatography eluting with EtOAc in heptane to afford racemic N-tert-butyl-4-[[-indane-1-carbonyl]amino]pyridine-2-carboxamide.

[1738] Example 21a: N-tert-butyl-4-[[(1R) or (1S)-indane-1-carbonyl]amino]pyridine-2-carboxamide and Example 21b: N-tert-butyl-4-[[(1R) or (1S)-indane-1-carbonyl]amino]pyridine-2-carboxamide

[1739]

[1740] Chiral separation of racemic N-tert-butyl-4-[[-indane-1-carbonyl]amino]pyridine-2-carboxamide was performed using Supercritical Fluid Chromatography [chiral column (25% IPA:75% CO2, on Chiralcel OD-H 25 cm column, at 15 ml / min)] to afford the individual enantiomers:

[1741] Example 21a: First eluting peak: N-tert-butyl-4-[[(1R)-indane-1-carbonyl]amino]pyridine-2-carboxamide or N-tert-butyl-4-[[(1S)-indane-1-carbonyl]amino]pyridine-2-carboxamide

[1742] SFC retention time: 5.46 min, MS m / z 338.3 = [M+H]+ (100% @ 215 nm)

[1743] 1H NMR (500MHz, DMSO-d6) δ10.85 (s, 1H), 8.46 (d, J = 5.5Hz, 1H), 8.23 ​​(d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7.87 (dd, J = 5.5, 2.2Hz, 1H), 7.32 (d, J = 7.4 Hz, 1H), 7.28 (d, J=7.3Hz, 1H), 7.20 (m, 1H), 7.16 (m, 1H), 4.16 (m, 1H), 3.11-3.03(m, 1H), 2.95-2.87(m, 1H), 2.40-2.27(m, 2H), 1.40(s, 9H).

[1744] ee 100%

[1745] Example 21b: Second eluting peak: N-tert-butyl-4-[[(1R)-indane-1-carbonyl]amino]pyridine-2-carboxamide or N-tert-butyl-4-[[(1S)-indane-1-carbonyl]amino]pyridine-2-carboxamide

[1746] SFC retention time: 8.00 min, MS m / z 338.3 = [M+H]+ (91% @ 215 nm)

[1747] 1H NMR (500MHz, DMSO-d6) δ10.85 (s, 1H), 8.46 (d, J = 5.5Hz, 1H), 8.23 ​​(d, J = 2.0Hz, 1H), 8.03 (s, 1H), 7.87 (dd, J = 5.5, 2.2Hz, 1H), 7.32 (d, J = 7.3 Hz, 1H), 7.28 (d, J=7.3Hz, 1H), 7.20 (m, 1H), 7.16 (m, 1H), 4.16 (m, 1H), 3.11-3.03(m, 1H), 2.95-2.87(m, 1H), 2.39-2.27(m, 2H), 1.40(s, 9H).

[1748] ee 88%

[1749] Embodiment 22

[1750] N-tert-Butyl-4-[(2-phenylacetyl)amino]pyridine-2-carboxamide

[1751]

[1752] To a mixture of 4-amino-N-tert-butyl-pyridine-2-carboxamide (Example 3, step 1) (50 mg, 0.26 mmol) in DCM (2.59 mL) was added TEA (113 μL, 0.65 mmol) and 2-phenylacetyl chloride (41 μL, 0.31 mmol) and the mixture was stirred for 16 hours. The resulting mixture was diluted with DCM (10 mL) and washed with water (2 x 10 mL) and then with NaHCO 3 The organic layer was separated and washed with saturated aqueous solution (10 mL). 2 SO 4 Dry, filter, and concentrate under vacuum. The crude residue was dissolved in a mixture of DMSO:MeCN (800 μl, 1:1), filtered, and purified by preparative HPLC (acidic pH, early elution method). The product fractions were combined and purified by NaHCO 3 The pH of the mixture was adjusted to pH 7 with saturated aqueous solution (20 mL) and extracted with DCM (3 x 20 mL). The combined organic extracts were purified by Na 2 SO 4 Dry, filter, and concentrate in vacuo to afford the title compound as an off-white solid.

[1753] 1H NMR (500MHz, DMSO-d6) δ10.75 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.18 (d, J = 1.9Hz, 1H), 8.02 (s, 1H), 7.81 (dd, J=5.5, 2.2Hz, 1H), 7.33 (d, J=4.4Hz, 4H), 7.29-7.23 (m, 1H), 3.71 (s, 2H), 1.39 (s, 9H).

[1754] LC-MS (Method A): Rt 3.23 min; MS m / z 312.2 = [M+H]+ (100% @ 215 nm)

[1755] Example 22.1

[1756] 4-(3,3-dimethylbutyrylamino)-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide

[1757]

[1758] The title compound was prepared in analogy to Example 22 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 3,3-dimethylbutyryl chloride.

[1759] 1H NMR (500MHz, DMSO-d6) δ10.41 (s, 1H), 8.45 (d, J = 5.5Hz, 1H), 8.31 (s, 1H), 8.22 (d, J = 2.1Hz, 1H), 7.81 (dd, J=5.5, 2.2Hz, 1H), 3.21 (s, 1H), 2.25 (s, 2H), 1.64 (s, 6H), 1.02 (s, 9H). LC-MS (method A): Rt 3.22min; MS m / z 302.2=[M+H]+(100%@215nm)

[1760] Example 22.2

[1761] 4-[(2-Cyclopentylacetyl)amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide

[1762]

[1763] The title compound was prepared in analogy to Example 22 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-cyclopentylacetyl chloride.

[1764] 1H NMR (500MHz, DMSO-d6) δ10.47 (s, 1H), 8.45 (d, J=5.5Hz, 1H), 8.31 (s, 1H), 8.21 (d, J=2.1Hz, 1H), 7.81 (dd, J=5.5, 2.2Hz, 1H), 3.21 (s , 1H), 2.39-2.35(m, 2H), 2.28-2.19(m, 1H), 1.80-1.72(m, 2H), 1.64(s, 6H), 1.63-1.56(m, 2H), 1.56-1.47(m, 2H), 1.23-1.13(m, 2H).

[1765] LC-MS (Method A): Rt 3.33 min; MS m / z 314.2 = [M+H]+ (97% @ 215 nm)

[1766] Example 22.3

[1767] 4-[[2-(3-chloro-4-pyridinyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide

[1768]

[1769] The title compound was prepared in analogy to Example 22 from 4-amino-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Example 78, Step 1) and 2-(3-chloro-4-pyridinyl)acetic acid hydrochloride.

[1770] 1H NMR (500MHz, DMSO-d6) δ10.95 (s, 1H), 8.63 (s, 1H), 8.49 (t, J=5.3Hz, 2H), 8.32 (s, 1H), 8.19 (d, J=2. 0Hz, 1H), 7.81 (dd, J=5.5, 2.2Hz, 1H), 7.51 (d, J=4.9Hz, 1H), 3.99 (s, 2H), 3.21 (s, 1H), 1.64 (s, 6H).

[1771] LC-MS (Method A): Rt 2.53 min; MS m / z 357.1 / 359.1 = [M+H]+ (100% @ 215 nm)

[1772] Embodiment 23

[1773] 4-[[2-(4-Chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide

[1774]

[1775] Step 1: 4-amino-N-(1-cyanocyclopropyl)pyridine-2-carboxamide

[1776]

[1777] To a mixture of 4-aminopyridine-2-carboxylic acid (1 g, 7.24 mmol), TBTU (2.79 g, 8.69 mmol) and TEA (1.21 mL, 8.69 mmol) in DMF (8 mL) was added 1-aminocyclopropanecarbonitrile (22.82 mL, 8.69 mmol) and the mixture was stirred at 40 ° C for 2 days. The resulting mixture was concentrated under vacuum, the crude residue was dissolved in EtOAc (15 mL), and the mixture was washed with water (20 mL), NaHCO 3 (15 mL) and washed with Na 2 SO 4 Drying and concentration in vacuo afforded the title compound as an orange solid.

[1778] 1H NMR (500MHz, DMSO-d6) δ9.41 (s, 1H), 8.01 (d, J = 5.6Hz, 1H), 7.22 (d, J = 2.3Hz, 1H) , 6.62 (dd, J=5.6, 2.4Hz, 1H), 6.37 (s, 2H), 1.51-1.47 (m, 2H), 1.31-1.27 (m, 2H).

[1779] LC-MS (Method E): Rt 0.25 min; MS m / z 203.1 = [M+H]+

[1780] Step 2: 4-[[2-(4-chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide

[1781] To a solution of 4-amino-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (step 1) (100 mg, 0.45 mmol), 2-(4-chlorophenyl)acetic acid (83.52 mg, 0.49 mmol) and TEA (155 μL, 0.89 mmol) in 1,4-dioxane (2 mL) was slowly added 50% The reaction mixture was stirred at room temperature for 1 hour and concentrated under vacuum. The crude residue was dissolved in EtOAc (10 mL) and washed with NaHCO 3 (15 mL), washed with brine (15 mL), and then with Na 2 SO 4 Drying and concentration under vacuum and purification by preparative HPLC (acidic pH, early elution method) afforded the title compound as an off-white solid.

[1782] 1H NMR (500MHz, DMSO-d6) δ = 10.80 (s, 1H), 9.65 (s, 1H), 8.49 (d, J = 5.5, 1H), 8.21 (d, J = 1.9, 1H), 7 .86 (dd, J=5.5, 2.2, 1H), 7.41-7.34 (m, 4H), 3.74 (s, 2H), 1.55-1.51 (m, 2H), 1.34-1.30 (m, 2H).

[1783] LC-MS (Method A): Rt 2.92 min; MS m / z 355.3 = [M+H]+ (98% @ 215 nm)

[1784] The compounds of the examples listed below (Table 8) were prepared in analogy to Example 23 by replacing 1-aminocyclopropane (step 1) with a suitable amine and by replacing 2-(4-chlorophenyl)acetic acid (step 2) with a suitable commercially available acid.

[1785]

[1786]

[1787]

[1788]

[1789]

[1790] Embodiment 24

[1791] 4-[[2-(2-Chloro-5-methoxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide

[1792]

[1793] Steps 1 and 2: N-(1-cyanocyclopropyl)-4-[[2-(3-methoxyphenyl)acetyl]amino]pyridine-2-carboxamide

[1794] The title compound was prepared in analogy to Example 23 by substituting 2-(3-methoxyphenyl)acetic acid for 2-(4-chlorophenyl)acetic acid (step 2).

[1795] 1H NMR (500MHz, DMSO-d6) δ = 10.77 (s, 1H), 9.65 (s, 1H), 8.49 (d, J = 5.5, 1H), 8.21 (d, J = 2.1, 1H), 7.86 (dd, J = 5.5, 2.2, 1H), 7.24 ( t, J=7.8, 1H), 6.92-6.88 (m, 2H), 6.83 (dd, J=8.0, 2.1, 1H), 3.74 (s, 3H), 3.68, (s, 2H), 1.55-1.51 (m, 2H), 1.34-1.30 (m, 2H).

[1796] LC-MS (Method E): Rt 1.03 min; MS m / z 351.0 = [M+H]+ (97% @ 215 nm)

[1797] Step 2: 4-[[2-(2-Chloro-5-methoxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide

[1798] To a solution of N-(1-cyanocyclopropyl)-4-[[2-(3-methoxyphenyl)acetyl]amino]pyridine-2-carboxamide (step 1) (81 mg, 0.23 mmol) in MeCN (33.7 mL) was added NCS (77 mg, 0.58 mmol) and the mixture was stirred at 60 °C for 16 h. The resulting mixture was concentrated under vacuum to give a crude dry residue, which was dissolved in EtOAc (10 mL), washed with water (10 mL), NaHCO3 (10 ml), and concentrated under vacuum and purified by preparative HPLC (acidic pH, standard elution method) to give the title compound as an off-white solid.

[1799] 1H NMR (500MHz, DMSO-d6) δ10.84 (s, 1H), 9.66 (s, 1H), 8.50 (d, J = 5.5Hz, 1H), 8.21 (d, J = 2.0Hz, 1H), 7.86 (dd, J = 5.5, 2.2Hz, 1H), 7.35 (d , J=8.8Hz, 1H), 7.04 (d, J=3.1Hz, 1H), 6.90 (dd, J=8.8, 3.1)Hz, 1H), 3.87 (s, 2H), 3.76 (s, 3H), 1.55-1.51 (m, 2H), 1.35-1.30 (m, 2H).

[1800] LC-MS (Method A): Rt 2.84 min; MS m / z 385.2 / 387.2 = [M+H]+ (100% @ 215 nm)

[1801] Embodiment 25

[1802] N-(3-Bicyclo[1.1.1]pentyl)-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1803]

[1804] Step 1: 4-[[2-(5-tert-Butyl-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid methyl ester

[1805]

[1806] 2-(5-tert-Butyl-2-methoxy-phenyl)acetic acid (700 mg, 3.15 mmol) was dissolved in thionyl chloride (2.5 mL, 28.37 mmol) and stirred at 70°C for 30 minutes. The resulting mixture was concentrated under vacuum and azeotroped with toluene (3 x 5 mL). The residue was dissolved in DCM (15 mL) to form an acid chloride solution and added to a stirred solution of methyl 4-aminopyridine-2-carboxylate (527 mg, 3.46 mmol) in DCM (15 mL). After stirring for 10 minutes, the mixture was concentrated under vacuum to give a brown gum which was purified by silica gel chromatography eluting with heptane containing 25-100% EtOAc to give the title compound as a dark yellow glass.

[1807] 1H NMR (250MHz, DMSO-d6) δ10.68 (s, 1H), 8.54 (d, J=5.5Hz, 1H), 8.31 (d, J=2.0Hz, 1H), 7.77 (dd, J=5.5, 2. 1Hz, 1H), 7.29-7.20 (m, 2H), 6.89 (d, J=9.3Hz, 1H), 3.86 (s, 3H), 3.72 (s, 3H), 3.68 (s, 2H), 1.26 (s, 9H).

[1808] LC-MS (Method E): Rt 1.17 min; MS m / z 357 = [M+H]+

[1809] Step 2: 4-[[2-(5-tert-butyl-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid

[1810]

[1811] To a solution of methyl 4-[[2-(5-tert-butyl-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylate (step 1) (594 mg, 1.55 mmol) in THF (12 mL) was added 1 M sodium hydroxide solution (1.86 mL, 1.86 mmol), the mixture was stirred for 30 minutes, and the pH of the resulting mixture was adjusted to pH 4 by the addition of hydrochloric acid. The mixture was partitioned between EtOAc (20 mL) and water (20 mL), at which point a precipitate formed in the organic layer. The organic suspension was washed with water (20 mL), brine (20 mL), filtered through a phase separator, and dried to give a fine powder of the title compound.

[1812] 1H NMR (250MHz, DMSO-d6) δ10.70 (s, 1H), 8.52 (d, J = 5.6Hz, 1H), 8.28 (d, J = 1.9Hz, 1H), 7.80 (dd, J = 5 .6, 2.2Hz, 1H), 7.29-7.20 (m, 2H), 6.89 (d, J=9.4Hz, 1H), 3.72 (s, 3H), 3.69 (s, 2H), 1.26 (s, 9H).

[1813] LC-MS (Method E): Rt 0.98 min; MS m / z 343 = [M+H]+

[1814] Step 3: 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid

[1815]

[1816] An ice-cold suspension of 4-[[2-(5-tert-butyl-2-methoxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid (step 2) (330 mg, 0.93 mmol) in DCM (9 mL) was treated with 1 M BBr 3 The mixture was treated with 10% DCM (1.85 mL, 1.85 mmol) and stirred for 70 min. The reaction was quenched with methanol (1 mL) and the mixture was partitioned between EtOAc (20 mL) and water (20 mL), resulting in the formation of a fine white precipitate, which was filtered and dried to give the title compound as a solid.

[1817] 1H NMR (250MHz, DMSO-d6) δ11.51 (s, 1H), 8.65 (d, J = 6.4Hz, 1H), 8.51 (d, J = 2.2Hz, 1H), 8.14 (dd, J = 6.4, 2.3Hz , 1H), 7.18 (d, J=2.4Hz, 1H), 7.10 (dd, J=8.4, 2.5Hz, 1H), 6.74 (d, J=8.4Hz, 1H), 3.75 (s, 2H), 1.23 (s, 9H).

[1818] LC-MS (Method E): Rt 0.97 min; MS m / z 329 = [M+H]+ (91% @ 215 nm)

[1819] Step 4: N-(3-Bicyclo[1.1.1]pentyl)-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide

[1820] To a suspension of 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid (step 3) (25 mg, 0.08 mmol) in DMF (0.5 mL) was added bicyclo[1.1.1]pentan-3-amine hydrochloride (11 mg, 0.09 mmol), DIPEA (0.05 mL, 0.3 mmol) and HATU (43 mg, 0.11 mmol). After stirring at room temperature for 18 h, the mixture was partitioned between EtOAc (10 mL) and water (10 mL), the aqueous portion was extracted with EtOAc (2 x 20 mL), the combined organic extracts were washed with water (20 mL), brine (20 mL), and purified by Na 2 O 4 3 4 2 0 4 0 0 4 0 0 4 0 0 2 SO 4 Dry and concentrate in vacuo. The crude residue is purified by C18 reverse phase chromatography eluting with 45-65% MeCN in water and 0.1% formic acid to afford the title compound as a white powder.

[1821] 1H NMR (500MHz, DMSO-d6) δ10.70 (s, 1H), 9.28 (s, 1H), 9.07 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.16 (d, J = 2.1Hz, 1H), 7.84 (dd, J = 5.5, 2.2Hz, 1H), 7 .16 (d, J=2.5Hz, 1H), 7.08 (dd, J=8.4, 2.5Hz, 1H), 6.72 (d, J=8.4Hz, 1H), 3.65 (s, 2H), 2.44 (s, 1H), 2.09 (s, 6H), 1.23 (s, 9H). LC-MS (Method A): Rt 3.71min; MS m / z 394=[M+H]+

[1822] Example 25.1

[1823] 4-[[2-(5-tert-Butyl-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide

[1824]

[1825] The title compound was prepared in analogy to Example 25, Step 4, from 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxylic acid (Example 25, Step 3) and 4-aminotetrahydropyran-4-carbonitrile.

[1826] 1H NMR (500MHz, methanol-d4) δ8.47 (d, J=5.5Hz, 1H), 8.17 (d, J=1.8Hz, 1H), 7.94 (dd, J=5.5, 2.2Hz, 1H), 7.22 (d, J=2.4Hz, 1H), 7.15 (dd, J=8.4, 2.5Hz , 1H), 6.75 (d, J=8.4Hz, 1H), 3.96 (dt, J=12.5, 4.0Hz, 2H), 3.80-3.74 ( m, 2H), 3.72 (s, 2H), 2.49-2.43 (m, 2H), 2.14-2.07 (m, 2H), 1.28 (s, 9H).

[1827] LC-MS (Method A): Rt 3.22 min; MS m / z 437 = [M+H]+ (100% @ 215 nm)

[1828] Embodiment 26

[1829] N-tert-Butyl-4-[[2-(2-hydroxy-5-phenyl-phenyl)acetyl]amino]pyridine-2-carboxamide

[1830]

[1831] Step 1: N-tert-butyl-4-[[2-(2-methoxy-5-phenyl-phenyl)acetyl]amino]pyridine-2-carboxamide

[1832]

[1833] The pressure tube was charged with 4-[[2-(5-bromo-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (Example 6, Step 1) (250 mg, 0.59 mmol), tripotassium phosphate (379 mg, 1.78 mmol), phenylboronic acid (80 mg, 0.65 mmol) in 1,4-dioxane (4 mL), and the suspension was degassed with nitrogen. Bis[3-(diphenylphosphino)cyclopenta-2,4-dien-1-yl]iron; dichloromethane; dichloropalladium (24 mg, 0.03 mmol) were added under nitrogen atmosphere, and the sealed tube was heated to 80 ° C for 23 hours. The reaction mixture was concentrated under vacuum, the crude residue was redissolved in EtOAc, and the mixture was passed through Filter through (filtrate) and concentrate the filtrate in vacuo to give a brown oil which is purified by silica gel chromatography eluting with 25-100% EtOAc in heptane to give the title compound as a white solid.

[1834] 1H NMR (250 MHz, chloroform-d) δ 8.38 (d, J = 5.6 Hz, 1H), 8.26-8.14 (m, 2H), 7.97 (s, 1H), 7.59-7.50 (m, 5H), 7.46-7.37 (m, 2H), 7.37-7.28 (m, 1H), 7.05 (d, J = 8.3 Hz, 1H), 4.01 (s, 3H), 3.80 (s, 2H), 1-47 (s, 9H).

[1835] LC-MS (Method E): Rt 1.29 min; MS m / z 418 = [M+H] +

[1836] Step 2: N-tert-butyl-4-[[2-(2-hydroxy-5-phenyl-phenyl)acetyl]amino]pyridine-2-carboxamide

[1837] To an ice-cold solution of N-tert-butyl-4-[[2-(2-methoxy-5-phenyl-phenyl)acetyl]amino]pyridine-2-carboxamide (step 1) (160 mg, 0.38 mmol) in DCM (2.5 mL) was added dropwise 1 M BBr 3 The mixture was concentrated under vacuum and the residue was partitioned between EtOAc (20 mL) and water (20 mL). The organic layer was separated and the aqueous portion was extracted again with EtOAc (2 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL) and Na 2 SO 4 Drying and concentration in vacuo afforded the title compound as an amber glass.

[1838] 1 H NMR (500 MHz, CHLOROFORM-d) δ 10.14-9.39 (m, 2H), 8.32 (d, J = 5.6 Hz, 1H), 8.16 (s, 1H), 8.04 (dd, J = 5.6, 1.9 Hz, 1H), 7.94 (s, 1H), 7.42 (d, J = 7.3 Hz, 2H), 7.39 (d, J = 2.1 Hz, 1H), 7.36-7.29 (m, 3H), 7.25 (t, J = 7.3 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1H), 3.83 (s, 2H), 1.49 (s, 9H). LC-MS (Method A): Rt 3.64 min; MS m / z 404 = [M+H]+

[1839] Embodiment 27

[1840] N-tert-Butyl-4-[[2-[5-chloro-2-hydroxy-4-(pyrrolidin-1-ylmethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1841]

[1842] Step 1: 2-(4-Bromo-5-chloro-2-methoxy-phenyl)acetic acid

[1843]

[1844] 2-(4-Bromo-2-methoxy-phenyl)acetic acid (2 g, 8.16 mmol) and NCS (1.14 g, 8.57 mmol) were dissolved in MeCN (40.8 mL) and stirred at 50 °C for 22 h. The resulting mixture was concentrated under vacuum and the residue was purified by silica gel chromatography eluting with 20-100% EtOAc in heptane. The product was dissolved in EtOAc (100 mL) and stirred in NaHCO 3 The product was further purified by extraction with saturated aqueous solution (3 x 100 mL). The combined aqueous extracts were acidified with 1 M HCl and extracted with EtOAc (3 x 150 mL). The combined organic extracts were purified by Na 2 SO 4 Dry, filter, and concentrate in vacuo to give the title compound as a colorless solid.

[1845] 1H NMR (250MHz, DMSO-d6) δ 11.97 (s, 1H), 7.46 (s, 1H), 7.34 (s, 1H), 3.79 (s, 3H), 3.50 (s, 2H).

[1846] LC-MS (Method E): Rt 1.07 min; MS m / z not observed = [M+H]+

[1847] Step 2: 4-[[2-(4-Bromo-5-chloro-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide

[1848]

[1849] The title compound was prepared in analogy to Example 3.5b Step 1 from 4-amino-N-tert-butyl-pyridine-2-carboxamide and 2-(4-bromo-5-chloro-2-methoxy-phenyl)acetic acid (Step 1).

[1850] 1H NMR (250MHz, DMSO-d6) δ10.70 (s, 1H), 8.44 (d, J = 5.6Hz, 1H), 8.16 (d, J = 1.9Hz, 1H), 8.03 (s, 1H) , 7.79 (dd, J=5.5, 2.2Hz, 1H), 7.51 (s, 1H), 7.36 (s, 1H), 3.78 (s, 3H), 3.71 (s, 2H), 1.40 (s, 9H).

[1851] LC-MS (Method E): Rt 1.28 min; MS m / z 454 = [M+H] + 97% @ 215 nm)

[1852] Step 3: N-tert-butyl-4-[[2-[5-chloro-2-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1853]

[1854] The tube was charged with 4-[[2-(4-bromo-5-chloro-2-methoxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide (step 2) (100 mg, 0.21 mmol), potassium trifluoropyrrolidine-1-ylmethyl)borate (45 mg, 0.23 mmol), Xphos (6 mg, 0.01 mmol), Pd(Oac) 2 (1.4 mg, 0.01 mmol) and Cs 2 CO 3 (209 mg, 0.64 mmol) and placed under nitrogen atmosphere. THF:water (1 mL of a 10:1 mixture) was added and the mixture was heated at 80°C for 20 hours. The resulting mixture was diluted with water (2 mL) and extracted with DCM (3 x 10 mL). The combined organic extracts were purified by Na 2 SO 4Dry, filter, and concentrate in vacuo. The residue is purified by silica gel chromatography eluting with 0-100% EtOAc in heptane to afford the title compound as a colorless solid.

[1855] 1H NMR (500MHz, DMSO-d6) δ10.68 (s, 1H), 8.44 (d, J=5.5Hz, 1H), 8.16 (dd, J=6.4, 2.0Hz, 1H), 8.03 (s, 1H), 7.80 ( dd, J=5.5, 2.2Hz, 1H), 7.29 (s, 1H), 7.07 (s, 1H), 3.75 (s, 3H), 3.69 (s, 2H), 3.65 (s, 2H), 2.51-2.49 (obscured m, 4H), 1.73-1.71 (m, 4H), 1.40 (s, 9H).

[1856] LC-MS (Method E): Rt 1.04 min; MS m / z 459 / 461 = [M+H]+ (78% @ 215 nm)

[1857] Step 4: N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-4-(pyrrolidin-1-ylmethyl)phenyl]acetyl]amino]pyridine-2-carboxamide

[1858] The title compound was prepared in analogy to Example 26, Step 2, from N-tert-butyl-4-[[2-[5-chloro-2-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Step 3).

[1859] 1H NMR (500MHz, DMSO-d6) δ10.72 (s, 1H), 9.70 (s, 1H), 8.44 (d, J = 5.5Hz, 1H), 8.17 (d, J = 2.0Hz, 1H), 8.03 (s, 1 H), 7.81 (dd, J=5.5, 2.2Hz, 1H), 7.18 (s, 1H), 6.97 (s, 1H), 3.64 (s, 2H), 3.57 (s, 2H), 2.51-2.49 (obscured m, 4H), 1.72-1.70 (m, 4H), 1.40 (s, 9H).

[1860] LC-MS (Method A): Rt 2.08 min; MS m / z 445.3 / 447.3 = [M+H]+ (99% @ 215 nm)

[1861] The compounds of the following examples (Table 9) were prepared in analogy to Example 27 by replacing potassium trifluoropyrrolidine 1-ylmethyl)borate (step 3) with the appropriate boranuide.

[1862]

[1863] Embodiment 28

[1864] N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxamide

[1865]

[1866] Step 1: N-(2-Chloro-5-fluoro-4-pyridinyl)-2-(5-chloro-2-methoxy-phenyl)acetamide

[1867]

[1868] The thionyl chloride (6.01mL, 68.24mmol) solution containing 2-(5-chloro-2-methoxy-phenyl)acetic acid (753mg, 3.75mmol) was stirred at 70°C for 1 hour, and the resulting mixture was concentrated to dryness and azeotroped with toluene (2x 10mL). The crude residue was dissolved in DMF (10mL), and treated dropwise with a DMF (3mL) solution containing 2-chloro-5-fluoro-pyridine-4-amine (500mg, 3.41mmol), and then treated with DIPEA (1.49mL, 8.53mmol). After stirring at room temperature under an inert atmosphere for 16 hours, the mixture was diluted with EtOAc (100mL), and washed with water (2x 50mL) and brine (2x50 mL). The organic part was purified by Na 2 SO 4 After drying and concentrating in vacuo, the crude material was purified by C18 reverse phase chromatography eluting with 0-100% MeCN in water with a 0.1% formic acid modifier to afford the title compound as a light yellow solid.

[1869] 1H NMR (250MHz, DMSO-d6) δ10.58 (s, 1H), 8.41 (d, J = 2.7Hz, 1H), 8.24 (d, J = 5.6 Hz, 1H), 7.33-7.28 (m, 2H), 7.01 (d, J=9.5Hz, 1H), 3.83 (s, 2H), 3.75 (s, 3H).

[1870] LC-MS (Method E): Rt 1.25 min; MS m / z 328.9, 330.9 = [M + H] +

[1871] Step 2: N-tert-Butyl-4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxamide

[1872]

[1873] All reagents were charged to a Coware apparatus (carbon monoxide generation system) according to the following procedure; N-(2-chloro-5-fluoro-4-pyridyl)-2-(5-chloro-2-methoxy-phenyl)acetamide (step 1) (170 mg, 0.52 mmol), sodium carbonate (164 mg, 1.55 mmol), XantPhos Pd-G3 (third generation (G3) Buchwald precatalyst) (49 mg, 0.05 mmol) and toluene (5 mL) were added to chamber A, followed by 2-methylpropan-2-amine (64 mg, 0.88 mmol). The resulting solution was degassed with nitrogen for 5 minutes. Toluene (5 mL) containing formic acid (49 / μL, 1.29 mmol) was added to chamber B, followed by methanesulfonyl chloride (100 μL, 1.29 mmol). The container was sealed and TEA (288 μL, 2.07 mmol) was added to chamber B to generate carbon monoxide. The Coware apparatus was heated at 100°C overnight and allowed to cool to room temperature. The resulting mixture was concentrated under vacuum, dissolved in EtOAc (30 mL) and washed with water (2 x 25 mL). The organic portion was purified by Na 2 SO 4 Dry and concentrate under vacuum.The crude residue was purified by preparative HPLC (acidic pH, early elution method) to give the title compound as a beige solid.

[1874] 1H NMR (250 MHz, methanol-d4) δ 8.91 (d, J = 6.5 Hz, 1H), 8.41 (d, J = 2.6 Hz, 1H), 7.29-7.23 (m, 2H), 7.00-6.94 (m, 1H), 3.84 (s, 3H), 3.79 (s, 2H), 1.45 (s, 9H).

[1875] LC-MS (Method E): Rt 1.25 min; MS m / z 394.1, 396.1 = [M+H]+ (97% @ 215 nm)

[1876] Step 3: N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxamide

[1877] To a cooled (0 °C) solution of N-tert-butyl-4-[[2-(5-chloro-2-methoxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxamide (step 2) (30 mg, 0.08 mmol) in DCM (2 mL) was added 1 M BBr 3The reaction mixture was warmed to room temperature and stirred for another hour. Water (0.5 mL) was added to quench the reaction and concentrated under vacuum. The crude material was redissolved in EtOAc (2 mL) and washed with saturated NaHCO 3 The organic portion was concentrated in vacuo and the crude residue was purified by C18 reverse phase chromatography (0-100% MeCN in water with 0.1% formic acid modifier) ​​and the product fractions were concentrated in vacuo and freeze-dried to give the title compound as a white solid.

[1878] 1H NMR (500MHz, DMSO-d6) δ10.02 (br.S, 1H), 8.82 (d, J=6.6Hz, 1H), 8.54 (d, J=2.5Hz, 1H), 7.91 (s, 1H), 7. 22 (d, J=2.7Hz, 1H), 7.12 (dd, J=8.6, 2.7Hz, 1H), 6.81 (d, J=8.6Hz, 1H), 3.79-3.74 (m, 2H), 1.38 (s, 9H).

[1879] LC-MS (Method A): Rt 3.37 min; MS m / z 380.3 / 381.3 / 382.3 = [M+H]+ (99% @ 215 nm)

[1880] Example 28.1

[1881] N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-3-fluoro-pyridine-2-carboxamide

[1882]

[1883] The title compound was prepared in analogy to Example 28 Steps 1-3 from 2-chloro-3-fluoro-pyridin-4-amine and 2-(5-chloro-2-methoxy-phenyl)acetic acid.

[1884] 1H NMR (500MHz, DMSO-d6) δ8.29-8.25 (m, 2H), 8.02 (s, 1H), 7.21 (d, J=2.7Hz, 1H) , 7.12 (dd, J=8.6, 2.7Hz, 1H), 6.81 (d, J=8.6Hz, 1H), 3.78 (s, 2H), 1.38 (s, 9H).

[1885] LC-MS (Method A): Rt 3.30 min; MS m / z 380.2 / 382.2 = [M+H] +

[1886] Embodiment 30

[1887] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide

[1888]

[1889] Step 1: 4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxylic acid methyl ester

[1890]

[1891] To a stirred solution of 2-(2-chlorophenyl)acetic acid (3.08 g, 18.07 mmol), methyl 4-aminopyridine-2-carboxylate (2.5 g, 16.43 mmol) and TEA (4.3 mL, 24.65 mmol) in 1,4-dioxane (40 mL) was added 50% The resulting mixture was stirred at room temperature for 2 hours, then diluted with EtOAc (100 mL) and water (100 mL), the organic layer was separated, and the mixture was purified by Na 2 SO 4 Dry and concentrate in vacuo. Purify the crude residue by silica gel chromatography eluting with 10-100% EtOAc in heptane to give the title compound as a light orange solid.

[1892] 1H NMR (500MHz, DMSO-d6) δ10.85 (s, 1H), 8.55 (d, J = 5.5Hz, 1H), 8.31 (d, J = 1.9Hz, 1H), 7.77 (dd, J=5.5, 2.2Hz, 1H), 7.48-7.40 (m, 2H), 7.36-7.28 (m, 2H), 3.91 (s, 2H), 3.86 (s, 3H).

[1893] LC-MS (Method E): Rt 1.00 min; MS m / z 305.0 / 307.0 = [M+H]+ (96% @ 215 nm)

[1894] Step 2: 4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxylic acid

[1895]

[1896] 2M LiOH (16.07 mL, 32-13 mmol) was added to a stirred solution of methyl 4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxylate (step 2) (3.4 g, 10.71 mmol) in THF (40 mL) and stirred at room temperature for 20 minutes. The resulting mixture was partially concentrated under vacuum to remove volatile solvents and acidified to pH 2 with 2M aq HCl. The resulting suspension was filtered and dried in a vacuum oven at 40°C to give the title compound as an off-white solid.

[1897] 1H NMR (500MHz, DMSO-d6) δ10.89 (s, 1H), 8.53 (d, J = 5.5Hz, 1H), 8.27 (d, J = 2.1Hz, 1H ), 7.79 (dd, J=5.5, 2.2Hz, 1H), 7.49-7.41 (m, 2H), 7.35-7.29 (m, 2H), 3.92 (s, 2H).

[1898] LC-MS (Method E): Rt 0.89 min; MS m / z 290.9 / 292.9 = [M+H] + (100% @ 215 nm)

[1899] Step 3: 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide

[1900] A solution of 1-aminocyclobutanecarbonitrile (33 mg, 0.34 mmol), DIPEA (0.07 mL, 0.41 mmol), HATU (131 mg, 0.34 mmol) and 4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxylic acid (step 2) (100 mg, 0.34 mmol) in DMF (2 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated in vacuo and the residue was partitioned between EtOAc (10 mL) and water (10 mL). The organic layer was separated and purified by Na 2 SO 4 3 4 4 2 0 4 0 0 2 SO 4 Dry and concentrate under vacuum.The residue was purified by preparative HPLC (acidic pH, early elution method) and the product fractions were lyophilized overnight to give the title compound as an off-white powder.

[1901] 1H NMR (500MHz, DMSO-d6) δ10.87 (s, 1H), 9.60 (s, 1H), 8.53 (d, J = 5.5Hz, 1H), 8.20 (d, J = 1.9Hz, 1H), 7.87 (dd, J = 5.5, 2.2 Hz, 1H), 7.52-7.38(m, 2H), 7.38-7.24(m, 2H), 3.92(s, 2H), 2.70-2.62(m, 2H), 2.59-2.52(m, 2H), 2.09-1.93(m, 2H).

[1902] LC-MS (Method A): Rt 3.02 min; MS m / z 369.2 = [M+H]+ (100% @ 215 nm)

[1903] Example 30.1

[1904] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide

[1905]

[1906] A solution of 2-methylbut-3-yn-2-amine (14 mg, 0.17 mmol), DIPEA (0.08 mL, 0.43 mmol), HATU (65 mg, 0.17 mmol) and 4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxylic acid (Example 30, Step 2) (50 mg, 0.17 mmol) in DMF (1 mL) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under vacuum, and the residue was then partitioned between EtOAc (10 mL) and water (10 mL). The organic layer was separated and the residue was purified by Na 2 O 4 3 O 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 45 47 48 49 50 51 52 2 SO 4 Dry and concentrate under vacuum.The residue was purified by preparative HPLC (acidic pH, early elution method) and the product fractions were combined and lyophilized overnight to give the title compound as an off-white powder.

[1907] 1H NMR (500MHz, DMSO-d6) δ10.85 (s, 1H), 8.48 (d, J = 5.5Hz, 1H), 8.32 (s, 1H), 8.19 (d, J = 2.0Hz, 1H), 7.83 (dd, J=5.5, 2.2Hz, 1H), 7.49-7.39(m, 2H), 7.37-7.29(m, 2H), 3.92(s, 2H), 3.21(s, 1H), 1.64(s, 6H).

[1908] LC-MS (Method A): Rt 3.25 min; MS m / z 356.3 / 358.2 = [M+H]+ (100% @ 215 nm)

[1909] Example 30.2

[1910] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[2.1.1]hexyl)pyridine-2-carboxamide

[1911]

[1912] A solution of 4-fluorobicyclo[2.1.1]hexan-1-amine hydrochloride (26 mg, 0.17 mmol), DIPEA (0.08 mL, 0.43 mmol), HATU (65 mg, 0.17 mmol) and 4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxylic acid (Example 30, Step 2) (50 mg, 0.17 mmol) in DMF (1 mL) was stirred at room temperature for 2 h. The resulting mixture was concentrated in vacuo and the residue was partitioned between EtOAc (10 mL) and water (10 mL). The organic layer was separated and purified by chromatography on a 4% HPLC-MS / MS. 2 SO 4 Dry and concentrate under vacuum.The residue was purified by preparative HPLC (acidic pH, early elution method) and the product fractions were combined and lyophilized overnight to give the title compound as an off-white powder.

[1913] 1H NMR (500MHz, DMSO-d6) δ10.83 (s, 1H), 9.05 (s, 1H), 8.48 (d, J = 5.5Hz, 1H), 8.16 (d, J = 2.0Hz, 1H), 7.83 (dd, J = 5.5, 2.2Hz, 1H), 7 .54-7.40(m, 2H), 7.40-7.25(m, 2H), 3.91(s, 2H), 2.14-2.08(m, 2H), 2.08-2.04(m, 2H), 2.00-1.94(m, 2H), 1.87-1.81(m, 2H).

[1914] LC-MS (Method A): Rt 3.39 min; MS m / z 388.3 / 390.3 = [M+H]+ (99% @ 215 nm)

[1915] Example 30.3

[1916] 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(1-cyclopropyl-1-methyl-ethyl)pyridine-2-carboxamide

[1917]

[1918] The title compound was prepared in analogy to Example 30, Step 3, from 4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxylic acid (Example 30, Step 2) and 2-cyclopropylpropan-2-amine.

[1919] 1H NMR (500MHz, DMSO-d6) δ10.84 (s, 1H), 8.47 (d, J = 5.5Hz, 1H), 8.20 (d, J = 2.1Hz, 1H), 8.03 (s, 1H), 7.81 (dd, J = 5.5, 2.2Hz, 1H), 7.49-7.42(m, 2H), 7.35-7.31(m, 2H), 3.92(s, 2H), 1.41-1.34(m, 1H), 1.31(s, 6H), 0.43-0.36(m, 4H).

[1920] LC-MS (Method A): Rt 3.73 min; MS m / z 372.2 / 374.2 = [M+H]+ (100% @ 215 nm)

[1921] The compounds of the examples listed below (Table 9a) were prepared in analogy to Example 30 by replacing 1-aminocyclobutanecarbonitrile (step 3) with a suitable commercially available amine.

[1922]

[1923]

[1924]

[1925]

[1926] Embodiment 31

[1927] 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)...

Claims

1. A compound of formula (Ia) or a salt thereof: in: R 1 H、CN、C(O)OR 12 , C 1-3 Alkyl or C 2-3 Alkynyl, either of the alkyl or alkynyl is unsubstituted or substituted by 1 substituent selected from: fluorine, OR 12 、N(R 12 )2. C(O)OR 12 、C(O)N(R 12 )2 and C(O)R 12 ; Where R 12 Each independently selected from H and C 1-6 alkyl; R 2 Is H or C 1-6 Alkyl, which is unsubstituted or substituted by OR 12 replace; R 3 yes: C 1-10 Alkyl or C 2-10 Alkynyl, any one of which is unsubstituted or substituted by 1 substituent selected from fluorine, CN, R 14 , OR 14 , OR 15 、N(R 15 )2. C(O)OR 15 、C(O)N(R 15 )2、N(R 16 )C(O)R 15 and N(R 15 )S(O)2R 16 ;or 3- to 7-membered non-aromatic carbocyclic or 3- to 7-membered non-aromatic heterocyclic ring system or 6- to 10-membered aryl or 5- to 10-membered heteroaryl ring system, each of which is unsubstituted or substituted with 1 substituent selected from the group consisting of halo, CN, C 1-4 Alkyl, C 1-4 Haloalkyl, OR 17 and N(R 17 )2; Where R 14 is a 6- to 10-membered aryl or 5- to 10-membered heteroaryl ring system or a 3- to 7-membered non-aromatic carbocyclic ring or a 3- to 7-membered non-aromatic heterocyclic ring system, any of which is unsubstituted or substituted with 1 substituent selected from the group consisting of halo, C 1-4 Alkyl, C 1-4 Haloalkyl, OR 17 and N(R 17 )2; where R 17 Each independently is H or C 1-4 alkyl; R 15 and R 16 Each independently is H, C 1-6 Alkyl or C 1-6 haloalkyl; or R 2 and R 3 Together with the carbon atoms to which they are attached, they form a 3- to 10-membered non-aromatic carbocyclic or 3- to 10-membered non-aromatic heterocyclic ring system which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of halo, CN, OR 9 、N(R 9 )2. C(O)OR 9 、C(O)N(R 9 )2. C(O)R 9 、N(R 9 )C(O)R 9 and unsubstituted or halogenated, OR 9 or N(R 9 )2 substituted C 1-4 Alkyl; or R 1 , R 2 and R 3 Together with the carbon atoms to which they are attached, they form a bridged 5- to 10-membered non-aromatic carbocyclic or 5- to 10-membered non-aromatic heterocyclic ring system or phenyl, any of which is unsubstituted or substituted with 1 substituent selected from the group consisting of halo, CN, OR 9 、N(R 9 )2. C(O)OR 9 、C(O)N(R 9 )2. C(O)R 9 、N(R 9 )C(O)R 9 and unsubstituted or halogenated, OR 9 or N(R 9 )2 substituted C 1-4 alkyl; R 9 Each independently selected from H or C 1-6 alkyl; X 1 is N; X 2 Yes CR 8 ; R 8 is H or a halide; R 5a It is H; R 10 H, OH, halogen, C 1-6 Alkyl or -O(C 1-6 alkyl); R 11 are independently H, halo, OH, CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C(O)O-(C 1-6 alkyl) or -O(C 1-6 alkyl); and n is 1 or 2.

2. The compound according to claim 1, wherein The compound of formula (Ia) is a compound of formula (Id) or (Ie): Where R 1 , R 2 and R 3 As defined in claim 1; R 11a H, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl or C(O)O(C 1-4 alkyl); R 11b H, halogen, C 1-4 Alkyl or C 1-4 haloalkyl; and R 11c H, halogen, CN, C 1-4 Alkyl or C 1-4 Halogenated alkyl.

3. A compound selected from: N-tert-Butyl-4-[[2-(2-hydroxyphenyl)acetyl]amino]pyridine-2-carboxamide; N-(1-adamantyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-methoxy-1,1-dimethyl-propyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclohexyl)pyridine-2-carboxamide; N-[3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]-3-methyl-butyl]carbamic acid tert-butyl ester; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-cyclohexyl-pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-(1,1-dimethylpropyl)-4-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(4-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-chloro-6-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(4-Bromo-5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide; 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide; 4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide; N-tert-butyl-4-[2-(2,5-dibromo-3-fluoro-6-hydroxyphenyl)acetylamino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(4-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-hydroxy-5-methoxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2,5-dibromo-3-chloro-6-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3-hydroxyphenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-fluoro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(4-chloro-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-chloro-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-chloro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3-chloro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(5-chloro-2-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3-chlorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3,4-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-(p-tolyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(4-fluorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(m-tolyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2,6-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(4-chloro-3-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3,5-dichlorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-chlorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3-chloro-4-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[1-(3-chlorophenyl)cyclopropanecarbonyl]amino]pyridine-2-carboxamide; N-(1,1-dimethylprop-2-ynyl)-4-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylbutyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1,2-trimethylpropyl)pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-isopropyl-pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-tetrahydropyran-4-yl-pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-sec-butyl-pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-hydroxy-1,1,2-trimethyl-propyl)pyridine-2-carboxamide; N-(3-Bicyclo[1.1.1]pentyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide; tert-Butyl 3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]piperidine-1-carboxylate; (1r,5s,6s)-6-{4-[2-(5-chloro-2-hydroxyphenyl)acetylamino]pyridine-2-amido}-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylpropyl)pyridine-2-carboxamide; N-tert-butyl-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-hydroxy-5-methyl-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3-hydroxy-2-pyridinyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[(2-phenylacetyl)amino]pyridine-2-carboxamide; 4-[[2-(4-Chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide; 4-[[2-(3-chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide; 4-[[2-(2-Chloro-5-fluoro-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide; N-tert-butyl-4-[[2-[2-(difluoromethoxy)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-[2-(difluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3,4-difluorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(3,5-difluorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2,3-difluorophenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-tetrahydropyran-4-yl-pyridine-2-carboxamide; N-tert-Butyl-4-[[2-[2-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; 4-[[2-(2-bromophenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-cyanophenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(2-Chloro-5-methoxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide; N-(3-Bicyclo[1.1.1]pentyl)-4-[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; -[[2-(5-tert-butyl-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-hydroxy-5-phenyl-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-4-(pyrrolidin-1-ylmethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[4-[(tert-butylamino)methyl]-5-chloro-2-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-4-(morpholinomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[5-chloro-4-[(3,3-difluoropyrrolidin-1-yl)methyl]-2-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-5-fluoro-pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-3-fluoro-pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyanocyclobutyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[ 2.1.1]hexyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyclopropyl-1-methyl-ethyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-methyl-3-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyano-3-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(2,2-difluorocyclopropyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(3-fluoro-1-bicyclo[1.1.1]pentyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(2-fluoro-1,1-dimethyl-ethyl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(4-ethynyltetrahydropyran-4-yl)pyridine-2-carboxamide; 4-[[2-(2-chlorophenyl)acetyl]amino]-N-(1-cyanocyclopentyl)pyridine-2-carboxamide; 4-[[2-(2-Chlorophenyl)acetyl]amino]-N-(2,2-difluoro-1,1-dimethyl-ethyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclopentyl)pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2S)-2-hydroxycyclohexyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2R)-2-hydroxycyclohexyl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-ethynyltetrahydropyran-4-yl)pyridine-2-carboxamide; N-[(6-amino-2-pyridinyl)methyl]-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 12-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]dodecanoic acid; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-pyridylmethyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-pyridinylmethyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-pyridinylmethyl)pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(2-hydroxyphenyl)methyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethyl-2-morpholino-ethyl)pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(2-hydroxy-1,1-dimethyl-ethyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3,3-difluoro-4-piperidinyl)pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1H-imidazol-2-yl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2R)-2-hydroxycyclopentyl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3R)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3S)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-hydroxy-4-methyl-cyclohexyl)pyridine-2-carboxamide as a 6:4 mixture of stereoisomers; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1s,2r)-2-(hydroxymethyl)cyclohexyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1s,3r)-3-hydroxycyclopentyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)-1-methyl-ethyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-hydroxycyclohexyl)pyridine-2-carboxamide, as a mixture of stereoisomers; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-phenoxypropyl)pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-methyl-1-(2-pyridinyl)ethyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-phenylpropyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[2-hydroxy-1-(2-pyridinyl)ethyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(5-methoxy-2-pyridinyl)methyl]pyridine-2-carboxamide; 3-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]-3-methyl-butyric acid ethyl ester; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-hydroxy-1,1-dimethyl-propyl)pyridine-2-carboxamide; N-Benzyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-phenyl-pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S,2R)-2-hydroxycyclopentyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclohexyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)oxetan-3-yl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-methoxy-1-methyl-ethyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1,2-dimethyl-propyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopentyl)pyridine-2-carboxamide; N-(4-tert-Butylcyclohexyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-chloro-3-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-chloro-5-fluoro-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[4-(2-hydroxyethyl)tetrahydropyran-4-yl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1,1-dimethyl-3-(2,2,2-trifluoroethylamino)propyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[ 2.1.1]hexyl)pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(2,2-dimethylpropionylamino)-1,1-dimethyl-propyl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-hydroxy-1-methyl-ethyl)pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-cyanotetrahydrofuran-3-yl)pyridine-2-carboxamide; 2-[4-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]tetrahydropyran-4-yl]acetic acid methyl ester; 4-[[4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carbonyl]amino]tetrahydropyran-4-carboxylic acid methyl ester; 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(3-cyanoxetan-3-yl)pyridine-2-carboxamide; 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide; N-(4-cyanotetrahydropyran-4-yl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-[3-(tert-Butylamino)-1,1-dimethyl-3-oxo-propyl]-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(methylsulfonylamino)-1,1-dimethyl-propyl]pyridine-2-carboxamide; N-(3-Acetylamino-1,1-dimethyl-propyl)-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[4-(hydroxymethyl)tetrahydropyran-4-yl]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-[3-(1-hydroxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-5-chloro-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[5-chloro-2-[(4-methoxyphenyl)methoxy]phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(2-cyclopropylphenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(3-Bromo-5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide; N-(4-fluoro-1-bicyclo[ 2.1.1]hexyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide; N-(1-cyano-2-hydroxy-1-methyl-ethyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide; N-(1,1-dimethylprop-2-ynyl)-4-[[2-(2-fluorophenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-3-isopropyl-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[5-chloro-2-hydroxy-3-(1-methoxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[2-hydroxy-5-(1-hydroxyethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[2-hydroxy-5-[1-(2,2,2-trifluoroethylamino)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-[3-(cyanomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-Butyl-4-[[2-[3-(methoxymethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-[2-hydroxy-5-(morpholinomethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-[3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)-2-methoxy-1-methyl-ethyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylbut-2-ynyl)pyridine-2-carboxamide; N-tert-Butyl-4-[[2-[2-hydroxy-5-(3-hydroxypropyl)phenyl]acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-chloro-4-fluoro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclobutyl)pyridine-2-carboxamide; 4-[[2-(2,5-difluorophenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide; 4-[[2-(2,5-difluorophenyl)acetyl]amino]-N-(4-fluoro-1-bicyclo[ 2.1.1]hexyl)pyridine-2-carboxamide; 4-[[2-(4-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide; N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-(1,1-dimethylprop-2-ynyl)-4-[[2-[2-hydroxy-5-(trifluoromethyl)phenyl]acetyl]amino]pyridine-2-carboxamide; N-(1-cyano-1-methyl-ethyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-(1-cyano-2-hydroxy-1-methyl-ethyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-isopropyl-pyridine-2-carboxamide; N-(1,1-dimethylprop-2-ynyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-(4-fluoro-1-bicyclo[ 2.1.1]hexyl)-4-[[2-(5-fluoro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(5-Fluoro-2-hydroxy-phenyl)acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide; 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[1-cyano-2-methoxy-1-(methoxymethyl)ethyl]pyridine-2-carboxamide; 4-[[2-(3-amino-4-tert-butyl-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide; 4-[[2-(2-amino-4-tert-butyl-phenyl)acetyl]amino]-N-tert-butyl-pyridine-2-carboxamide; N-tert-butyl-4-[[2-(4-tert-butyl-3-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-(4-tert-butyl-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; N-tert-butyl-4-[[2-(4-tert-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide; 4-[[2-(4-chloro-3-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide; 4-[[2-(4-Chloro-3-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide; 4-[[2-(4-chloro-3-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide; 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-[(2S)-2-hydroxycyclohexyl]pyridine-2-carboxamide; 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-[(2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide; 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-(4-cyanotetrahydropyran-4-yl)pyridine-2-carboxamide; 4-[[2-(4-tert-Butyl-3-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide; 4-[[2-(4-tert-butyl-3-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide; and 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1-methyl-1-phenyl-ethyl)pyridine-2-carboxamide; or a salt thereof.

4. A compound which is N-tert-butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide or a salt thereof.

5. A compound which is 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3R)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide or 4-[[2-(5-Chloro-2-hydroxy-phenyl)acetyl]amino]-N-[(3S)-3-(hydroxymethyl)tetrahydrofuran-3-yl]pyridine-2-carboxamide or a salt thereof.

6. A compound which is 4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide or a salt thereof.

7. A compound which is N-(1,1-dimethylprop-2-ynyl)-4-[[2-[3-(trifluoromethyl)-1H-pyrazol-4-yl]acetyl]amino]pyridine-2-carboxamide or a salt thereof.

8. Use of a compound according to any one of claims 1 to 7 or a salt thereof for the preparation of a medicament for the treatment or prevention of diseases and disorders affected by TMEM16A modulation.

9. The use according to claim 8, wherein the disease or condition affected by TMEM16A modulation is selected from respiratory diseases and conditions, dry mouth, overactive intestine, cholestasis and ocular symptoms.

10. The use according to claim 9, wherein: The respiratory diseases and disorders are selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma and primary ciliary dyskinesia; The dry mouth is caused by Sjögren's syndrome, radiation therapy, or medications that cause dry mouth; The intestinal overactivity is associated with gastric dyspepsia, gastroparesis, chronic constipation, or irritable bowel syndrome; The eye symptom is dry eyes.

11. Use according to any one of claims 8 to 10, wherein the compound of formula (I) is used in combination with another active agent for the treatment or prevention of respiratory disorders.

12. The use according to claim 11, wherein the additional active agent for treating or preventing a respiratory disorder is selected from: a β2 adrenergic receptor agonist selected from metaproterenol, isoproterenol, albuterol, salbutamol, formoterol, salmeterol, indacaterol, terbutaline, metaproterenol, bitolterol mesylate, pirbuterol, olodaterol, vilanterol and abeterolide; an antihistamine selected from loratadine, cetirizine, desloratadine, levocetirizine, fexofenadine, astemizole, astemizole and chlorpheniramine or an H4 receptor antagonist; Streptodornase alpha; Corticosteroids selected from prednisone, corticosterone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, mometasone furoate and fluticasone furoate; A leukotriene antagonist selected from montelukast and zafirlukast; an anticholinergic compound selected from ipratropium, tiotropium, glycopyrrolate, aclidinium bromide and umeclidinium bromide; CFTR repair therapy selected from ivacaftor, QBW251, VX659, VX445, VX561 / CPT-656, VX152, VX440, GLP2737, GLP2222, GLP2451, PTI438, PTI801, PTI808, FDL-169, and FDL-176, and a CFTR corrector selected from lumacaftor and tizaftor; ENaC modulator selected from: Amiloride, VX-371, AZD5634, QBW276, SPX-101, BI443651, ETD001, and a compound having a cation selected from: 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)ethyl]-6-(4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}piperidine-1-carbonyl)-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-6-{[2-(4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}piperidin-1-yl)ethyl]carbamoyl}-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-5-[4-({bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}methyl)piperidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-6-[(3R)-3-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}pyrrolidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-6-[(3S)-3-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}pyrrolidine-1-carbonyl]-1,3-diethyl-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}carboxamido)methyl]-1,3-diethyl-6-{[(1r,4r)-4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}cyclohexyl]carbamoyl}-1H-1,3-benzodiazol-3-ium; 2-[({3-amino-5H-pyrrolo[2,3-b]pyrazin-2-yl}formamido)methyl]-1,3-diethyl-6-{[(1s,4s)-4-{bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]amino}cyclohexyl]carbamoyl}-1H-1,3-benzodiazol-3-ium; and an anion selected from halide, sulfate, nitrate, phosphate, formate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate or p-toluenesulfonate; antibiotic; A respiratory moisturizer selected from hypertonic saline and mannitol; and Mucolytic agent.

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 and a pharmaceutically acceptable excipient.

14. A pharmaceutical composition according to claim 13, formulated for oral, rectal, nasal, bronchial, topical, vaginal or parenteral administration.